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Background: Invasive mechanical ventilation (IMV) is a life-saving intervention. Following resolution of the
condition that necessitated IMV, a spontaneous breathing trial (SBT) is used to determine patient readiness
for IMV discontinuation. In patients who fail one or more SBTs, there is uncertainty as to the optimum
management strategy.
Objective: To evaluate the clinical effectiveness and cost-effectiveness of using non-invasive ventilation
(NIV) as an intermediate step in the protocolised weaning of patients from IMV.
Design: Pragmatic, open-label, parallel-group randomised controlled trial, with cost-effectiveness analysis.
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Setting: A total of 51 critical care units across the UK.
Participants: Adult intensive care patients who had received IMV for at least 48 hours, who were
categorised as ready to wean from ventilation, and who failed a SBT.
Interventions: Control group (invasive weaning): patients continued to receive IMV with daily SBTs.
A weaning protocol was used to wean pressure support based on the patient’s condition. Intervention
group (non-invasive weaning): patients were extubated to NIV. A weaning protocol was used to wean
inspiratory positive airway pressure, based on the patient’s condition.
Main outcome measures: The primary outcome measure was time to liberation from ventilation.
Secondary outcome measures included mortality, duration of IMV, proportion of patients receiving
antibiotics for a presumed respiratory infection and health-related quality of life.
Results: A total of 364 patients (invasive weaning, n = 182; non-invasive weaning, n = 182) were randomised.
Groups were well matched at baseline. There was no difference between the invasive weaning and non-invasive
weaning groups in median time to liberation from ventilation {invasive weaning 108 hours [interquartile range
(IQR) 57–351 hours] vs. non-invasive weaning 104.3 hours [IQR 34.5–297 hours]; hazard ratio 1.1, 95%
confidence interval [CI] 0.89 to 1.39; p = 0.352}. There was also no difference in mortality between groups
at any time point. Patients in the non-invasive weaning group had fewer IMV days [invasive weaning 4 days
(IQR 2–11 days) vs. non-invasive weaning 1 day (IQR 0–7 days); adjusted mean difference –3.1 days, 95% CI
–5.75 to –0.51 days]. In addition, fewer non-invasive weaning patients required antibiotics for a respiratory
infection [odds ratio (OR) 0.60, 95% CI 0.41 to 1.00; p = 0.048]. A higher proportion of non-invasive weaning
patients required reintubation than those in the invasive weaning group (OR 2.00, 95% CI 1.27 to 3.24). The
within-trial economic evaluation showed that NIV was associated with a lower net cost and a higher net effect,
and was dominant in health economic terms. The probability that NIV was cost-effective was estimated at 0.58
at a cost-effectiveness threshold of £20,000 per quality-adjusted life-year.
Conclusions: A protocolised non-invasive weaning strategy did not reduce time to liberation from
ventilation. However, patients who underwent non-invasive weaning had fewer days requiring IMV and
required fewer antibiotics for respiratory infections.
Future work: In patients who fail a SBT, which factors predict an adverse outcome (reintubation,
tracheostomy, death) if extubated and weaned using NIV?
Trial registration: Current Controlled Trials ISRCTN15635197.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 23, No. 48.
See the NIHR Journals Library website for further project information.
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SF-12 Short Form questionnaire-12 items
SpO2 saturation of oxygen in peripheral
blood
TMG Trial Management Group
TSC Trial Steering Committee
VAP ventilator-associated pneumonia
VAS visual analogue scale
WCTU Warwick Clinical Trials Unit
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Plain English summary
Patients who become very unwell may require help from a breathing machine. This requires the patientto be given drugs to put them to sleep (sedation) and have a tube placed through their mouth directly
into the windpipe (tube ventilation). This can be life-saving, but may cause harm if used for long periods of
time. Non-invasive ventilation (mask ventilation) provides breathing support through a mask that covers the
face. Mask ventilation has several advantages over tube ventilation, such as less need for sedation, and it
enables the patient to cough and communicate. In previous studies, switching patients from tube to mask
ventilation when they start to get better seemed to improve survival rates and reduce complications. The
Breathe trial tested if using a protocol to remove tube ventilation and replace it with mask ventilation is
better than continuing with tube ventilation until the patient no longer needs breathing machine support.
The trial recruited 364 patients. Half of these patients were randomly selected to have the tube removed
and replaced with mask ventilation and half were randomly selected to continue with tube ventilation until
they no longer needed breathing machine support. The mask group spent 3 fewer days receiving tube
ventilation, although the overall time needing breathing machine help (mask and tube) did not change.
Fewer patients in the mask group needed antibiotics for chest infections. After removing the tube, twice as
many patients needed the tube again in the mask group as in the tube group. There were no differences
between the groups in the number of adverse (harm) events or the number of patients who survived to
leave hospital. Mask ventilation was no more expensive than tube ventilation.
In conclusion, mask ventilation may be an effective alternative to continued tube ventilation when patients
start to get better in intensive care.
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Scientific summary
Background
Invasive mechanical ventilation (IMV) is a life-saving medical intervention. Each year in the UK, 110,000
people require IMV. Acute respiratory failure is the most common indication for IMV. Following resolution
of the illness that led to the requirement for IMV, clinical focus shifts to the process of weaning the patient
from IMV. A key component of this process is the spontaneous breathing trial (SBT). In a SBT, much of the
assistance from the mechanical ventilator is removed, in order to assess the patient’s readiness to breathe
without its support. Patients who pass the SBT proceed to extubation.
In patients who fail a SBT, the traditional approach has been to continue IMV and to administer a further
SBT the following day. However, an alternative approach that has been advocated is to extubate the
patient to non-invasive ventilation (NIV). The potential benefits of this approach are the avoidance of
further ventilator-induced lung injury, a reduced likelihood of ventilator-associated pneumonia (VAP) and
increased patient comfort. The key risk is that, if the strategy fails, the patient will require reintubation,
which may be associated with increased mortality.
Sixteen small, typically single-centre, trials (n = 994) that compared these approaches were meta-analysed
in a Cochrane review (Burns KE, Meade MO, Premji A, Adhikari NK. Noninvasive positive-pressure
ventilation as a weaning strategy for intubated adults with respiratory failure. Cochrane Database Syst Rev
2013;12:CD004127). The review found evidence that the use of NIV in weaning patients from IMV
reduced mortality, VAP and duration of mechanical ventilation. However, subgroup analyses found that
the beneficial effect was limited to patients with chronic obstructive pulmonary disease (COPD).
In view of the limited generalisability of previous trials to the UK setting and the recognised importance of
the clinical issue to the UK critical care community, the National Institute for Health Research (NIHR) Heath
Technology Assessment (HTA) programme issued a commissioned call for a study to identify the optimal
strategy of liberating patients from IMV.
Objective
The objective of this trial was to determine the clinical effectiveness and cost-effectiveness of NIV as an
intermediate step in the protocolised weaning of patients from IMV.
Methods
Design
A pragmatic, open-label, multicentre, randomised controlled trial was conducted to determine if protocolised
weaning that includes early extubation on to NIV is clinically effective and cost-effective compared with
weaning without NIV (the Breathe trial). The trial was sponsored by Heart of England NHS Foundation Trust.
The trial was reviewed and approved by the Oxford C Research Ethics Committee (REC). The trial was managed
on a day-to-day basis by a Trial Management Group. Independent oversight was provided through a Trial
Steering Committee, and a Data Monitoring and Ethics Committee.
Setting and participants
Patients in critical care units were eligible to participate in the trial if they were aged > 16 years, had
received IMV for > 48 hours, were classified as ready to wean by the critical care clinical team and had
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failed a SBT. Key exclusion criteria included pregnancy, contraindication to NIV, inability to protect airway
because of neurological deficit, and decision not to reintubate or planned withdrawal of treatment.
Interventions
The method [T-piece, continuous positive airway pressure (CPAP) or low-pressure support (Psupp)] and
duration (30–120 minutes) of the SBT were at the discretion of the clinical team. To be deemed to have
failed the SBT, the patient were required to meet one of the predefined failure criteria, such as tachypnoea
(≥ 50% of baseline value or > 35 breaths per minute), hypercapnia (> 6.5 kPa or increase by > 1 kPa),
acidaemia (a pH of < 7.32 or a fall in pH by > 0.07) or increased respiratory effort (e.g. accessory muscle
use, facial distress, dyspnoea).
Following confirmation of eligibility and patient consent or consultee agreement, patients were randomised
in a 1 : 1 ratio to invasive or non-invasive weaning strategies using an electronic randomisation system.
Randomisation was minimised by centre, presence of COPD and reason for critical care admission
(postoperative/non-operative).
Participants in the invasive weaning group were returned to Psupp ventilation after the failed SBT. Psupp was
reduced every 2 hours during daytime based on patient condition, in accordance with a weaning protocol.
Participants underwent daily SBTs to assess readiness for extubation. The weaning process was followed until
a tracheostomy was performed or the participant was extubated.
Participants in the non-invasive weaning group were extubated to NIV after the failed SBT. Initial NIV
settings were based on ventilatory settings prior to extubation. Psupp was reduced every 2 hours during
daytime, based on the participant’s condition, in accordance with a weaning protocol. If the participant
was considered suitable by the clinical team, a trial of face-mask oxygen was attempted. The weaning
process was discontinued when the participant tolerated 12 hours of unsupported spontaneous ventilation.
In both groups, the clinical team titrated fraction of inspired oxygen and/or positive end-expiratory pressure
(PEEP)/expiratory positive airway pressure (depending on treatment group) to maintain saturation of
oxygen in peripheral blood (SpO2) of > 90%. The decision to reintubate or perform a tracheostomy was at
the discretion of the clinical team, although teams were encouraged not to perform a tracheostomy until
at least 7 days after randomisation.
Main outcome measures
The primary effectiveness outcome was time (in hours) from randomisation to successful liberation from
ventilation. Liberation from ventilation was defined as the time point at which the patient was free of ventilatory
(invasive or non-invasive) support for > 48 hours. Secondary outcomes included mortality (30/90/180 days),
duration of IMV, total number of ventilator days (IMV and NIV), time to meeting intensive care unit (ICU)
discharge criteria, proportion of patients receiving antimicrobials for presumed respiratory infection and total
number of days receiving antimicrobials, reintubation rates and the proportion of patients receiving a
tracheostomy. Safety outcomes were adverse events (AEs) and serious adverse events (SAEs). Health-related
quality of life (HRQoL) was assessed by the EuroQol-5 Dimensions, three-level version (EQ-5D-3L), and Short
Form questionnaire-12 items (SF-12) at baseline (estimated retrospectively), and at 90 and 180 days.
The primary economic outcome was incremental cost per quality-adjusted life-year (QALY) gained from the
perspective of the NHS and Personal Social Services.
The original sample size was 920 participants to reliably detect a hazard ratio (HR) of 0.8 between the
intervention and control groups for the primary outcome at 80% power, allowing for attrition as a result
of ICU death and missing outcome data. This equated to a 36-hour difference in the time to liberation
from ventilation, based on an average of 6.4 days in the control group. Interim data analysis identified a
skewed data distribution, such that 2.9 days was considered a better estimate for the sample size calculation.
Based on these data, it was calculated that a sample size of 280 participants would provide 90% power to
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detect a clinically meaningful median difference of 24 hours between the intervention and control groups for
the primary outcome at a 5% significance level. This was inflated to 364 participants to account for attrition.
The primary statistical analysis was based on intention-to-treat principles. For analysis of the primary
outcome and other time-to-event outcomes, survival analysis methods were used to estimate the HR and
the associated 95% confidence interval (CI). For mortality outcomes, logistic regression models were used
to estimate the odds ratio (OR) and 95% CIs for differences between groups. Linear regression models
were used to estimate the mean treatment difference and 95% CIs for continuous outcomes. For count
data, depending on the distribution of the data, negative binomial models were used to estimate the
incidence rate ratio and the associated 95% CI or non-parametric tests. All of the analyses were adjusted
for age, sex, centre, post-SBT partial pressure of carbon dioxide in arterial blood (PaCO2) and stratification
variables (COPD and operative status).
In addition, sensitivity analyses were conducted, namely a per-protocol analysis to explore any apparent
baseline differences between the groups. Predefined subgroup analyses comprised presence/absence of
COPD and postoperative/non-operative status.
The complementary health economic evaluation examined the cost-effectiveness of interventions. It
incorporated the costs of the intervention and the broader health and social care costs over the trial period.
Health and social care resource and HRQoL (measured using the EQ-5D-3L and SF-12) data were collected
through questionnaires at 3 and 6 months. Multiple imputation was used to impute missing data. For the
cost-effectiveness analysis, the incremental cost-effectiveness ratio was estimated as the difference between
trial groups in mean total cost divided by the difference in mean total QALYs.
Results
The Breathe trial was conducted between March 2013 and October 2016 across 51 hospitals. In total,
17,126 patients were screened, of whom 1752 underwent a SBT. A total of 432 patients failed the SBT
and were therefore eligible for the trial, of whom 68 declined participation and 364 (invasive weaning,
n = 182; non-invasive weaning, n = 182) were randomised.
Groups were well matched at baseline, in relation to demographics, diagnosis, ventilation/haemodynamic
characteristics and the SBT process. The mean age of participants was 63.1 years [standard deviation (SD)
14.8 years] and half were male (n = 184, 50.5%). The mean duration of ventilation prior to randomisation
was 5.8 days (SD 3.5 days). The two most common diagnoses were pneumonia/respiratory infection
(n = 130, 35.7%) and post-surgery respiratory failure (n = 78, 21.4%). The mean baseline PEEP was
6.2 cmH2O (SD 1.8 cmH2O) and PaCO2 was 5.7 kPa (SD 1.3 kPa). The most common SBT strategy was
CPAP with a mean duration of 47.4 minutes (SD 36.5 minutes). Tachypnoea and increased respiratory
effort were the most frequently cited reasons for SBT failure.
Treatment compliance was high in both groups (invasive weaning n = 158, 86.8%; non-invasive weaning
n = 175, 96.2%). Follow-up data at 3 and 6 months were available for 186 (51%) participants in the
invasive weaning group and 177 (49%) participants in the non-invasive weaning group.
For the primary outcome, the median time to liberation from ventilation was similar between groups
{invasive weaning 108 hours [interquartile range (IQR) 57–351 hours vs. non-invasive weaning 104.3 hours
(IQR 34.5– 297 hours); HR 1.10, 95% CI 0.89 to 1.39]. There was also no difference in mortality between
groups at any time point [e.g. 30-day mortality in the invasive weaning group was 86.3% (n = 157) vs. 86.8%
(n = 158) for the non-invasive weaning group; adjusted OR 0.90, 95% CI 0.51 to 1.73].
There was no difference in median total (non-invasive and invasive) ventilator days between groups
[invasive weaning 4 days (IQR 2–12 days) vs. non-invasive weaning 3 days (IQR 1–9 days); adjusted mean
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difference –2 days, 95% CI –4.61 to 0.69]. However, participants in the non-invasive weaning group had
fewer IMV days [invasive weaning 4 days (IQR 2–11 days) vs. non-invasive weaning 1 day (IQR 0–7 days);
adjusted mean difference –3.1 days, 95% CI –5.75 to –0.51]. In addition, fewer participants in the
non-invasive weaning group required antibiotics for a respiratory infection than participants in the invasive
weaning group (OR 0.60, 95% CI 0.41 to 1.00).
A higher proportion of participants in the non-invasive weaning group required reintubation than those in
the invasive weaning group (OR 2.00, 95% CI 1.27 to 3.24). The frequencies and types of AEs and SAEs
were similar between groups. Findings from subgroup and sensitivity analyses were similar to those from
the main analysis.
In the cost-effectiveness analysis, a complete QALY profile was available for 182 (50%) participants.
Between randomisation and hospital discharge, mean cost was similar between groups [invasive weaning
£32,052 vs. non-invasive weaning £29,697; mean difference –£2355, 95% CI –£7292 to £2750].
HRQoL outcomes were similar between groups. The within-trial economic evaluation showed that NIV
was associated with a lower net cost and a higher net effect and was dominant in health economic
terms; the probability that NIV was cost-effective was estimated at 0.58 at a cost-effectiveness threshold
of £20,000 per QALY.
Conclusions
Protocolised weaning that included early extubation to NIV did not reduce overall time to liberation from
ventilation. However, patients who underwent non-invasive weaning were less likely to require respiratory
antibiotics and had fewer days requiring IMV. The economic evaluation revealed that the non-invasive
weaning has some potential to be cost-effective.
In patients who fail a SBT, which factors predict an adverse outcome (reintubation, tracheostomy, death)
if extubated and weaned using NIV?
Trial registration
This trial is registered as ISRCTN15635197.
Funding
Funding for this study was provided by the HTA programme of the NIHR.
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Chapter 1 Introduction
Scientific background
The widespread use of positive-pressure ventilation in intensive care units (ICUs) can be traced back to
the polio epidemic in Denmark in 1952. Among a cohort of 316 patients admitted to hospital with polio
affecting the bulbar muscles, mortality fell from 80% to 23% following the introduction of early tracheostomy
and positive-pressure ventilation.1 The lack of mechanical ventilators at the time required teams of medical
students to work around the clock in shifts to provide positive-pressure ventilation manually. The demonstrated
life-saving potential of invasive positive-pressure ventilation led to an acceleration in the development of
mechanical ventilators and the birth of modern-day intensive care.2
Epidemiology of positive-pressure ventilation
Each year, an estimated 20 million people worldwide receive invasive mechanical ventilation (IMV).3 In the
UK, approximately 110,000 people require IMV annually.4 In a large cohort study, the main reasons for
requiring mechanical ventilation were acute respiratory failure (69%), coma (16%), acute exacerbation of
chronic lung disease (10%) and neuromuscular disease (2%). The causes of acute respiratory failure were
postoperative (20%), pneumonia (14%), congestive cardiac failure (10%), sepsis (9%), trauma (8%),
acute respiratory distress syndrome (4.5%) and other (12%).5,6 Reports from the Intensive Care National
Audit and Research Centre (ICNARC) indicate that the median duration of ventilation is 5 days [interquartile
range (IQR) 3–10 days] and the median length of stay on an ICU is 7 days (IQR 4–14 days).4 Patients spend,
on average, 17 days in hospital (IQR 9–31 days). Mortality during ICU admission has fallen over recent years
and is currently around 28%.5,6
Weaning from ventilation
Weaning is the process of liberating a patient from mechanical ventilation. It involves transferring the work
of breathing from the ventilator to the patient. Weaning accounts for 40–50% of the time a patient requires
positive-pressure ventilation.7 Strategies to optimise weaning should find a balance between withdrawing
ventilator support too early and unnecessarily prolonging ventilation. Premature withdrawal runs the risk of
reintubation, which is associated with prolonged hospital stay, increased costs, increased tracheostomy use
and increased mortality.8,9 By contrast, delayed weaning is associated with increased adverse effects, such as
ventilator-associated pneumonia (VAP),10,11 sinusitis,12 upper airway damage,13 respiratory muscle weakness13
and increased mortality.14,15 The requirement for sedative and muscle relaxant drugs during mechanical
ventilation may further contribute to delirium, immobility and generalised weakness.16 The observations that
10–15%7 of patients require reintubation during the weaning process and that almost half of patients with
an unplanned self-extubation during the weaning period do not require reintubation17 suggest that there is
scope for improvement in current weaning approaches.
Weaning involves several stages (Figure 1). After treating the underlying illness and ensuring that there are
no contraindications to weaning, a spontaneous breathing trial (SBT) is undertaken.7 During a SBT, minimal
support is provided from the ventilator and a combination of clinical and physiological measurements is
used to determine whether or not the patient can breathe unaided.
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Patients who ‘pass’ the SBT and are considered otherwise ready for extubation have their tube removed.
This group of patients, which represents two-thirds of mechanically ventilated patients, has a good
prognosis, with an ICU mortality of approximately 5%.7 The one-third of patients who ‘fail’ the SBT have a
reported mortality of 25–30%.7 Weaning practices after failing an initial SBT are variable. SBTs are often
repeated on a daily basis until either extubation or a tracheostomy is performed.
Non-invasive ventilation as an adjunct to weaning
Non-invasive ventilation (NIV) refers to the delivery of mechanical ventilation using a mask, nasal pillows,
helmet or mouthpiece interface instead of an endotracheal tube. Similar to IMV, NIV reduces the work of
breathing and can improve gas exchange.18 NIV may avoid some complications associated with prolonged
endotracheal intubation, such as VAP, sinusitis and ventilator-induced lung injury.19 In the context of
weaning, NIV has been used to facilitate early extubation, to prevent respiratory failure after extubation in
high-risk patients and as a rescue therapy when respiratory failure occurs following extubation.18
Existing knowledge
A Cochrane review examined the effectiveness of NIV for weaning from IMV across 16 randomised
controlled trials (RCTs) that recruited 994 patients.20 Nine trials enrolled only patients with chronic
obstructive pulmonary disease (COPD), whereas seven trials included mixed or non-COPD populations.
The review found strong evidence that weaning using NIV reduced mortality [risk ratio (RR) 0.53, 95%
confidence interval (CI) 0.36 to 0.80], although heterogeneity was moderate (I2 = 37%). The beneficial
effect seemed limited to studies that enrolled only patients with COPD (RR 0.36, 95% CI 0.24 to 0.56)
in contrast to the studies that enrolled mixed populations (RR 0.81, 95% CI 0.47 to 1.40). As shown in
Table 1, NIV in this context had a number of other benefits.
Need for a trial
The generalisability of the findings from the Cochrane review20 to current UK practice is limited. There are
four main reasons for this. First, the treatment pathway for an exacerbation of COPD has changed since
these early trials were conducted. Many patients who would have previously received IMV for respiratory
failure now have ward- or ICU-based NIV as a strategy to prevent the need for IMV.21 IMV is now reserved
mainly for patients who fail a trial of NIV. The population of patients ventilated for COPD in contemporary
UK practice therefore differs from that enrolled in trials ≥ 10 years ago. Second, none of the trials recruited
patients from the UK. This research team’s collaboration in the International Survey of Weaning practices
Treat ARF
Admission Discharge
Assess
readiness
Suspicion SBT
Extubation
FIGURE 1 Steps involved in liberating a patient from IMV. ARF, acute respiratory failure.
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shows marked differences in weaning practices between countries.22 Third, 3 out of the 12 studies
(comprising nearly 20% of patients) are either unpublished or published as abstracts only. This limits
assessment of methodological quality, and minimal information is available about the population recruited
and the interventions tested. Fourth, when it was possible to assess the methodological quality of index trials,
the quality of the methods was variable and eight trials had evidence of being at high risk of bias. There was
also variation in the methods used to identify patients for weaning (e.g. four trials used a unique resolution
of pulmonary infection criterion, which is rarely used in UK practice) and in the approaches to titration and
discontinuation of ventilator support.
Although the results of the Cochrane review20 are encouraging, the size and limitations of trials conducted
to date leave uncertainty as to the clinical effectiveness and cost-effectiveness of NIV as a routine tool to
facilitate weaning from mechanical ventilation. This is likely to explain the limited penetration of this
weaning approach into UK ICU practice. This topic is important to the intensive care community. The need
for additional trials in this area was identified by the Intensive Care Society during its Research Prioritisation
Exercise in 2008.23 With these considerations it was timely to conduct a well-designed, appropriately
powered randomised control trial (RCT) to examine the clinical effectiveness and cost-effectiveness of
NIV-facilitated weaning in the NHS.
The UK’s National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme
called for applications to examine the clinical effectiveness and cost-effectiveness of using NIV as an
intermediate step in weaning patients from IMV.
The objective of the trial was defined in the commissioning brief (Table 2).
The Breathe trial investigators were competitively selected to conduct a pragmatic, randomised, controlled,
open, multicentre, effectiveness trial to determine if the use of NIV as an intermediate step in the protocolised
weaning of patients from IMV is clinically effective and cost-effective.
TABLE 1 Effect of non-invasive weaning on clinically relevant outcomes
Outcome
Patient population
COPD Mixed
Weaning failure, RR (95% CI) 0.52 (0.36 to 0.74) 0.73 (0.35 to 1.51)
Nosocomial pneumonia, RR (95% CI) 0.22 (0.13 to 0.37) 0.38 (0.15 to 0.93)
Hospital LOS (days), mean difference (95% CI) –6.91 (–10.83 to –1.00) –4.02 (–9.41 to 1.36)
ICU LOS (days), mean difference (95% CI) –6.66 (–9.41 to –3.92) –3.32 (–6.78 to 0.15)
Average total duration of mechanical ventilatory support (days),
mean difference (95% CI)
–5.77 (–10.64 to –0.91) 0.17 (–4.01 to 4.35)
Duration of endotracheal mechanical ventilation (days),
mean difference (95% CI)
–7.53 (–11.47 to –3.60) –6.85 (–10.75 to –2.95)
Reintubation, RR (95% CI) 0.49 (0.35 to 0.70) 0.82 (0.47 to 1.43)
Tracheostomy, RR (95% CI) 0.04 (0.00 to 0.60) 0.23 (0.09 to 0.57)
Arrhythmia, RR (95% CI) 2.0 (0.20 to 19.78) 0.74 (0.26 to 2.17)
LOS, length of stay.
Note
Data were extracted from Burns et al.20
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TABLE 2 The NIHR HTA programme 10/134 commissioning brief
Research question What is the clinical effectiveness and cost-effectiveness of using NIV as an intermediate
step in weaning patients off IMV?
Technology NIV as an intermediate step in the protocolised weaning of patients off IMV
Patient group Patients with respiratory failure requiring IMV
Setting ICUs
Control/comparator treatment Protocolised weaning that does not include the use of NIV
Design RCT with internal pilot study. The pilot study should include clear continuation criteria,
including an assessment of the likelihood of satisfactory recruitment to the full trial
Important outcomes Reintubation rate, time from extubation to meeting discharge criteria, ventilator days,
cost-effectiveness. Other outcomes: adverse events, ICU LOS, mortality
Minimum follow-up 1 month
LOS, length of stay.
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Chapter 2 Methods and assessment
Trial summary
The Breathe trial was a pragmatic, randomised, controlled, open-label, multicentre, effectiveness trial to
determine if protocolised weaning that includes early extubation on to NIV is clinically effective and
cost-effective compared with weaning without NIV.
Patients with respiratory failure who had received IMV for > 48 hours (from the time of intubation) and
failed a SBT were randomised in a 1 : 1 ratio to either the invasive or the non-invasive weaning strategy.
Data were collected on patient demographic characteristics, mechanical ventilation and other relevant
variables relating to acute care. Variables required to determine health-related quality of life (HRQoL)
were sought from all surviving patients at 90 and 180 days after randomisation.
The primary effectiveness outcome was time from randomisation to successful liberation from ventilation.
Liberation from ventilation was defined as the time point at which the patient was free of ventilatory
(invasive or non-invasive) support for > 48 hours.
Secondary clinical outcome measures were mortality at 30, 90 and 180 days; duration of IMV and total
ventilator days (IMV and NIV); time to meeting ICU discharge criteria; proportion of patients receiving
antimicrobials for presumed respiratory infection and total days receiving antimicrobials; reintubation rates;
and the proportion of patients receiving a tracheostomy. Safety outcomes were adverse events (AEs) and
serious adverse events (SAEs). HRQoL was assessed by completion of the EuroQol-5 Dimensions, three-level
version (EQ-5D-3L), and Short Form questionnaire-12 items (SF-12) at baseline (estimated retrospectively),
and at 90 and 180 days.
The primary economic outcome was incremental cost per quality-adjusted life-year (QALY) gained from the
perspective of the NHS and Personal Social Services (PSS). Secondary economic outcomes were cost of ICU
stay (level 2 or 3 days), cost of hospital stay and utilisation of NHS and PSS resources after discharge.
A within-trial economic evaluation that covered the follow-up period of the RCT (to 180 days after
randomisation) and a modelling-based economic evaluation that extrapolated cost-effectiveness over a
lifetime time horizon were performed. Both were expressed in terms of incremental cost per QALY gained.
The trial was reviewed and approved by the Oxford C Research Ethics Committee (REC) (REC reference
number 12/SC/0515).
Eligibility criteria for participants
Adult patients in a participating ICU who had received IMV continuously for > 48 hours (from the time
of intubation) were assessed daily for their readiness to commence weaning. Readiness to wean was
assessed and declared by the treating clinician/ICU clinical team. The trial eligibility criteria are presented
in Box 1.
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Assessment of readiness to start weaning
The clinician with overall responsibility for managing the patient’s ICU treatment assessed the patient’s
readiness to start weaning and to undergo a SBT.
Clinicians were provided with information about the Walsh criteria, which were suggested as guidance to
indicate when the patient was ready commence weaning.24 The Walsh criteria recommend that all the
following conditions be met to indicate readiness for weaning:
l co-operative and pain free; good cough
l ratio of partial pressure of oxygen in arterial blood to fraction of inspired oxygen (PaO2 : FiO2 ratio)
of > 24 kPa
l positive end-expiratory pressure (PEEP) of < 10 cmH2O
l haemoglobin level of > 7 g/dl
l axillary temperature of 36.0–38.5 °C
l vasoactive drugs reduced or unchanged over previous 24 hours
l spontaneous ventilatory frequency of > 6 breaths per minute.
Patients who were judged to be ready to wean were established on pressure support (Psupp) ventilation. The
level of Psupp was titrated to achieve patient comfort, tidal volumes of 6–8 ml per kg of ideal body weight
and respiratory rate of < 30 breaths per minute. Once the patient was stable on Psupp ventilation for at least
60 minutes, a SBT was undertaken.
BOX 1 Eligibility criteria
Patients were eligible to be included in the trial if they met all of the
following criteria
l Aged ≥ 16 years.
l Respiratory failure requiring IMV for > 48 hours (from the time of intubation).
l Readiness to wean.
l Failed a SBT.
Patients were ineligible if one or more of the following criteria were met
l Known to be pregnant.
l Presence of tracheostomy.
l Unable to protect airway because of neurological deficit.
l Any absolute contraindication to NIV.
l Home ventilation prior to ICU admission (excluding nocturnal CPAP support).
l Decision not to reintubate or withdrawal of care anticipated.
l Further surgery/procedure requiring sedation planned in next 48 hours.
l Previous participation in the Breathe trial.
l Ventilator unavailable to deliver NIV.
CPAP, continuous positive airway pressure.
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Spontaneous breathing trial
A survey of practice identified that there were three main types of SBT used in the UK – a T-piece trial,
use of continuous positive airway pressure (CPAP) and low-level Psupp (5–7 cmH2O). A T-piece trial involves
the patient breathing spontaneously through their endotracheal tube, with the appropriate inspired oxygen
concentration being maintained by a crossflow device (T-piece). CPAP involves leaving a standing pressure
of 5–10 cmH2O, delivered via the ventilator, at the top of the endotracheal tube but with no assistance on
inspiration. Low-level Psupp provides minimal inspiratory assistance. Clinicians were able to undertake one of
these three types of SBT in accordance with local unit practices. The SBT was scheduled to last for at least
30 minutes and could be increased to up to 120 minutes in patients who were considered to be at higher
risk of reintubation (e.g. prolonged ventilation, past history of COPD, heart failure).
During the SBT, patients were closely monitored for signs of distress or fatigue as described by the International
Consensus Conference on Weaning (Box 2).25 A patient was considered to pass the SBT if no signs of distress
or fatigue developed. A patient who displayed any sign of distress or fatigue was judged to have failed the
SBT. These patients required further weaning and were potentially eligible to be enrolled in the Breathe trial.
Consent
The two-stage consent process adopted for the Breathe trial maximised patient involvement in the
decision-making process. It was developed with support from patient representatives and based on
national laws where the trial was being conducted.
First, whenever possible, the patient’s view on enrolment was sought. Owing to the presence of an
endotracheal tube, which limited communication, and likely recent exposure to sedative drugs, this process
consisted of briefly imparting information about the trial and inviting the patient to give a view on
participation. If the patient expressed a willingness to be involved or was unwilling to express an opinion,
then we proceeded to stage two.
BOX 2 Signs of distress/fatigue as described by the International Consensus Conference on Weaning
Physiological assessment
l Heart rate at ≥ 20% of baseline or > 140 beats per minute.
l Systolic blood pressure ≥ 20% of baseline or > 180 mmHg or < 90 mmHg.
l Cardiac arrhythmias.
l Respiratory rate of ≥ 50% of baseline value or > 35 breaths per minute.
l Respiratory rate (minutes)/tidal volume (l) of > 105 breaths per minute per litre.
¢ Arterial blood gases: PaO2 of < 8 kPa on FiO2 of ≥ 0.5 or SpO2 of < 90%.
¢ PaCO2 of > 6.5 kPa or an increase of > 1 kPa.
l pH of < 7.32 or a reduction in pH of > 0.07.
Clinical assessment
l Agitation and anxiety.
l Depressed mental status.
l Sweating/clammy.
l Cyanosis.
l Increased respiratory effort (i.e. accessory muscle use, facial distress, dyspnoea).
FiO2, fraction of inspired oxygen; PaCO2, partial pressure of carbon dioxide in arterial blood; PaO2, partial
pressure of oxygen in arterial blood; SpO2, saturation of oxygen in peripheral blood.
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In stage two, a full overview of the trial was provided to the patient’s (personal or professional) consultee.
The consultee was asked to express a view on what the patient would have decided if they had capacity to
make a decision.
Randomisation
Eligible patients were randomised by a web- or telephone-based secure electronic randomisation system.
Randomisation was minimised by centre, presence/absence of COPD and postoperative/non-operative
reason for ICU admission to ensure that there was an equal balance between treatment groups. Patients
were randomised to invasive or non-invasive weaning groups using a 1 : 1 allocation. The randomisation
procedure used variable block sizes to reduce the risk of selection bias. Moreover, all allocations remained
concealed prior to randomisation. The study flow diagram is shown in Figure 2.
Excluded
Ventilated for
< 48 hours
20%
randomised
after failing SBT Fail
Pass
80%
Follow up until
discharge.
Complete CRF 1
Ventilated admissions to 41 ICUs over
30 months
Daily screening for
eligibility
Consent
Assess for readiness to
wean
SBT
Randomised
(n = 364)
Protocolised NIV
weaning arm
(n = 182)
(n = 364)
(n = 1820)
(n = 24,000)
Available patient numbers
(n = 30,000)
Protocolised invasive
weaning arm
(n = 182)
Follow-up
ICU discharge
Hospital discharge
Follow-up
ICU discharge
Hospital discharge
Complete
CRFs 1 and 2
30% deaths in ICU
10% deaths between ICU and
hospital discharge
75% response rate from patients alive at
hospital discharge
60% response rate from patients alive at discharge
3 months 3 months
6 months 6 months
FIGURE 2 Flow diagram. CRF, case report form.
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Trial interventions
The health technology being assessed was the use of NIV as an adjunct to protocolised weaning compared
with protocolised weaning that does not include NIV, following a failed SBT.
Protocolised invasive weaning group
Participants randomised to the invasive weaning group were re-established on Psupp ventilation using the
settings that had been in place prior to undertaking the SBT. If necessary, the level of Psupp was titrated to
achieve patient comfort and a respiratory rate of < 30 breaths per minute. The participant was assessed for
signs of distress/fatigue every 2 hours. In the absence of distress/fatigue, Psupp was reduced by 2 cmH2O.
This cycle was repeated every 2 hours as tolerated. If, at any point, the participant developed signs of
distress/fatigue, then clinical teams sought to identify and treat non-ventilation-associated reversible causes.
When these did not lead to a reduction in distress/fatigue, the level of Psupp was increased by 2 cmH2O. The
fraction of inspired oxygen (FiO2) and PEEP were titrated to maintain saturation of oxygen in peripheral blood
(SpO2) of > 90%. This active weaning protocol was used between 08.00 and 22.00. Unless the participant
developed signs of distress/fatigue, ventilator settings were not changed overnight. A further SBT was
undertaken the next day. This cycle continued until either the participant was extubated (as a result of passing
the SBT) or a tracheostomy was performed.
If a participant continued to show signs of distress/fatigue despite increases to Psupp and the treatment of
any reversible causes, the weaning protocol could be temporarily discontinued and the ventilation strategy
determined by the treating clinician. The participant was reassessed at least daily for readiness to wean.
When the participant was ready to wean again, the weaning protocol was recommenced. The IMV weaning
protocol was discontinued after the participant was extubated.
Non-invasive weaning protocol
Participants randomised to the non-invasive weaning group were re-established on Psupp using the settings
that had been in place prior to undertaking the SBT. If necessary, the level of Psupp was titrated further
to achieve patient comfort and a respiratory rate of < 30 breaths per minute. When the participant had
recovered from the SBT (physiological parameters had returned to baseline and a clinician judged that they
were ready for extubation), they were extubated and immediately provided with NIV with an appropriate
level of inspiratory positive airway pressure and expiratory positive airway pressure (EPAP) to match the PEEP
and Psupp prior to extubation. The level of Psupp was titrated to achieve patient comfort and a respiratory rate
of < 30 breaths per minute. FiO2 and EPAP were titrated to maintain SpO2 of > 90%. The participant was
assessed for signs of distress/fatigue every 2 hours. In the absence of distress/fatigue, the treating clinician
either removed the NIV to allow a self-ventilation trial or reduced the level of Psupp by 2 cmH2O.
In the self-ventilation trial, supplemental oxygen (equivalent to the previous FiO2) was provided via a standard
oxygen mask and titrated as necessary to maintain SpO2 of > 90%.
If no signs of distress/fatigue developed during the self-ventilation trial, the trial was continued. If the participant
subsequently developed distress/fatigue, NIV was restarted.
If, at any time, the participant developed persistent signs of distress/fatigue/weaning failure, despite
increases in Psupp and treating any reversible causes, the clinician could temporarily or permanently suspend
the weaning protocol.
This active weaning protocol was used between 08.00 and 22.00. Ventilator settings were not changed
overnight unless the participant developed signs of fatigue/distress. The NIV weaning protocol was discontinued
when the participant tolerated 12 hours of unsupported spontaneous ventilation.
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Outcome measures
Primary outcome
The primary outcome measure was time (in hours) from randomisation to liberation from ventilation.
Liberation from ventilation was defined based on the International Consensus Conference on Weaning’s
recommendations7 as the time point following which the patient was free of ventilatory (invasive or
non-invasive) support for > 48 hours. This defined the duration of weaning process (randomisation to
liberation from ventilation).
Reintubation as a consequence of weaning failure generally occurs within the first 12–48 hours.26
Defining weaning success as being free from ventilator support for 48 hours from liberation of ventilation
captured weaning failures (requiring reintubation within 48 hours) but reduced confounding by late events
unrelated to the weaning process, such as the need for an unrelated surgical procedure or other event
requiring intubation and ventilation.
Secondary outcomes
Secondary outcome measures were:
Efficacy –
l mortality at 30, 90 and 180 days
l duration of IMV and total ventilator days (IMV and NIV)
l time (days) to meeting ICU discharge criteria
l proportion of participants receiving antibiotics for presumed respiratory infection and total of days
l reintubation (met criteria for reintubation and whether or not they were reintubated)
l tracheostomy.
Safety –
l AEs
l SAEs.
Patient-focused outcomes –
l HRQoL: EQ-5D-3L, SF-12 at baseline (estimated), and at 3 and 6 months.
Withdrawal of consent
Participants, their consultee (personal or professional) or the ICU consultant responsible for their care could
request withdrawal from the trial at any time without prejudice. In the event that the participant was withdrawn
during the protocolised weaning element of the trial, the clinician responsible for their care would determine
the safest and most appropriate way to continue the weaning process outside the trial protocol.
In the event of a request to withdraw from the trial, the researcher determined which elements of the trial
were to be withdrawn, from the following possibilities:
l the protocolised weaning intervention
l ongoing data collection during hospital admission
l confirmation of status at 30, 90 and 180 days
l contact for follow-up questionnaires.
If the participant requested withdrawal from all four elements, only anonymised data recorded up to the
point of withdrawal were included in the trial analysis.
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Standardised care protocols and assessments
Daily assessment of need for critical care
Participants were assessed daily (days 0–30) by the clinical team for their need for critical care. Patients are
classified as part of national data reporting arrangements in one of four categories.27 Patients who receive
level 0/1 care are classified as requiring ward-based care. Patients who receive level 2/3 care are classified
as requiring critical care support.
Level 0: patients whose needs can be met through normal ward care in an acute hospital.
Level 1: patients at risk of their condition deteriorating, or those recently relocated from higher levels of care,
whose needs can be met on an acute ward with additional advice and support from the critical care team.
Level 2: patients requiring more detailed observation or intervention, including support for a single failing
organ system or postoperative care, and those ‘stepping down’ from higher levels of care.
Level 3: patients requiring advanced respiratory support alone or basic respiratory support together with
support of at least one other organ system. This level includes all complex patients who require support for
multiorgan failure.
A participant was considered to have met ICU discharge criteria when they were discharged from the ICU or
they no longer required level 2 or level 3 care. This approach was chosen to overcome administrative delays
to discharge because of bed capacity issues in the hospital.
Daily assessment of sedation and organ support requirements
The number of sedative drugs administered to the participant in the preceding 24 hours and the number
of organs that required support were assessed daily by the clinical team. Organ support requirements
were assessed based on the critical care minimum data set definitions of the need for advanced or basic
cardiovascular support, advanced or basic respiratory support, and renal support.28
Antibiotic use
Whether or not antibiotics had been administered in the previous 24 hours was recorded daily. The clinical
team reported whether antibiotics were used primarily for a respiratory or non-respiratory infection. This
allowed the calculation of the proportion of participants requiring antibiotics for presumed respiratory
infection. In addition, total antibiotic usage (number of days) was calculated.
Criteria for reintubation
The decision to reintubate a participant was a clinical decision, made by the clinician responsible for the
participant at the time of assessment. The decision to reintubate or not was complex and included factors
outside the predefined reintubation criteria below (e.g. when a subsequent decision to limit treatment
was taken).
The following were recorded on a case report form (CRF): when a participant met the predefined reintubation
criteria and when they were actually reintubated.
Predefined reintubation criteria were any of the following:
l cardiac or respiratory arrest
l respiratory pauses with loss of consciousness or gasping for air
l severe psychomotor agitation inadequately controlled by sedation
l persistent inability to remove respiratory secretions
l heart rate of ≤ 50 or ≥ 140 beats per minute with loss of alertness
l haemodynamic instability, unresponsive to fluids and vasoactive drugs
l requirement for surgery or other interventional procedure that required deep sedation or anaesthesia.
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Criteria for tracheostomy
The decision about the timing of a tracheostomy rested with the treating clinician. It was suggested that a
tracheostomy may be considered after at least 7 days after the time of initial intubation. Indications for
tracheostomy were (1) persistent requirement for IMV, (2) inability to protect airway and (3) persistent
inability to remove respiratory secretions.
Standardised ventilation bundle
The Department of Health and Social Care’s (DHSC’s) High Impact Intervention: Care Bundle to Reduce
Ventilation-association Pneumonia29 mandates ICUs to have sedation protocols and protocols for VAP
prevention [head-up position, oral decontamination, sedation hold, peptic ulcer prophylaxis (drug or
enteral feeding)] in place. The team ensured that each site had relevant protocols in place.
Blinding
By the nature of the interventions, it was not possible to blind clinicians to whether a participant had been
randomised to the invasive or non-invasive treatment group. Careful consideration was given to the
strategies that were used to minimise the risk of bias as a consequence of this knowledge.
The use of secure electronic randomisation with a randomisation sequence of variable block size reduced
the risk of selection bias. The use of standardised adjunctive care bundles decreased the likelihood of
performance bias. The risk of detection bias was minimised by the use of protocols with clear, unambiguous
criteria for the discontinuation of IMV and NIV. Intensive care clinical charts provided contemporaneous,
hour-by-hour records of a participant’s physiology and current treatments. This enabled outcomes to be
verified by both site staff and the co-ordinating centre. On the rare occasions that a participant or their legal
representative chose to withdraw from the trial, their permission was sought to retain data collected up until
that point and to continue to collect the main outcome data. These approaches minimised the risk of attrition
bias. Source verification (from clinical records) and hospital computer records were used to minimise the risk
of reporting bias. The main clinical and resource utilisation outcomes of this trial [e.g. ventilation status
(hourly), death, level 2/3 care, AEs, antibiotic use] were recorded contemporaneously on patient clinical
records and hospital information systems.
Schedule of delivery of intervention and data collection
Trial assessments are summarised in Table 3. It was anticipated that, after randomisation, most participants
would be in the ICU for an average of 5–10 days, followed by a hospital stay of a similar duration.
Clinical data were recorded daily during a participant’s stay in the ICU. The only daily clinical data that
were collected after ICU discharge were antibiotic usage (for antibiotics started in ICU).
Data collection and management
All data for an individual participant were collected by each principal investigator or their delegated
nominees and recorded in the CRF. Participant identification in the CRF was through their unique participant
trial number, allocated at the time of randomisation, and their initials. Data were collected from the time a
participant was considered for entry into the trial through to their discharge from hospital. In the event that
a participant was transferred to another hospital, the trial team liaised with the receiving hospital to ensure
complete data collection.
Data were collected in duplicate using no-carbon-required forms. Once a participant had been discharged
from hospital and all data were entered into the CRF, the top copy of each form was returned to the trial
co-ordinating centre. The bottom copy of the CRF was retained at the recruiting centre. The trial number,
name, address and other contact details of all participants who survived and agreed to follow-up were supplied
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to the trial co-ordinating centre at the time of hospital discharge to allow follow-up questionnaires to be
posted to the participant at 3 and 6 months post intervention.
Submitted data were reviewed for completeness and entered onto a secure, backed-up, bespoke database.
Due care was taken to ensure data safety and integrity, and compliance with the Data Protection Act 1998.30
Data collection used instruments that had been optimised using data collection pilots before recruitment
started. Data collection was restricted to those variables required to define patient characteristics at
enrolment, to monitor the treatment received, to monitor adverse effects and to determine quality of life
and the use of health-care resources.
In brief, the data set included:
l variables describing baseline characteristics –
¢ participant identifiers
¢ inclusion and exclusion criteria
¢ Acute Physiology and Chronic Health Evaluation version II (APACHE II) score (24 hours after admission)
¢ admission diagnosis
¢ presence of COPD [defined by the British Thoracic Society/National Institute for Health and Care
Excellence (NICE) criteria or current treatment for COPD]
¢ measured or estimated height and weight, and calculated body mass index
¢ duration of ventilation prior to randomisation
¢ presence of delirium, as measured by the Confusion Assessment Method-Intensive Care Unit (CAM-ICU).
l variables collected daily from randomisation until discharge from ICU –
¢ ventilation status (IMV, NIV, self-ventilating)
¢ organ support requirements (defined by the mandatory DHSC Critical Care Minimum Data set)28
¢ level of ICU support required (level 0–3, for which 0 and 1 define readiness for ICU discharge)
¢ antibiotic use for respiratory and non-respiratory infections
¢ tracheostomy
¢ criteria met for reintubation and actual reintubation
¢ AEs
¢ deaths
¢ sedation use.
TABLE 3 Trial assessments
Assessment
Visit
Initial ICU stay Hospital stay 30 days 3 months 6 months
Informed consent ✓
Medical history ✓
Inclusion/exclusion criteria ✓
Intervention ✓ ✓
Clinical variables ✓ ✓ ✓
Quality of life/health economic outcomes ✓ ✓ ✓
AEs ✓ ✓ ✓
Survival status ✓ ✓ ✓ ✓ ✓
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l variables collected after ICU discharge –
¢ antibiotic use for respiratory and non-respiratory infections started within ICU
¢ acute hospital discharge date and status (to calculate acute hospital length of stay).
l variables collected after hospital discharge –
¢ vital status up to 180 days post randomisation
¢ EQ-5D-3L and SF-12 questionnaire at 3 and 6 months, after verification of vital status with
telephone follow-up for non-responders.
¢ Health-care resource use questionnaire at 3 and 6 months after verification of vital status with
telephone follow-up for non-responders.
Participant survival after discharge from hospital was determined by the trial office contacting a participant’s
general practice. This information was provided by the participant on the participant contact details form.
All survivors were followed up at 3 and 6 months after randomisation by postal questionnaire. The trial
office identified any deaths after discharge from hospital by calling a participant’s general practice first to
avoid sending questionnaires to participants who had died. Participants were asked to let the co-ordinating
centre know if they moved house at any time after hospital discharge. The follow-up questionnaire
collected data on disability and HRQoL, using the EQ-5D-3L and SF-12 questionnaires. If questionnaires
were not returned, a maximum of two telephone contacts were made to a participant to check that the
questionnaire had been received and that the participant was happy to complete it, followed by a second
copy of the questionnaire and telephone contacts in the event of non-return. If the second questionnaire
was not returned, the participant was contacted and the outcome data were collected over the telephone,
when possible.
Estimating baseline health-related quality of life
Owing to the challenges of collecting baseline data from very frail patients, these data were not collected
through patient questionnaires. However, assume a baseline utility score of –0.402 (the value assigned by
the EQ-5D-3L tariff to an unconscious health state) was assumed and this was considered to be the same
for each participant, regardless of underlying heterogeneity in health states.
Database
The database was set up by the Programming Team at Warwick Clinical Trials Unit (WCTU) and all
specifications (i.e. database variables, validation checks, screens) were agreed between the programmer,
statistician and trial co-ordinator. All data were entered by the data clerk and all data were periodically
reviewed by the trial co-ordinator to assure accuracy and consistency. Only authorised and approved
members of staff had access to the database.
Data storage
All essential documentation and trial records were stored by WCTU in conformance with the applicable
regulatory requirements and access to stored information was restricted to authorised personnel.
All available data can be obtained from the corresponding author.
Archiving
Trial documentation and data will be archived for 5 years after completion of the trial. Trial master files
and associated data were archived by WCTU; trial data generated at trial sites were archived in accordance
with local policy.
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Serious adverse events
A SAE was an AE that fulfilled one or more of the following criteria:
l resulted in death
l was immediately life-threatening
l required hospitalisation or prolongation of existing hospitalisation
l resulted in persistent or significant disability or incapacity
l was a congenital abnormality or birth defect
l any other important medical condition that, although not included in the above, required medical or
surgical intervention to prevent one of the outcomes listed.
The causality (i.e. relationship to trial treatment, Table 4) and expectedness (expected or unexpected) was
assessed by the investigator(s) and recorded on the SAE form.
Related and unexpected SAEs that occurred between trial entry and 30 days post randomisation were
reported using the mechanism described in Chapter 5, Measurement of resource use and costs.
Expected serious adverse events that did not require separate reporting
Because the Breathe trial was recruiting a population that was already in a life-threatening situation, it was
expected that many of the participants would experience SAEs. Events that were expected in this population
and those that were collected as outcomes of the trial were not reported as SAEs. These included:
l death
l organ failure
l pneumonia
l reintubation
l tracheostomy.
Reporting serious adverse events
All SAEs, as defined above, were entered onto the SAE reporting form and faxed to a dedicated fax at WCTU
within 24 hours of the investigator becoming aware of them. Once received, causality and expectedness were
confirmed by the chief investigator. SAEs that were deemed to be unexpected and related to the trial were
notified to the REC within 15 days. All such events were reported to the sponsor, Trial Steering Committee
(TSC) and Data Monitoring Committee (DMC) at their subsequent meetings.
TABLE 4 Relationship of SAEs to trial intervention
Relationship to trial
intervention Description
Unrelated There was no evidence of any causal relationship
Unlikely to be related There was little evidence to suggest that there was a causal relationship (e.g. the event did
not occur within a reasonable time after administration of the trial medication or device).
There was another reasonable explanation for the event (e.g. the participant’s clinical
condition, other concomitant treatment)
Possible relationship There was some evidence to suggest that there was a causal relationship (e.g. because the
event occurred within a reasonable time after administration of the trial medication or device).
However, the influence of other factors contributed to the event (e.g. the participant’s clinical
condition, other concomitant treatments)
Probable relationship There was evidence to suggest that there was a causal relationship and the influence of other
factors was unlikely
Definitely related There was clear evidence to suggest that there was a causal relationship and other possible
contributing factors can be ruled out
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All participants who experienced SAEs were followed up as per protocol until the end of the trial.
Adverse events
Participants were screened daily for the following AEs known to be associated with the use of NIV:
l nasal/skin/mouth sores/irritation
l vomiting
l gastric distension
l barotrauma (e.g. pneumothorax)
l non-respiratory infection
l arrhythmia.
Statistical methods
Power and sample size
The original sample size was set at 920 participants to detect a hazard ratio (HR) of 0.8 between the
intervention and control groups for the primary outcome with 80% power, allowing for time to discontinuation
of ventilation to be undefined for 30% of participants because of death in the ICU, and for 2% of participants
to have missing outcome data because of withdrawal from the trial. This equated to 36 fewer hours for the
intervention group in the time to liberation from ventilation, based on an average of 6.4 days in the standard
care group, drawn from a five-centre audit of weaning duration in the UK.
At the request of the Trial Management Group (TMG), the DMC and TSC reviewed the sample size
requirements 18 months into trial recruitment in the light of slower than anticipated recruitment. Analysis
of the duration of ventilation among participants in the control group revealed that the distribution of data
was skewed, indicating that the median duration of weaning, which was 2.9 days, would be a better
estimate for the sample size calculation.
Using a median value of 2.9 days and a minimally clinically important difference of 24 hours provided
an associated HR of 1.53. However, it was anticipated that the hazards may not be constant over time
(as assumed for the exponential distribution) and that the hazards were quite likely to decrease over time.
For this reason, a Weibull distribution was used, as it computes a shape parameter, p, that allows for
non-constant hazards. The p-value was estimated to be 0.918, thus giving a HR of 1.48.
Based on these data, a minimum sample size of 280 participants would provide 90% power to detect a
clinically meaningful median difference of 24 hours between the intervention and control groups for the
primary outcome at a 5% significance level. However, it was anticipated that around 23% of participants
would be lost to follow-up. The sample size (n = 280) was therefore inflated by 23% to allow for loss to
follow-up, resulting in a final sample size of 364 (n = 182 participants in each group).
The revised sample size was approved following review by the DMC, TSC and NIHR.
Primary analyses
Data were reported and summarised in accordance with the Consolidated Standards of Reporting Trials
(CONSORT) guidelines for RCTs.31 The primary analysis method for the trial was intention to treat, that is
all participants were analysed as part of the group to which they were originally randomised, regardless
of what treatment they actually received. Analysis of the primary outcome [time from randomisation to
liberation from ventilation (hours)] and other time-to-event outcomes used survival analysis methods to
estimate the HR and the associated 95% CI. Logistic regression models were used to estimate the odds
ratios (ORs) and 95% CIs for differences in mortality between the two trial groups at 30, 90 and 180 days.
Linear regression models were used to estimate the mean treatment difference and 95% CIs for
continuous outcomes. The distribution of count data, for example the number of days on advanced
METHODS AND ASSESSMENT
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respiratory support, could be either overdispersed with zero inflation, that is several participants with no
days on advanced respiratory support, or non-normal. For the former, negative binomial models were used
to estimate the incidence rate ratio (IRR) and the associated 95% CI; otherwise, non-parametric tests were
applied. All of the analyses were adjusted for age, sex, centre, post-SBT partial pressure of carbon dioxide
in arterial blood (PaCO2) and for both of the stratification variables (presence/absence of COPD and
whether or not the patient was being treated after surgery).
Sensitivity analyses
A per-protocol analysis was performed as a sensitivity analysis to see how the treatment effect estimate
differed when analysed by treatment received. Moreover, additional sensitivity analyses explored the
effects of adjustment for any potential baseline differences between the groups.
Subgroup analyses data set access
After data lock, all members of the trial team were able to access the final data set. The chief investigator
had full access to the trial data and assumed overall responsibility for the analysis.
Subgroup analyses
In the protocol, it was stated that three predefined subgroup analyses would be undertaken: (1) responsibility
for weaning processes (physician led/multiprofessional), (2) presence/absence of COPD and (3) postoperative/
non-operative. Of these, data on the first subgroup were not collected; thus, this subgroup analysis was not
conducted. Subgroup analyses were performed, for the primary outcome, by the inclusion of interaction
terms in the Cox regression models.
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Chapter 3 Trial organisation and oversight
Sponsor
The Heart of England NHS Foundation Trust and the University of Warwick acted as cosponsors for the
trial. Agreed responsibilities were subcontracted to the University of Warwick, as employer of the chief
investigator and co-ordinating centre for the trial.
Subcontracts that delegated responsibilities to research sites were established using the University of
Warwick’s standard contracting processes with NHS organisations.
Indemnity
NHS indemnity covered NHS staff, medical academic staff with honorary contracts and those conducting
the trial. NHS bodies carried this risk themselves or spread it through the Clinical Negligence Scheme for
Trusts,32 which provided unlimited cover for this risk.
The University of Warwick provided indemnity for any harm caused to patients by the design of the
research protocol.
Trial timetable and milestones
The trial timetable is displayed in Table 5. The first site opened within 3 months of initiating the grant and
all sites were open within 12 months. The internal pilot ran between 3 and 9 months from grant initiation.
Following successful confirmation of recruitment rates, the internal pilot ran seamlessly into the main trial.
Additional trial sites were recruited throughout the recruitment period. As most ICUs have the equipment
necessary to deliver NIV, this did not present a challenge.
Criteria for progression to the main trial
The following criteria were used to determine progression from the pilot to the main trial:
l recruitment > 75% of target (target 32 participants)
l protocol compliance (> 75%)
¢ daily sedation hold (yes/no)
¢ compliance with allocated intervention (IMV or NIV use)
¢ proportion of weaning time within relevant protocol (assessed daily)
¢ adherence with ventilator care bundle (yes/no)
l protocol compliance sent to the NIHR HTA programme.
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The progression criteria listed above were not met during the pilot phase. Recruitment was < 75% of the
target (17/32, 53%; see pilot trial recruitment graph in Figure 3) and protocol compliance was also lower
than the 75% target. However, the NIHR HTA programme acknowledged that proactive steps to boost
recruitment were in place and the trial question remained important. On this basis, it was recommended that
the trial progressed from the pilot phase to the main trial.
TABLE 5 Trial timetable
Trial stage
Project activity (months)
< 0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48
Set up
Recruit research staff ✓
Ethics approval ✓
Refine protocol ✓
Pilot trial
R&D approvals ✓ ✓ ✓
Sites open (n) 5 7
Participant recruitment ✓ ✓
3-month follow-up ✓ ✓
6-month follow-up ✓
Participant accrual
(pilot) (n)
11 32
Main trial
R&D approvals ✓ ✓ ✓
Sites open (n) 15 25 25 25 25 25 25 25 25 25
Participant recruitment ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
3-month follow-up ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
6-month follow-up ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Trial management/reporting
Data processing ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Data analysis ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
DMC meeting ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
TSC meeting ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Monitoring reports ✓ ✓ ✓ ✓ ✓ ✓ ✓
HTA monograph ✓ ✓
Other publications ✓ (protocol) ✓ ✓ ✓ ✓
Participant accrual
(pilot and main) (n)
11 32 77 190 302 415 527 640 752 865 977 1090
R&D, research and development.
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Administration
The trial was co-ordinated at WCTU. All day-to-day co-ordination of the trial was the responsibility of the
trial co-ordinator. All clinical co-ordination was the responsibility of the chief investigator. The trial was
managed by a multidisciplinary team.
The trial office team assisted with and facilitated the setting up of centres that wished to collaborate in the
trial. In addition, the trial office team:
l distributed the standardised data collection forms to collaborators
l organised the telephone randomisation service for formal trial entry
l monitored the collection and processing of data, and sought missing data
l trained local staff in recruitment processes and data collection
l ensured the confidentiality and security of all forms and data
l conducted extensive data-checking and cleaning
l organised any interim and main analyses
l organised TMG, TSC, DMC and collaborators’ meetings.
The trial office received completed data forms via the postal service. On receipt, data forms were checked
for completeness and entered into a trial-specific dedicated computer program that checked the validity of
the data.
Patient and public involvement
The Intensive Care Society’s Patients and Relatives Committee helped to ensure that the research question,
design, conduct and interpretation were considered from the users’ perspective. Patient and public
involvement in the trial was formally facilitated through the involvement of two representatives on the TSC
(a former patient and a relative).
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FIGURE 3 Pilot trial recruitment graph.
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Trial Management Group
The TMG met monthly. Meetings were minuted and a list of actions recorded.
Trial Steering Committee
The role of the TSC was to provide overall supervision for a trial on behalf of the trial sponsor and trial
funder and to ensure that the trial was conducted to the rigorous standards set out in the DHSC’s
Research Governance Framework for Health and Social Care33 and the Guidelines for Good Clinical
Practice (GCP).34 The TSC membership comprised independent clinicians, methodologists and two patient
and public involvement representatives.
The main tasks of the TSC were to:
l provide advice, through its chairperson, to the chief investigator(s), the trial sponsor, the trial funder,
the host institution and the contractor on all appropriate aspects of the trial
l monitor the progress of the trial, adherence to the protocol and participant safety, and to consider new
information of relevance to the research question
l ensure that the rights, safety and well-being of the trial participants were the most important
consideration and that they prevailed over the interests of science and society
l ensure that appropriate ethics and other approvals were obtained in line with the project plan
l agree proposals for substantial protocol amendments and to provide advice to the sponsor and funder
regarding approvals of such amendments
l provide advice to the investigators on all aspects of the trial.
The TSC adhered to the following guidelines:
l A minimum of 75% were independent members. Only appointed members were entitled to vote and
the chairperson had a casting vote.
l The minimum quoracy for a meeting to conduct business was 67% of appointed members.
l The chairperson and members signed and maintained a log of potential conflicts of interest.
l Attendance at TSC meetings by non-members was at the discretion of the chairperson. The primary
TSC reporting line was via the chairperson to the NIHR HTA programme director.
Data Monitoring and Ethics Committee
A DMC was appointed comprising two clinicians with experience in undertaking clinical trials and caring
for subjects who are critically ill and a statistician who was independent of the trial.
During the period of recruitment, interim analyses of the proportion of participants alive at 28 days and
analyses of deaths from all causes at 28 days were supplied, in strict confidence, to the DMC, along with
any other analyses that the committee requested. The intervals for these analyses were determined by
the committee.
The DMC advised the chairperson of the TSC if, in their view, the randomised comparisons had provided
(1) proof beyond reasonable doubt that for all, or some, the treatment was clearly indicated or clearly
contraindicated and (2) evidence that might reasonably be expected to materially influence future patient
management.
Following a report from the DMC, the TSC decided what actions, if any, were required. Unless the DMC
requested cessation of the trial, the TSC and the collaborators remained blinded to the interim results.
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Essential documentation
A trial master file was set up according to WCTU standard operating procedures and was held securely at
the co-ordinating centre.
Monitoring and quality assurance of trial procedures
Definitions
Trial protocol deviation
Deviations from clinical trial protocols and GCP occur commonly in clinical studies. The majority of these
instances are technical deviations that do not result in harm to the trial subjects or significantly affect the
scientific value of the reported results of the trial. These cases were documented in the protocol deviation
section of the CRF for the trial and appropriate corrective and preventative actions were taken. Deviations
were included and considered when the clinical study report was produced, as they may have had an impact
on the analysis of the data. A clinical decision to take the patient ‘off protocol’ (for the weaning protocol)
was recorded in the weaning log as opposed to a trial protocol deviation. Adherence with the weaning
regime was recorded in the CRF under the adherence section in the daily data record.
Serious breach
A serious breach was defined as any protocol deviation or breach of the principles of GCP in connection
with the Breathe trial that had a significant effect on the safety or physical or mental integrity of the
subjects or the scientific value of the trial.
Local monitoring of protocol compliance
The following elements, related to protocol compliance, were assessed daily and recorded on the CRF by a
member of the local research team:
l daily sedation hold (yes/no)
l compliance with allocated intervention (IMV or NIV use)
l proportion of weaning time within relevant protocol (assessed daily)
l adherence to ventilator care bundle (yes/no).
Monitoring
All sites were monitored by WCTU during the first few weeks after they were recruited. Monitoring sought
to ensure protocol compliance, quality of data collection and storage of documentation. Monitors had
access to relevant participant notes/charts and trial documentation. The primary purpose of the monitoring
visit was to ensure the safety of the trial participant and the integrity of the trial data. Monitoring visits were
conducted in a supportive manner with the objective of supporting centres in delivering the trial safely and
in accordance with the principles of GCP.
Participating institutions permitted trial-related monitoring, audits, REC review and regulatory inspections,
and provided direct access to source data/documents as required.
Reporting
Protocol deviations (and actions taken to prevent recurrence) were recorded in the CRF. Deviations from
the weaning protocol were recorded in the weaning log and daily data form.
Any serious breaches of the trial protocol or GCP were immediately reported to the chief investigator.
The chief investigator, in consultation with the principal investigator, took whatever immediate action was
required to safeguard the well-being of the participant.
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Financial support
Research costs
Research costs for this trial were funded by the NIHR HTA programme (project reference 10/124/06).
NHS service support costs
This trial was included on the NIHR portfolio and received NHS service support costs. NHS service support
costs were produced through the lead comprehensive local research network (CLRN) (West Midlands South
CLRN). The costing was based on their experience of similar trials in this setting and was calculated as
£79.65 per participant.
End of the trial
The trial ended when 364 participants had been randomised and the last participant had completed the
final follow-up (28 April 2017).
However, prior to reaching the trial target, it had been agreed that the trial would have been stopped
prematurely if:
l mandated by the REC
l following recommendations from the DMC
l funding for the trial ceased.
The REC that originally gave a favourable opinion of the trial would have been notified in writing if the
trial had been concluded or terminated early.
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Chapter 4 Results
Participant flow
The CONSORT flow diagram in Figure 4 details the overall flow of participants through the trial.
Recruitment
Recruitment for the overall trial (including the internal pilot trial) occurred between March 2013 and
October 2016, when 364 participants were recruited from across 51 hospitals (Figures 5 and 6). A total of
17,126 potential participants were identified through the screening process and were assessed for eligibility,
of whom 90% (15,374/17,126) were ineligible (see Figure 4). A breakdown of the screening process and
detailed reasons for exclusion are summarised by site in Appendix 1. The remaining 1752 patients underwent
a SBT, of whom 75% (1320/1752) passed the SBT and were thus excluded. Of the 432 eligible participants
who failed the SBT, 16% (68/432) declined to participate and the remaining 84% (364/432) consented to trial
participation and were thus randomised. There were no participants randomised in error. Most patients were
randomised between 11.00 and 16.00 (Figure 7). The proportion of randomised participants in each group
across all sites and also across the randomisation strata is detailed in Appendix 2. The three highest-recruiting
sites [Birmingham Heartlands Hospital (BHH), Queen Elizabeth Hospital, Birmingham (QEHB) and St Thomas’
Hospital, London (GST)] were part of the pilot trial and were therefore open for recruitment for the most time.
The screening logs (see Appendix 1) from these three sites had higher than average screening rates (n = 609,
n = 1838 and n = 1054 for BHH, QEHB and GST, respectively) than the centre average of 335. The proportion
of patients excluded after screening was lower than the 90% centre average at BHH (76%) and QEHB (88%).
The proportion of patients who underwent a SBT was higher than the centre average of 9% in BHH (24%)
in QEHB (12%) and in GST (10%), of whom 34%, 32% and 43%, respectively, of patients failed the SBT
(centre average 23%). The proportion of patients who failed the SBT and went on to be randomised was
higher than the centre average (81%) at two of these sites: BHH (100%) and GST (100%).
Participant baseline data
Participant baseline and demographic data
The baseline and demographic data of participants are summarised in Table 6. Overall, the characteristics of
the participants were well matched at baseline between the two treatment groups. Participants had a mean
age of around 63 years [standard deviation (SD) 14.8 years]. The proportion of males and females was similar.
Around 11% (40/364) had evidence of delirium. The risk of mortality was similar across both groups, with
participants having an overall mean APACHE II score of 18.9 (SD 6.4). Most admissions were diagnosed as
either pneumonia/respiratory infection (35.7%) or post-surgery respiratory failure (21.4%). The type of
diagnosis was similar across both groups, apart from pneumonia/respiratory infection, for which there was
around a 9% difference between the two groups (see Sensitivity analysis).
Participant baseline physiology data
The baseline physiology data of the trial participants are summarised in Table 7. The ventilation measures,
haemodynamic measures and arterial blood gas measures were similar across both treatment groups.
The distribution of participants’ PEEP, Psupp, PaO2 : FiO2 ratio and spontaneous tidal volume is shown in
Figure 8. Participants required high levels of ventilator support when the mean Psupp reported was
11.5 cmH2O (SD 4.8 cmH2O). The mean PaO2 : FiO2 ratio was 33.3 kPa (SD 10.4 kPa).
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Analysis
Follow-up completed at 3 months
(n = 91)
• Withdrawn from follow-up, n = 20
• Died, n = 43
• Lost to follow-up, n = 28
Follow-up completed at 6 months
(n = 84)
• Withdrawn from follow-up, n = 24
• Died, n = 47
• Lost to follow-up, n = 27
Analysed at primary end point
(N = 182)
• Participants liberated, n = 160
• Censored from analysis, n = 22
   • Withdrawn from follow-up, n = 2
   • Died, n = 19
   • Discharged without liberating and lost
      to follow-up, n = 1
Enrolment
Allocation
Follow-up
Allocated to IMV
(n = 182)
• Withdrawn from follow-up during
   inpatient stay, n = 3
• Died during inpatient stay, n = 34
Follow-up completed at 3 months
(n = 95)
• Withdrawn from follow-up, n = 17
• Died, n = 38
• Lost to follow-up, n = 32
Follow-up completed at 6 months
(n = 93)
• Withdrawn from follow-up, n = 23
• Died, n = 38
• Lost to follow-up, n = 28
Analysed at primary end point
(N = 182)
• Participants liberated, n = 159
• Censored from analysis, n = 23
   • Died, n = 22
   • Discharged without liberating and lost
      to follow-up, n = 1
Allocated to NIV
(n = 182)
• Withdrawn from follow-up during
   inpatient stay, n = 3
• Died during inpatient stay, n = 33
Assessed for eligibility
(n = 17,126)
Underwent
SBT
(n = 1752)
Randomised
(n = 364)
Underwent SBT but excluded
(n = 1388)
• Excluded as passed SBT, n = 1320
• Eligible but declined, n = 68
Ineligible
(n = 15,374)
• Aged < 16 years, n = 116
• Pregnant, n = 29
• Tracheostomy, n = 4002
• Neurological deficit, n = 2515
• Contraindication to NIV, n = 1066
• Home ventilation prior to ICU
   admission, n = 77
• Further surgery/procedure
   requiring sedation planned in
   next 48 hours, n = 79
• Previous participation in study,
   n = 22
• Withdrawal/died, n = 5311
• Other/unknown, n = 2157
FIGURE 4 The CONSORT flow diagram for the Breathe trial.
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TABLE 6 Baseline demographic data of the trial participants
Characteristic
Trial group
Total
(N= 364)
Invasive weaning
(N= 182)
Non-invasive
weaning (N= 182)
Age (years), mean (SD) 61.8 (15.8) 64.3 (13.6) 63.1 (14.8)
Sex (male), n (%) 94 (51.6) 90 (49.5) 184 (50.5)
Evidence of delirium (CAM-ICU result), n (%)
Positive 17 (9.3) 23 (12.6) 40 (11.0)
Negative 132 (72.5) 130 (71.5) 262 (72.0)
Missing 33 (18.2) 29 (15.9) 62 (17.0)
continued
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TABLE 6 Baseline demographic data of the trial participants (continued )
Characteristic
Trial group
Total
(N= 364)
Invasive weaning
(N= 182)
Non-invasive
weaning (N= 182)
Height (cm)
Mean (SD) 166.6 (10.7) 167.3 (10.5) 167.0 (10.6)
Missing (n) 4 4 8
Weight (kg)
Mean (SD) 76.7 (18.8) 78.7 (19.7) 77.7 (19.3)
Missing (n) 0 1 1
BMI (kg/m2)
Mean (SD) 27.7 (6.6) 28.2 (6.9) 28.0 (6.7)
Missing (n) 4 5 9
Type of NIV interface used, n (%)
Mask 1 (0.5) 174 (95.6) 175 (48.1)
Helmet 0 2 (1.1) 2 (0.5)
Not applicable 181 (99.5) 6 (3.3) 187 (51.4)
Duration of ventilation prior to randomisation (days),
mean (SD)
5.3 (3.0) 6.3 (3.8) 5.8 (3.5)
APACHE II score
Mean (SD) 18.8 (6.2) 18.9 (6.6) 18.9 (6.4)
Missing (n) 15 11 26
Diagnosis, n (%)
Pneumonia/respiratory infection 73 (40.1) 57 (31.3) 130 (35.7)
COPD/asthma exacerbation 7 (3.9) 7 (3.9) 14 (3.8)
Non-respiratory infection 21 (11.5) 16 (8.8) 37 (10.2)
Traumatic injuries 5 (2.8) 3 (1.6) 8 (2.2)
Post-surgery respiratory failure 39 (21.4) 39 (21.4) 78 (21.4)
GI bleed 3 (1.7) 7 (3.9) 10 (2.8)
Cardiac 18 (9.9) 27 (14.8) 45 (12.4)
Neuromuscular 8 (4.4) 7 (3.9) 15 (4.1)
Overdose 0 4 (2.2) 4 (1.1)
Pancreatitis 0 4 (2.2) 4 (1.1)
Stroke 1 (0.5) 0 1 (0.3)
Other 7 (3.8) 11 (6.0) 18 (4.9)
GI, gastrointestinal.
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TABLE 7 Baseline physiology data of the trial participants
SBT characteristics
Trial group
Total
(n= 364)
Invasive weaning
(n= 182)
Non-invasive
weaning (n= 182)
Ventilation
Exhaled minute volume (l per minute), mean (SD) 10.9 (3.6) 10.8 (3.9) 10.8 (3.8)
Total respiratory rate (breaths per minute), mean (SD) 22.5 (7.7) 22.1 (7.7) 22.3 (7.7)
PEEP (cmH2O), mean (SD) 6.2 (1.6) 6.3 (2.0) 6.2 (1.8)
Plateau pressure (cmH2O)
Mean (SD) 17.4 (5.4) 18.0 (4.7) 17.7 (5.1)
Missing (n) 1 3 4
Psupp (cmH2O)
Mean (SD) 11.3 (5.2) 11.7 (4.3) 11.5 (4.8)
Missing (n) 1 3 4
PaO2 : FiO2 ratio (kPa)
Mean (SD) 34.4 (11.3) 32.2 (9.2) 33.3 (10.4)
Missing (n) 1 1 2
Spontaneous tidal volume (ml/kg)
Mean (SD) 8.6 (3.3) 8.6 (3.7) 8.6 (3.5)
Missing (n) 4 4 8
Haemodynamics
Heart rate (beats per minute), mean (SD) 91.8 (19.8) 89.6 (18.9) 90.7 (19.3)
Systolic BP (mmHg), mean (SD) 135.0 (25.9) 137.7 (27.0) 136.4 (26.4)
Arterial blood gas
PaO2 (kPa)
Mean (SD) 11.2 (2.5) 11.0 (2.7) 11.1 (2.6)
Missing (n) 1 1 2
PaCO2 (kPa)
Mean (SD) 5.7 (1.4) 5.7 (1.2) 5.7 (1.3)
Missing (n) 1 2 3
FiO2
Mean (SD) 0.34 (0.07) 0.35 (0.08) 0.35 (0.07)
Missing (n) 0 1 1
pH
Mean (SD) 7.4 (0.06) 7.4 (0.06) 7.4 (0.06)
Missing (n) 5 7 12
H+ (nmol)
Mean (SD) 37.2 (2.9) 37.2 (2.0) 37.2 (2.3)
Missing (n) 177 176 353
Haemoglobin level (g/dl)
Mean (SD) 9.7 (1.7) 9.6 (1.6) 9.6 (1.7)
Missing (n) 1 1 2
BP, blood pressure.
DOI: 10.3310/hta23480 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 48
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Perkins et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
31
Pe
r 
ce
n
t
0 5 10 15 20
PEEP (cmH2O)
IMV
NIV
(a)
60
40
20
0
Trial group
Pressure support (cmH2O)
0 5 10 15 20 25
(b)
IMV
NIV
Pe
r 
ce
n
t
25
20
15
10
5
0
Trial group
0 20 40 60 80 100
PaO2 : FiO2 (kPa)
(c)
IMV
NIV
Pe
r 
ce
n
t
30
20
10
0
Trial group
FIGURE 8 Distribution of baseline physiology data by treatment group. (a) PEEP; (b) Psupp; (c) PaO2 : FiO2 ratio; and
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Participant baseline outcome measures
Participants who survived to hospital discharge were asked to rate their pre-admission quality of life. The
pre-admission quality-of-life measurements were similar across the two groups (Table 8).
Participant spontaneous breathing trial characteristics
Table 9 summarises the participants’ SBT characteristics along with reasons for failure. The majority of
participants had CPAP (51.1%) or Psupp (32.7%) as the type of SBT performed, with an overall mean SBT
duration of 47.4 minutes (SD 36.5 minutes). Most participants (73%) failed up to three of the criteria.
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FIGURE 8 Distribution of baseline physiology data by treatment group. (a) PEEP; (b) Psupp; (c) PaO2 : FiO2 ratio; and
(d) spontaneous tidal volume.
TABLE 8 Baseline health-related quality of life
Baseline measure
Trial group
Total
(N= 364)Invasive weaning (N= 182) Non-invasive (N= 182) weaning
EQ-5D-3L (prior to hospital admission)
n 120 120 240
Mean (SD) 0.67 (0.37) 0.66 (0.35) 0.67 (0.36)
Median (IQR) 0.75 (0.52–1) 0.8 (0.52–1) 0.78 (0.52–1)
EQ VAS (today)
n 119 115 234
Mean (SD) 58.7 (21.7) 60.8 (22.6) 59.7 (22.1)
Median (IQR) 60 (45–75) 60 (45–80) 60 (45–75)
SF-12 (mental)
n 112 105 217
Mean (SD) 42.9 (13.4) 44.0 (12.9) 43.4 (13.1)
SF-12 (physical)
n 112 105 217
Mean (SD) 37.3 (11.3) 37.2 (12.4) 37.2 (11.8)
EQ VAS, EuroQol visual analogue scale.
Note
The number of participants providing baseline summary data is low, primarily as a result of participants dying.
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TABLE 9 Summary of the participants’ SBT characteristics and reasons for failure
SBT charateristics
Trial group
Total
(N= 364)
Invasive weaning
(N= 182)
Non-invasive
weaning (N= 182)
Type of SBT performed, n (%)
T-piece 21 (11.5) 20 (11.0) 41 (11.3)
CPAP 94 (51.6) 92 (50.5) 186 (51.1)
Psupp 58 (31.9) 61 (33.5) 119 (32.7)
Missing 9 (5.0) 9 (5.0) 18 (4.9)
Duration of SBT (minutes)
Mean (SD) 46.3 (35.3) 48.5 (37.8) 47.4 (36.5)
Missing 6 6 12
Number of criteria failed, n (%)
1 37 (20.3) 32 (17.6) 69 (19.0)
2 42 (23.1) 56 (30.8) 98 (26.9)
3 49 (26.9) 48 (26.4) 97 (26.7)
4 24 (13.3) 18 (9.9) 42 (11.5)
5 18 (9.9) 15 (8.2) 33 (9.1)
6 6 (3.3) 8 (4.4) 14 (3.8)
7 3 (1.6) 4 (2.2) 7 (1.9)
8 3 (1.6) 1 (0.5) 4 (1.1)
Failed physiological assessments, n (%)
Heart rate of > 20% of baseline or > 140 beats per minute 56 (30.8) 34 (18.7) 90 (24.7)
Systolic blood pressure of > 20% of baseline or > 180mmHg
or < 90mmHg
55 (30.2) 65 (35.7) 120 (33.0)
Cardiac arrhythmias 4 (2.2) 5 (2.8) 9 (2.5)
Respiratory rate of ≥ 50% of baseline value or > 35 breaths
per minute
109 (60.0) 106 (58.2) 215 (59.1)
Respiratory rate (breaths per minute)/tidal volume (l) of
> 105 breaths per minute per l
30 (16.5) 23 (12.6) 53 (14.6)
Failed on arterial blood gases, n (%)
PaO2 of < 8 kPa on FiO2 of > 0.5 or SpO2 of < 90% 28 (15.4) 33 (18.1) 61 (16.8)
PaCO2 of > 6.5 kPa or increase by > 1 kPa 24 (13.2) 22 (12.1) 46 (12.6)
pH of < 7.32 or a reduction in pH of > 0.07 11 (6.0) 13 (7.1) 24 (6.6)
Failed clinical assessment, n (%)
Agitation and anxiety 76 (41.8) 79 (43.4) 155 (42.6)
Depressed mental status 12 (6.6) 3 (1.7) 15 (4.1)
Sweating/clammy 43 (23.6) 45 (24.7) 88 (24.2)
Cyanosis 3 (1.7) 1 (0.6) 4 (1.1)
Increased respiratory effort (accessory muscle use,
facial distress, dyspnoea)
84 (46.2) 90 (49.5) 174 (47.8)
Note
Patients can have multiple reasons for failing a SBT.
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Compliance with allocated treatment
Compliance was defined as whether or not a participant received their allocated intervention up to the
point of death, liberation, reintubation or tracheostomy (whichever came first). There was a high level of
compliance in both groups: 86.8% (158/182) of the participants in the IMV group and 96.2% (175/182)
in the NIV group received their allocated intervention after randomisation.
Participant follow-up
Mortality data were available on all participants at hospital discharge and, when possible, were collected
during follow-up. During the study, 51% (186/364) and 49% (177/364) of the participants provided
follow-up at 3 months and 6 months, respectively (see Figure 4). The proportion of participants providing
follow-up was similar in both groups at each time point.
Withdrawals
A summary of the withdrawals during the trial is provided in Table 10. A total of 12.9% (47/364) of the
participants withdrew completely, 0.6% (2/364) withdrew in the ICU/high-dependency unit (HDU) and
1.1% (4/364) withdrew while in hospital. Most participants were happy to provide data during their
inpatient stay but requested to withdraw completely from follow-up post hospital discharge; hence, 11.3%
(41/364) withdrew at follow-up. In addition, 1.9% (7/364) of the participants withdrew from intervention
only but remained in the trial. The different components of the trial from which participants withdrew
have been summarised in Table 11.
Outcomes and analyses
Primary outcome: time to liberation from ventilation
Table 12 presents a summary of the primary outcome data. The proportion of participants liberated from
ventilation was similar in both groups, with 87.9% (160/182) liberated in the invasive weaning group and
87.4% (159/182) liberated in the non-invasive weaning group. Moreover, there was no evidence of a
statistically significant difference in the number of hours from randomisation to liberation from ventilation
with an adjusted HR of 1.10 (95% CI 0.89 to 1.39). Figure 9 presents a Kaplan–Meier plot of the time to
liberation from ventilation summarised by treatment group. Figure 10 presents a Kaplan–Meier plot of time
to liberation from ventilation summarised by treatment group focused on days 0–30.
TABLE 10 Summary of withdrawals during the trial
Timing of withdrawal
Trial group, n (%)
Total, n (%)
(N= 364)
Invasive weaning
(N= 182)
Non-invasive
weaning (N= 182)
Withdrew from intervention only during inpatient stay 3 (1.7) 4 (2.2) 7 (1.9)
In ICU/HDU (from randomisation to ICU discharge) 2 (1.1) 0 2 (0.6)
In hospital (from ICU/HDU discharge to hospital discharge) 1 (0.6) 3 (1.7) 4 (1.1)
From hospital discharge to 3 months’ follow-up 17 (9.3) 14 (7.7) 31 (8.5)
3–6 months’ follow-up 4 (2.2) 6 (3.3) 10 (2.8)
HDU, high-dependency unit.
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Secondary outcomes
Mortality at 30, 90 and 180 days
There was no statistically significant difference in the participants’ mortality status at 30 days, 90 days and
180 days post randomisation (Table 13). The mortality status of participants at ICU discharge and hospital
discharge is also presented in Table 13.
Duration of invasive mechanical ventilation and total ventilation days
The duration of IMV was 3.1 days (95% CI 0.51 to 5.75 days) fewer in the non-invasive weaning group
than the invasive weaning group (Table 14). Figure 11 presents a box-and-whisker plot of the IMV days
and total ventilator days by treatment group.
TABLE 11 Details of withdrawal during inpatient stay
Withdrawn from Withdrawal decision made by
Trial group, n (%)
Total, n (%)
(N= 364)
Invasive weaning
(N= 182)
Non-invasive
weaning (N= 182)
The protocolised weaning
intervention
Participant 1 (0.5) 0 (0.0) 1 (0.3)
Personal consultee/next of kin 3 (1.6) 2 (1.1) 5 (1.4)
Clinical 2 (1.1) 2 (1.1) 4 (1.1)
Ongoing data collection
during hospital admission
Participant 1 (0.5) 3 (1.6) 4 (1.1)
Personal consultee/next of kin 2 (1.1) 0 (0.0) 2 (0.5)
Clinical 0 (0.0) 0 (0.0) 0 (0.0)
Confirmation of status at
30, 90 and 180 days
Participant 3 (1.6) 4 (2.2) 7 (1.9)
Personal consultee/next of kin 5 (2.7) 0 (0.0) 5 (1.4)
Clinical 0 (0.0) 0 (0.0) 0 (0.0)
Contact for follow-up
questionnaires
Participant 3 (1.6) 6 (3.3) 9 (2.5)
Personal consultee/next of kin 5 (2.7) 0 (0.0) 5 (1.4)
Clinical 0 (0.0) 0 (0.0) 0 (0.0)
Note
Participants could withdraw from one or more of the above.
TABLE 12 Summary of the primary outcome with estimated treatment effect
Number of hours from
randomisation to liberation
from ventilation
Trial group
Adjusted estimate (95% CI);
p-valuea
Invasive weaning
(N= 182)
Non-invasive
weaning (N= 182)
nb 182 182 HR 1.10 (0.89 to 1.39); 0.352
Median (IQR) 108 (57–351) 104.3 (34.5–297)
a Model adjusted for age, sex, centre, presence/absence of COPD, non-operative/operative and post-SBT PaCO2.
b Liberation status is missing for three participants. One participant moved to another hospital that was not a participating
site; therefore, this information could not be collected. The other two participants withdrew from the study completely;
hence, these data were not collected.
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FIGURE 9 Kaplan–Meier curve of the time to liberation from ventilation by treatment group.
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FIGURE 10 Kaplan–Meier curve of the time to liberation from ventilation by treatment group, focused on
days 0–30.
TABLE 13 Mortality at 30, 90 and 180 days
Mortality
Trial group, n (%)
Adjusted OR (95% CI);
p-valueInvasive weaning (N= 182) Non-invasive weaning (N= 182)
30 days 157 (86.3) 158 (86.8) 0.90 (0.51 to 1.73); 0.856
90 days 137 (75.3) 142 (78.0) 0.80 (0.49 to 1.33); 0.393
180 days 134 (73.1) 142 (78.0) 0.70 (0.44 to 1.18); 0.189
ICU discharge 157 (86.3) 160 (87.9) 0.90 (0.48 to 1.70); 0.764
Hospital discharge 146 (80.2) 147 (80.8) 0.90 (0.54 to 1.58); 0.776
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Antibiotics for respiratory infection and total antibiotic usage
Figure 12 presents a summary of the proportion of participants that required respiratory antibiotics as well
as details of the total number of days of respiratory and non-respiratory antibiotic usage. A lower proportion
of participants required respiratory antibiotics (OR 0.60, 95% CI 0.41 to 1.00) in the non-invasive weaning
group compared with the invasive weaning group. There was no difference between the two groups in
the total (respiratory and non-respiratory) number of days that antibiotics were used (IRR 0.90, 95% CI
0.68 to 1.08).
Reintubation and tracheostomy
There was a statistically significant difference in reintubation rates between the two groups (Figure 13) in
which participants in the non-invasive weaning group were twice as likely to be reintubated at any time
(OR 2.00, 95% CI 1.27 to 3.24). There was no difference in the tracheostomy rates between the two
groups (OR 0.70, 95% CI 0.44 to 1.15).
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FIGURE 11 Box-and-whisker plots of IMV days and total ventilator days by treatment group. (a) IMV days; and
(b) total ventilator days.
TABLE 14 Summary of the duration of IMV and total ventilator days
Outcome
Trial group
Adjusted IRR estimate
(95% CI); p-valuea
Adjusted mean difference
(95% CI); p-value
Invasive weaning
(n= 182)
Non-invasive
weaning (n= 182)
Number of days on IMV
Mean (SD) 9.1 (13.6) 6.0 (11.5) 0.6 (0.47 to 0.87); 0.005 –3.1 (–5.75 to –0.51); 0.019
Median (IQR) 4 (2–11) 1 (0–7)
Total ventilator days (IMV and NIV)
Mean (SD) 9.6 (13.8) 7.7 (11.5) 0.8 (0.62 to 1.00); 0.049 –2.0 (–4.61 to 0.69); 0.146
Median (IQR) 4 (2–12) 3 (1–9)
a Model adjusted for age, sex, centre, presence/absence of COPD, non-operative/operative and post-SBT PaCO2.
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Time to meeting intensive care unit discharge criteria
The length of time (in days) until meeting ICU discharge criteria was similar between both groups (HR 1.10,
95% CI 0.91 to 1.42). Figure 14 presents a Kaplan–Meier plot of the time to meeting discharge criteria.
Process variables
A number of process variables were explored to provide a richer understanding of the weaning process and
to enable the findings of the Breathe trial to be incorporated into future meta-analyses. This included time
to extubation, sedative use, duration of organ support, duration of critical care stay and weaning failure.
Time to extubation
As expected, there is evidence of a significant difference in the time (days) from randomisation to
extubation (HR 2.50, 95% CI 1.99 to 3.12): participants had a median time of 0.5 days (IQR 0.5–1 day)
in the NIV group compared with a median time of 3 days (IQR 2–10 days) in the IMV group. Figure 15
presents a Kaplan–Meier plot for the time to being extubated.
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FIGURE 13 Reintubation and tracheostomy rates summarised by treatment group.
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FIGURE 12 Respiratory antibiotic and total antibiotic usage summarised by treatment group. (a) Respiratory
antibiotic usage; and (b) total number of days of antibiotic usage.
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Sedative use, support/organ monitoring and care status
Table 15 presents a summary of the participants’ sedative use, support/organ monitoring and care status
by treatment group. Compared with the invasive weaning group, participants in the non-invasive weaning
group required fewer days on one or more class of sedative (IRR 0.7, 95% CI 0.60 to 0.90), fewer days on
advanced respiratory support (IRR 0.7, 95% CI 0.51 to 0.90) and more days on basic respiratory support
(IRR 1.3, 95% CI 1.04 to 1.51). There was no difference between the two groups in the number of days
on advanced cardiovascular support, basic cardiovascular support or renal support. There was evidence of
a significant difference in the number of days participants required level 2/3 care with participants in the
non-invasive weaning group requiring fewer days of level 2/3 care than those in the invasive weaning
group (p = 0.024).
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FIGURE 15 Kaplan–Meier curve for the time from randomisation to extubation.
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FIGURE 14 Kaplan–Meier plot of the time to meeting discharge criteria.
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Weaning failure
Weaning failure, which was defined as reintubation within 48 hours of extubation, or as death (day 0–7),
tracheostomy (day 0–7) or on IMV (on day 7), has been summarised in Table 16. There was no evidence of
a difference between the two groups for either definition of weaning failure.
Reintubation
The median time from randomisation to reintubation was significantly shorter (p < 0.001) in the non-invasive
weaning group than in the invasive weaning group (Table 17) [invasive weaning, 3.2 days (IQR 2.3–4.7 days),
vs. non-invasive weaning, 2 days (IQR 0.9–3.0 days)]. There was no difference in the final outcome of those
participants who were reintubated.
TABLE 15 Summary of sedative use, support/organ monitoring data and care status
Outcomes
Trial group
Adjusted IRR estimate
(95% CI); p-valuea
Invasive weaning
(n= 182)
Non-invasive weaning
(n= 182)
Number of days participant on one or more class of sedative
Mean (SD) 5.5 (5.1) 4.1 (5.0) 0.7 (0.60 to 0.90); 0.003
Median (IQR) 3 (2–8) 2 (1–5)
Number of days participant on advanced respiratory support
Mean (SD) 9.4 (13.7) 6.5 (11.7) 0.7 (0.51 to 0.90); 0.007
Median (IQR) 4 (2–13) 1 (0– 7)
Number of days participant on basic respiratory support
Mean (SD) 4.1 (4.5) 5.3 (5.6) 1.3 (1.04 to 1.51); 0.019
Median (IQR) 3 (1–6) 4 (2–7)
Number of days participant on advanced cardiovascular support
Mean (SD) 1.1 (3.1) 0.6 (1.6) 0.6 (0.30 to 1.07); 0.081
Median (IQR) 0 (0–0) 0 (0–0)
Number of days participant on basic cardiovascular support
Mean (SD) 11.3 (13.0) 10.0 (10.8) 0.9 (0.71 to 1.04); 0.129
Median (IQR) 7 (5–14) 6.5 (4–13)
Number of days participant on renal support
Mean (SD) 2.1 (8.1) 1.7 (5.2) 1.0 (0.45 to 2.06); 0.919
Median (IQR) 0 (0–0) 0 (0–0)
Number of days participant at care level 2 or 3
Mean (SD) 12.2 (8.4) 10.8 (8.8) 0.024
Median (IQR) 10 (5–17) 7.5 (4–14)
a A negative binomial model was used to estimate the adjusted IRR effect sizes; otherwise, only the p-value is presented from
a non-parametric Wilcoxon rank-sum test. Model adjusted for age, sex, centre, presence/absence of COPD, non-operative/
operative and post-SBT PaCO2.
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Intensive care unit/high-dependency unit and hospital discharge data
Table 18 presents a summary of the ICU/HDU and hospital discharge data. There were no differences
found in the discharge data between the two groups. Approximately 87% of the participants were
discharged alive from ICU/HDU, most of whom were discharged to a ward. Approximately 80% of the
participants were discharged alive from hospital, with most (74%) of the participants returning home.
Adverse events
The AE data have been detailed in Table 19. Approximately 25% of the participants in each group
experienced a new AE during their ICU stay. There was no difference between the two groups in the
number of days for which new AEs were reported or in the type of event reported.
Serious adverse events
The SAEs reported during the trial have been detailed in Table 20. In total, 42 SAEs were reported: 16 in
the invasive weaning group and 26 in the non-invasive weaning group. Most of the reported SAEs were
unrelated to the trial intervention.
TABLE 16 Summary of weaning failure by treatment group
Outcome
Trial group, n (%)
Adjusted OR estimate
(95% CI); p-valueaInvasive weaning (N= 182) Non-invasive weaning (N= 182)
Weaning failure: reintubation within 48 hours of extubation
No 174 (95.6) 165 (90.7) 2.30 (0.96 to 5.61); 0.063
Yes 8 (4.4) 17 (9.3)
Weaning failure: death (day 0–7), tracheostomy (day 0–7) or on IMV (on day 7)
No 109 (89.9) 123 (67.6) 0.70 (0.48 to 1.13); 0.163
Yes 73 (40.1) 59 (32.4)
a Model adjusted for age, sex, centre, presence/absence of COPD, non-operative/operative and post-SBT PaCO2.
TABLE 17 Summary of the time to reintubation and final outcome of those reintubated
Outcome
Trial group
Adjusted estimate
(95% CI); p-valueaInvasive weaning (N= 182) Non-invasive weaning (N= 182)
Time from randomisation to reintubation (days)
n 42 68 < 0.001
Mean (SD) 4.0 (3.0) 2.7 (2.7)
Median (IQR) 3.2 (2.3–4.7) 2 (0.9–3.0)
Final outcome of those reintubated, n (%)
Liberated 34 (80.9) 51 (75.0) OR 1.40 (0.43 to 4.26); 0.601
Died 6 (14.3) 16 (23.5)
Missing 2 (4.8) 1 (1.5)
a Model adjusted for age, sex, centre, presence/absence of COPD, non-operative/operative and post-SBT PaCO2. Only a
p-value is presented from a non-parametric Wilcoxon rank-sum test when data are non-normal.
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TABLE 18 Summary of ICU/HDU and hospital discharge data
Outcomes
Trial group
p-valuea
Invasive weaning
(N= 182)
Non-invasive
weaning (N= 182)
Discharged alive from ICU/HDU (yes), n (%) 157 (86.3) 160 (87.9) 0.842
Discharged location from ICU, n (%)
Ward 150 (95.5) 153 (95.6) 0.246
Other critical care facility 3 (1.9) 6 (3.8)
Other 4 (2.6) 1 (0.6)
Discharged alive from hospital (yes), n (%) 145 (79.7) 146 (80.2) 0.896
Discharged location from hospital, n (%)
Home 108 (74.5) 108 (72.6) 0.231
Rehabilitation 8 (5.5) 8 (5.5)
Other 9 (6.2) 3 (2.0)
Nursing/residential home 4 (2.8) 10 (6.9)
Another hospital 16 (11.0) 18 (12.3)
Time from ICU admission to hospital discharge (days)
n 145 146 0.558
Mean (SD) 41.0 (39.9) 40.8 (28.6)
Median (IQR) 31.9 (18.9–31.9) 32.6 (21.9–51.8)
a The p-value was computed using either the chi-squared test or the Fisher’s exact test for categorical data and the Wilcoxon
rank-sum test for continuous non-normal data.
TABLE 19 Summary of new adverse events reported
Outcomes
Trial group
Adjusted estimate (95% CI);
p-valuea
Invasive weaning
(N= 182)
Non-invasive
weaning (N= 182)
Number of days new AEs reported
Mean (SD) 0.5 (1.2) 0.6 (1.4) IRR 1.20 (0.71 to 1.92); 0.538
Median (IQR) 0 (0–1) 0 (0–0)
Participant experienced new AE (yes),
n (%)
47 (25.8) 45 (24.7) OR 0.90 (0.57 to 1.49); 0.739
Type of new AE reported, n (%)b
Nasal/skin/mouth sores/irritation 14 (7.7) 19 (10.4) OR 1.30 (0.64 to 2.82); 0.433
Vomiting 8 (4.4) 14 (7.7) OR 1.90 (0.76 to 4.62); 0.173
Gastric distension 6 (3.3) 7 (3.9) OR 1.00 (0.32 to 3.25); 0.964
Barotrauma (e.g. pneumothorax) 3 (1.7) 3 (1.7) OR 1.40 (0.25 to 7.43); 0.725
Non-respiratory infection 12 (6.6) 11 (6.0) OR 0.80 (0.35 to 2.00); 0.691
Arrhythmia 22 (12.1) 14 (7.7) OR 0.60 (0.29 to 1.22); 0.156
a The model was adjusted for age, sex, centre, presence/absence of COPD, non-operative/operative and post-SBT PaCO2.
b Each type of AE has been summarised separately for all participants, as participants can report one or more new AE types.
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Health-related quality of life
A summary of the HRQoL of participants at follow-up is presented in Table 21. There were no differences
found between the two groups in terms of their reported quality of life.
Subgroup analyses
The results of the prespecified (i.e. COPD status and operative status) and exploratory (i.e. site and Psupp)
subgroup analyses are presented in Table 22. None of the explored subgroups showed evidence of a
moderating treatment effect.
TABLE 20 Summary of SAEs reported
Outcomes
Trial group, n (%)
Invasive weaning Non-invasive weaning
Events (N= 16) Events (N= 26)
Event type
Death 3 (18.8) 5 (19.2)
Life-threatening 8 (50.0) 13 (50.0)
Hospitalisation or prolongation of existing hospitalisation 10 (62.5) 10 (38.5)
Persistent or significant disability/incapacity 1 (6.3) 2 (7.7)
Congenital anomaly/birth defect 0 (0.0) 0 (0.0)
Other reason 2 (12.5) 4 (15.4)
Event related to trial intervention (in the opinion of the reporting clinician)
Definitely 1 (6.3) 0 (0.0)
Probably 0 (0.0) 0 (0.0)
Possibly 0 (0.0) 4 (15.4)
Unlikely 2 (12.5) 6 (23.1)
Unrelated 10 (62.5) 16 (61.5)
Missing 3 (18.7) 0 (0.0)
Event expectedness
Expected 1 (6.2) 1 (3.9)
Unexpected 0 (0.0) 3 (11.5)
Not applicable 15 (93.8) 22 (84.6)
Outcome of event
Resolved – no sequelae 6 (37.6) 10 (38.5)
Resolved – with sequelae 4 (25.0) 3 (11.5)
Unresolved 3 (18.7) 4 (15.4)
Death 3 (18.8) 9 (34.6)
RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
44
TABLE 21 Summary of the HRQoL data
Outcomes
Trial group
Adjusted estimate
(95% CI); p-valueaInvasive weaning (N= 182) Non-invasive weaning (N= 182)
EQ-5D-3L change
Baseline to 3 months
n 81 81 0.01 (–0.12 to 0.14); 0.920
Mean (SD) 0.13 (0.40) 0.14 (0.42)
Baseline to 6 months
n 74 81 0.08 (–0.05 to 0.21); 0.215
Mean (SD) 0.04 (0.38) 0.14 (0.40)
EQ VAS
3 months
n 91 92 –0.5 (–6.77 to 5.84); 0.885
Mean (SD) 62.5 (20.2) 60.9 (20.0)
6 months
n 82 91 –2.8 (–9.45 to 3.93); 0.417
Mean (SD) 65.0 (21.2) 61.7 (22.4)
SF-12 (mental)
3 months
n 80 82 –1.0 (–4.92 to 2.83); 0.594
Mean (SD) 45.8 (10.9) 43.8 (12.6)
6 months
n 75 84 –0.3 (–4.62 to 4.00); 0.888
Mean (SD) 45.4 (13.3) 44.7 (12.1)
SF-12 (physical)
3 months
n 80 82 –0.4 (–3.81 to 3.01); 0.815
Mean (SD) 33.7 (9.7) 33.4 (10.3)
6 months
n 75 84 –1.3 (–4.95 to 2.43); 0.499
Mean (SD) 37.0 (10.4) 35.5 (11.6)
EQ VAS, EuroQol visual analogue scale.
a Model adjusted for age, sex, centre, presence/absence of COPD, non-operative/operative and post-SBT PaCO2.
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Sensitivity analysis
Adjustment for baseline pneumonia
There was some indication of a difference between the two groups in the number of participants diagnosed
with pneumonia/respiratory infection at baseline. A sensitivity analysis was undertaken but no difference
was found (HR 1.10, 95% CI 0.88 to 1.38).
Per-protocol analysis
A per-protocol sensitivity analysis was undertaken to estimate the treatment effect, having excluded
protocol violators, to see if the treatment effect estimates differed from the primary analysis results. The
results of the sensitivity analysis were similar to those of the primary analysis results, which suggested that
there was no difference between the two groups (HR 1.10, 95% CI 0.89 to 1.43).
TABLE 22 Subgroup analyses results
Subgroups
Trial group, n; median (IQR) Effect (95% CI); p-valuea
Invasive weaning
Non-invasive
weaning
Within-group
treatment Interaction
COPD status
Absence of
COPD
150; 108 (57.9–322.3) 151; 91 (34–301.7) HR 1.10 (0.85 to 1.39);
0.517
HR 1.20 (0.63 to 2.12);
0.640
Presence of
COPD
32; 128 (38–442) 31; 107.6 (45.7–269) HR 1.40 (0.78 to 2.59);
0.252
Operative status
Non-operative 126; 156.2 (58.5–416) 126; 111.5 (41–276) HR 1.20 (0.94 to 1.64);
0.124
HR 0.70 (0.45 to 1.21);
0.231
Postoperative 56; 85.5 (35.4–255.5) 56; 57 (18.5–442) HR 1.00 (0.63 to 1.44);
0.816
Three main sites vs. other
Three main sites 82; 128 (40–273) 79; 83 (32–297) HR 1.00 (0.73 to 1.44);
0.899
HR 1.20 (0.76 to 1.87);
0.438
Other 100; 108 (59.7–472.6) 103; 107 (35–301.7) HR 1.20 (0.89 to 1.64);
0.218
Psupp (cmH2O)
< 10 63; 79 (38–259) 52; 42 (18–320) HR 1.10 (0.73 to 1.62);
0.674
HR 1.10 (0.67 to 1.76);
0.731
≥ 10 118; 174 (58–370) 127; 125 (54–297) HR 1.10 (0.84 to 1.47);
0.443
a Model adjusted for age, sex, centre, presence/absence of COPD, non-operative/operative and post-SBT PaCO2.
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Chapter 5 Economic evaluation
Overview of the economic evaluation
This prospective economic evaluation was conducted alongside a pragmatic, randomised, controlled,
open, multicentre, effectiveness trial (Breathe RCT) with the objective of estimating the cost-effectiveness
of IMV using protocolised weaning that includes NIV as an intermediate step compared with protocolised
weaning without NIV. Patients with respiratory failure who received IMV for > 48 hours (from the time of
intubation) and failed a SBT were randomised in a 1 : 1 ratio to either the invasive or the non-invasive
weaning strategy. The economic evaluation took the form of a cost–utility analysis, expressed in terms
of incremental cost per QALY gained. The primary analysis is based on both a NHS and PSS perspective as
recommended by NICE, and excludes costs borne by sectors of the economy other than the health and
social service sectors, and costs borne by trial participants and their families/informal carers.35 Costs are
expressed in Great British pounds (GBP) (2015–16 prices). A sensitivity analysis was conducted to
recalculate cost-effectiveness from a societal perspective.
Measurement of resource use and costs
The incremental costs associated with the NIV strategy were determined through a comprehensive strategy
that encompassed two strands of research: (1) estimation of costs associated with the delivery of the
intervention and (2) estimation of broader health and PSS resource inputs and costs.
Resource use associated with non-invasive ventilation (intervention)
A specific focus of the economic evaluation was the assessment of hospital resource inputs associated
with delivering the NIV intervention. This was based on data associated with ICU-related length of stay
for organ support (advanced or basic cardiovascular or respiratory support, renal support, dermatological
support, antimicrobial use, whether respiratory or non-respiratory) collected from randomisation on a daily
basis for the first 30 days during a participant’s stay in ICU. In addition, daily data on the highest level
of care (levels 0, 1, 2 or 3) over each 24-hour period over the first 30 days during the ICU stay and on use
of antibiotics, sedatives and antiviral medications were collected. Similarly, hospital resource use data were
also collected beyond the first 30 days, including the nature of respiratory support (advanced or basic),
renal support, dermatological support and antimicrobial use (respiratory or non-respiratory) up to ICU
discharge. Furthermore, data on the length and intensity of hospital stay, post ICU discharge until final
hospital discharge, were collected; details of hospital transfers between the hospital at randomisation and
other hospitals (or residence) were also included. Information on the use of high-cost medications was
collected on a daily basis.
Collection of broader resource use data
Health and social service resource use data were collected at 3 and 6 months post randomisation, using
self-completed postal questionnaires. Postal reminders were sent to non-responders and, when required,
further telephone contacts when made to encourage the return of questionnaires or to request the completion
of missing data. The postal questionnaires provided details on the frequency and duration of use of hospital
inpatient care (including readmissions), hospital outpatient care, residential care services, community health and
social care services, medications and any equipment or aids that were needed by participants. Medication use
was categorised by drug name (or active constituent), mode of administration, dosage frequency and duration
of administration. Health and social care resource inputs were subsequently converted into economic cost
estimates using unit cost data. For broader societal resource impacts, the actual costs incurred by participants
and their families and carers for items such as travel, child care and lost income were valued directly by trial
participants and recorded on the data collection forms in monetary terms.
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Valuation of resource use
Resource inputs were valued using a combination of primary research and data collated from secondary
national tariff sets, using standard accounting methods. For ICU-related resource inputs, the overall costs
of intensive care were derived using individual-level data on the number of days of each form of organ
support, the number of days of each level of intensive care and the overall duration of the intensive care
stay. These patient-level data on duration, number and type of organ support, the duration and level
of intensive care and the overall duration of the intensive care stay were used as inputs to generate
Healthcare Resource Group (HRG) codes that were subsequently valued using NHS Reference Costs 2014
to 2015.36 Each ICU-related HRG code is associated with a mean length of hospital stay. For all individuals
in the ICU, costs were determined over their length of stay for their derived HRG code.
The unit costs of high-cost drugs not included within ICU-specific HRG values (e.g. antifungals and
antivirals) were taken from the Prescription Cost Analysis – England, 2016 database.37 The unit costs
associated with hospital readmissions, hospital day-case admissions, hospital outpatient services costs and
accident and emergency attendances were extracted from NHS reference costs36 or, when necessary, the
unit cost compendia published by the Personal Social Services Research Unit (PSSRU) at the University of
Kent.38–40 Residential care costs were taken from national tariffs reported in Unit Costs of Health and Social
Care 2013.38 Similarly, community health and social care costs were obtained from Unit Costs of Health
and Social Care 2015.39 NHS medication prices (per milligram) were obtained from the Prescription
Cost Analysis – England, 2016 database37 and equipment and adaptation costs from the NHS Supply Chain’s
National Catalogue (2014–15).41 Unit Costs of Health and Social Care 2016 was used to inflate or deflate costs
when necessary to 2015–16 prices (GBP).40 No discounting of costs was applied because cost-effectiveness for
the purposes of the within-trial economic evaluation was determined over a 6-month time horizon.
Calculation of utilities and quality-adjusted life-years
The economic evaluation estimated QALY profiles for trial participants based on patient reports of
preference-based HRQoL outcomes. The HRQoL of trial participants was assessed using the EQ-5D-3L,42
measured at baseline, and at 3 and 6 months post ICU discharge as a secondary outcome in the trial.
The EQ-5D-3L descriptive system consists of the following five dimensions: ‘mobility’, ‘self-care’, ‘usual
activities’, ‘pain/discomfort’ and ‘anxiety/depression’. Each dimension is divided into three ordinal levels
coded: (1) no problems, (2) some or moderate problems and (3) severe or extreme problems.43,44 For the
purposes of this study, the UK time trade-off tariff was applied to each set of responses to generate an
EQ-5D-3L utility score (preference weight) for each participant.42 The utility scores generated through this
method range from –0.59 to 1.0, with 1.0 representing full health, zero representing death and values
below 0 indicating health states that are considered to be worse than death. The second measurement
component of the EQ-5D-3L is the EuroQol visual analogue scale (EQ VAS), which records the respondent’s
self-reported health on the day of the survey on a 20-cm, vertical VAS; the scale ranges from 100 (best
imaginable health state) to 0 (worst imaginable health state).43 QALYs were calculated as the area under
the curve, assuming a fixed baseline utility score of –0.402 (equivalent to an unconscious health state)
and using linear interpolation between baseline and follow-up utility scores.45
The SF-12 was also completed at the same time point as the EQ-5D-3L and responses were converted into
Short Form questionnaire-6 Dimensions (SF-6D) utilities based on the algorithm provided by Brazier et al.46
For the SF-6D utility scores, the fixed baseline value was set to zero when constructing QALYs for the
purpose of a sensitivity analysis. No discounting of QALYs was applied for the purposes of the within-trial
economic evaluation because cost-effectiveness was determined over a 6-month time horizon. Participants
surviving to hospital discharge were also asked to recollect their pre-admission (pre-randomisation) health
state using both the EQ-5D-3L and the SF-12; utility scores generated by these HRQoL assessments were
used to inform a separate sensitivity analysis.
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Missing data
Multiple imputation (MI) using the Markov chain Monte Carlo method of chained equations was used for
the base-case analysis to impute missing data. This avoids potential biases associated with complete-case
analysis and is consistent with good practice guidance. MI was used at the aggregate level (i.e. on missing
total costs or QALYs). When data are missing at random (MAR), MI provides unbiased estimates of treatment
effect. The MAR assumption was explored in the data, using logistic regression for missingness of total costs
and QALYs for each time point (separately) as a function of baseline variables. A model was used to generate
multiple imputed data sets for treatment groups, in which missing values were estimated conditionally on
available covariates: age, sex, centre, presence/absence of COPD, non-operative/operative and post-SBT
PaCO2, such that a complete data set was generated, reflecting the distributions and correlations between
variables in the observed data. Mean matching using predictive methods was used to improve estimates of
imputed values as normality could not be assumed. Each imputed data set was analysed independently using
model-based approaches; estimates obtained were pooled to generate mean and variance estimates of costs
and QALYs using Rubin’s rule in order to capture within and between variances for imputed samples.47
Information loss from finite imputation sampling was minimised using 20 data sets, resulting in minimal loss
of efficiency (< 0.5%) when compared with infinite sampling. Imputed and observed values were compared
in order to establish that imputation did not introduce bias into subsequent estimations.
Analyses of resource use, costs and outcome data
Resource use items were summarised by treatment group and assessment point; differences between groups
were analysed using two sample t-tests for continuous variables. The mean [standard error (SE)] of each
resource type, including by resource category, was estimated by trial allocation group for each time period.
Costs were estimated from both a NHS and a PSS perspective and, for the purposes of a sensitivity analysis,
from a broader societal perspective. Differences between groups in terms of costs, along with their CIs, were
estimated and reported. Non-parametric bootstrap estimates using 10,000 replications35 were also calculated
for differences, along with their CIs. For each EQ-5D-3L dimension, the proportion of participants with
suboptimal levels of function (some or moderate problems, or severe or extreme problems) at each assessment
point was compared between treatment groups using chi-squared tests. EQ-5D-3L utility score differences
between the groups at each follow-up point were tested using two-sample t-tests for unequal variance.
Model-based methods (seemingly unrelated regression) were used to estimate mean incremental changes
in costs and QALYs and accounted for the correlation between costs and outcomes within the data while
adjusting for covariates, including baseline costs (for the cost equation) and baseline utility scores (for the
QALY equation) to adjust for potential baseline imbalances. Non-parametric bootstrap methods were
used to generate the joint distributions of costs and outcomes to populate the cost-effectiveness plane.
Bootstrapping (using the bias-corrected non-parametric approach) is a resampling method that jointly
resamples costs and outcomes from the observed data while holding the sample correlation structure.
From each bootstrap sample (of 10,000 samples), changes in costs and QALYs were estimated. Mean
estimates are reported with 95% CIs.
Cost-effectiveness analyses
The incremental cost-effectiveness ratio (ICER) was estimated as the difference between the trial comparators in
mean total costs divided by the difference in mean total QALYs. Value for money was determined by comparing
the ICER value with a cost-effectiveness threshold value; the NICE cost-effectiveness threshold for British studies
typically ranges between £20,000 and £30,000 per QALY. In addition, a £15,000 cost-effectiveness threshold
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was used to reflect more recent trends in health-care decision-making.48 This represents society’s willingness to
pay for an additional QALY; ICER values lower than the threshold could be considered to be cost-effective for
use in the NHS. Base-case assumptions were explored using a range of supportive sensitivity analyses.
The incremental net monetary benefit (INMB) of using the NIV protocol was also reported as a recalculation
of the ICER at a range of cost-effectiveness thresholds. The INMB succinctly describes the resource gain
(or loss) when investing in a new intervention when resources can be used elsewhere at the same threshold.
INMB estimates were used to generate cost-effectiveness acceptability curves (CEACs). A CEAC compares
the likelihood that interventions are cost-effective as the cost-effectiveness threshold varies.
All statistical analyses and cost-effectiveness modelling were conducted in SAS® software version 9.4
(SAS Institute Inc., Cary, NC, USA) on a Microsoft Windows® (Microsoft Corporation, Redmond, WA,
USA) platform.
Sensitivity and subgroup analyses
Several sensitivity analyses were undertaken to assess the impact on the base-case economic evaluation.
The following sensitivity analyses were considered for the cost-effectiveness outcomes: (1) recalculation
from a broader societal perspective (adopting a wider societal perspective that includes costs incurred
by all sectors of the economy and by patients, families and informal carers), (2) complete-case analysis
(i.e. those with complete cost and outcome data throughout the trial time horizon), (3) using the SF-6D
utility scores estimated from the SF-12 for the purposes of QALY estimation and (4) additionally using the
pre-randomisation EQ-5D-3L utility value (recalled at hospital discharge) as a covariate for the purpose
of adjusting for QALY differences. Prespecified subgroup analyses were also conducted for the main
cost-effectiveness results to explore heterogeneity in the trial population. These were conducted by
(1) presence/absence of COPD and (2) operative status (non-operative vs. operative).
Long-term cost-effectiveness model
Modelling survival data
Long-term cost-effectiveness was determined over a 5-year time horizon by modelling and extrapolating
survival time between randomisation and death, after examining the observed survival curves (Figure 16a).
A flexible parametric model using cubic splines (Royston–Parmar approach) was used.49 The approach
adopted avoids the use of life tables to estimate projected survival rates. Extrapolation beyond 5 years is
considered to be highly speculative and uncertain because most deaths occurred between randomisation
and hospital discharge.
The fitted model (Royston–Parmar model) was used to predict the survival rates at each time point
(Figure 16b). The survival rates at each 3-monthly interval (3, 6, 9, 12 . . . 60 months) were used to
determine the expected costs and derive the QALYs (at an aggregate level).
Modelling health utilities between hospital discharge and death
Health utilities were extrapolated between 6 months post randomisation and death for each treatment
group separately. The extrapolation was determined under the main assumption that utilities remained
constant at 6 months post randomisation.
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Adjusted health utilities and quality-adjusted life-years
The estimated health utilities at each time point between 6 months post randomisation and 60 months
post randomisation were multiplied by the predicted proportion of participants alive at the corresponding
time point. These values were then used to compute the 5-year QALY estimate for each group by
computing the area under the curve using the linear trapezoidal rule after discounting at 3.5% per annum
in each of years 2–5.
Modelling longer-term costs
Costs between 6 months post randomisation and death were estimated by using the observed 3- to
6-month post-randomisation total costs, adjusted for covariates (e.g. age, centre, COPD status), and
multiplying by the predicted survival probabilities over the period extending to 5 years post randomisation
(see Table 33 in Appendix 3). The primary long-term cost-effectiveness analyses was considered under the
assumption that the longer-term costs and benefits (health utilities) for the NIV group are equal to those
for the IMV group and only the proportion of participants alive beyond 6 months adjusts these costs and
benefits (see Table 33 in Appendix 3).
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FIGURE 16 (a) Observed Kaplan–Meier survival; and (b) extrapolated and observed survival over 5 years.
R–P, Royston–Parmar three-knot; K–M, Kaplan–Meier.
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Additional sensitivity analyses included:
1. assuming that, after 6 months post randomisation, costs and health utilities were the same between
groups, but survival rates in the NIV group were 10% lower (justified by an examination of the plots of
log-survival and hazard function) and similar to those of the IMV group
2. assuming that, after 6 months post randomisation, costs and health utilities are carried forward
(unequal) from 3 to 6 months onwards until 5 years post randomisation
3. assuming that, after 6 months post randomisation, costs were the same between groups, but health
utilities were carried forward from the last estimates observed.
In summary, for the long-term cost-effectiveness analyses, the analyses in Table 34 (see Appendix 3)
were applied.
Results
Trial population
A total of 364 participants were randomised into the Breathe trial: 182 to the ‘non-invasive weaning’
group and 182 to the ‘invasive weaning’ group. Complete health resource information was available for
all 354 participants between randomisation and ICU discharge. Consequently, the base-case economic
analyses include data from all 354 participants. Approximately 52% and 50% of all health resource use
data were complete at 3 months for the NIV and IMV groups, respectively; this diminished to 51% and
46%, respectively, by 6 months (Table 23). A complete QALY profile was available for 182 out of 364
(50%) participants. For about 65% of participants (see Table 35, Appendix 3), a complete QALY profile was
available after deaths were taken into account. Consequently, about 35% of QALY data and between 6%
and 40% of costs (at the component level) were missing (and subsequently imputed) for the primary analysis.
TABLE 23 Summary of data completeness of economic measures
Resource use item Time point
Trial group, n (%)
Non-invasive weaning group
(N= 182) Invasive weaning group (N= 182)
Completeda Unavailableb Missingc Completeda Unavailableb Missingc
ICU admission
length of stay by
organ support and
level of care
Initial
hospitalisation
182 (100) 0 (0) 0 (0) 182 (100) 0 (0) 0 (0)
Post-ICU admission
length of stay and
procedures
Initial
hospitalisation
182 (100) 0 (0) 0 (0) 182 (100) 0 (0) 0 (0)
Inpatient care
(readmissions)
3 months 95 (52) 87 (48) 0 (0) 91 (50) 89 (49) 2 (1)
6 months 93 (51) 88 (48) 1 (1) 84 (46) 97 (53) 1 (1)
Outpatient care
(hospitals/clinics)
3 months 95 (52) 87 (48) 0 (0) 91 (50) 89 (49) 2 (1)
6 months 93 (51) 88 (48) 1 (1) 84 (46) 97 (53) 1 (1)
Residential care
services
3 months 95 (52) 87 (48) 0 (0) 91 (50) 89 (49) 2 (1)
6 months 93 (51) 88 (48) 1 (1) 84 (46) 97 (53) 1 (1)
Community health
and social care
3 months 95 (52) 87 (48) 0 (0) 91 (50) 89 (49) 2 (1)
6 months 93 (51) 88 (48) 1 (1) 84 (46) 97 (53) 1 (1)
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Resource use and costs
Direct resource and cost implications of the intervention
Table 35 (see Appendix 3) summarises resource use values by trial allocation, resource category and trial
period for complete cases. Table 36 (see Appendix 3) summarises the unit cost values applied to each resource
input, whereas Table 24 summarises the economic cost values by trial allocation, resource category and trial
period. The resource and cost components associated with the intervention are aggregated into five groups:
(1) intensive care support, which includes organ support, level of care and use of sedatives; (2) tracheostomy;
(3) use of high-cost antiviral and antifungal or other high-cost drugs in the ICU; (4) hospital care between ICU
discharge and hospital discharge; and (5) use of any emergency transport to transfer patients between hospital
sites. Total intervention costs are also presented by treatment group. These varied between £2862 and £172,543
for the non-invasive weaning group and between £5146 and £195,855 for the invasive weaning group.
There were no statistical differences in the mean costs between randomisation and initial hospital discharge,
which were £29,697 and £32,052 for the non-invasive weaning and invasive weaning groups, respectively
(mean cost difference –£2355, 95% CI –£7292 to £2750; p = 0.4472). There were no statistical differences
in any of the component costs related to ICU stay (see Table 24), although, on average, the mean costs
were lower for the non-invasive group for most cost components.
TABLE 23 Summary of data completeness of economic measures (continued )
Resource use item Time point
Trial group, n (%)
Non-invasive weaning group
(N= 182) Invasive weaning group (N= 182)
Completeda Unavailableb Missingc Completeda Unavailableb Missingc
Medications 3 months 95 (52) 87 (48) 0 (0) 91 (50) 89 (49) 2 (1)
6 months 93 (51) 88 (48) 1 (1) 84 (46) 97 (53) 1 (1)
Equipment or aids 3 months 95 (52) 87 (48) 0 (0) 91 (50) 89 (49) 2 (1)
6 months 93 (51) 88 (48) 1 (1) 84 (46) 97 (53) 1 (1)
Broader societal
resource use
3 months 95 (52) 87 (48) 0 (0) 91 (50) 89 (49) 2 (1)
6 months 93 (51) 88 (48) 1 (1) 84 (46) 97 (53) 1 (1)
EQ-5D-3L index Prior to hospital
admissiond
121 (66) 58 (32) 3 (2) 120 (66) 62 (34) 0 (0)
3 months 91 (50) 87 (48) 4 (2) 88 (48) 91 (50) 3 (2)
6 months 90 (49) 89 (49) 3 (2) 80 (44) 99 (54) 3 (2)
EQ VAS Prior to hospital
admission
121 (66) 58 (32) 3 (2) 120 (66) 62 (34) 0 (0)
3 months 91 (50) 87 (48) 4 (2) 88 (48) 91 (50) 3 (2)
6 months 91 (50) 90 (49) 3 (2) 82 (45) 101 (55) 3 (2)
SF-12 Prior to hospital
admission
120 (66) 59 (32) 3 (2) 120 (66) 62 (34) 0 (0)
3 months 91 (50) 87 (48) 4 (2) 88 (48) 91 (50) 3 (2)
6 months 91 (50) 90 (49) 3 (2) 82 (45) 101 (55) 3 (2)
a Assessments were made; data available.
b Assessments not made; data collection forms missing (because of deaths, withdrawals from study or losses to follow-up).
c Assessments made, but data collection forms returned with incomplete data.
d These data were recollected using questionnaires administered at the point of discharge following the initial hospitalisation.
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Broader resource use
Table 35 (see Appendix 3) also shows resource use values for participants with complete data by trial group
allocation, resource use category and trial period. The resource values are presented for subcategories of
resource use, including hospital inpatient and outpatient care, residential care, community health and social
care, medications, and equipment and aids. Broader societal resource input and costs included travel, child
care, income lost, housework help and laundry services costs.
In terms of specific health resource use for non-invasive weaning versus invasive weaning at 3 months, notable
differences were observed for residential rehabilitation use (0.7 vs. 1.6 days; p = 0.296), home help/care work
support (6.8 vs. 3.9 visits; p = 0.1868) and occupational therapist visits (0.8 vs. 0.4 visits; p = 0.3318); in
addition, a smaller proportion of non-invasive weaning group participants were supported through equipment
and aids (56% vs. 65%; p = 0.2113). Between 3 and 6 months, 10% fewer participants were admitted for an
inpatient stay, such that the average length of stay was lower with non-invasive weaning (3.1 vs. 4.3 days);
similarly, 20% fewer participants had outpatient clinic visits (53% vs. 73%; p = 0.00634). However, between
randomisation and 6 months post discharge, the mean length of stay during hospital readmissions was
higher for the non-invasive weaning group than for the invasive weaning group (9.5 vs. 5.2 days; p = 0.0604),
suggesting the potential for later longer-term costs associated with survivors of non-invasive weaning.
This feature is also noted for other health resource items in Table 35 (see Appendix 3): rehabilitation days
(3.1 vs. 0.6 days; p = 0.1262); general practitioner (GP) home visits (0.8 vs. 0.4 visits; p = 0.5768); district nurse
visits (8.4 vs. 6.6 visits; p = 0.4588); and purchase of aids and equipment (26% vs. 12%; p = 0.01878). For all
other resource use items, there were no noticeable differences between the trial groups.
Economic costs
Economic costs for participants with complete data are presented in Table 24 by trial group, trial period
and cost category. Based on complete cost data, non-invasive weaning was, on average, less costly.
The total mean cost for the non-invasive weaning group was lower from a NHS/PSS perspective (£31,711
vs. £32,468), although this difference was not statistically significant (bootstrap 95% CI –£6642 to £5246;
p = 0.8321). This was also true when costs were considered from a broader societal perspective: £31,934
versus £32,999 (bootstrap 95% CI –£6804 to £5056; p = 0.7981).
Between randomisation and 6 months, initial hospitalisation costs were lower (see Table 24) for the
non-invasive weaning group (£28,842 vs. £30,719; p = 0.593). Similarly, residential care costs and
equipment and aids costs were higher, on average, for the non-invasive weaning group than for the
invasive weaning group (residential care costs £405 vs. £42; p = 0.0180; equipment and aid costs £59 vs.
£29; p = 0.0276). Moreover, the total post-initial-hospitalisation health and social care burden (in terms of
costs) from the NHS/PSS perspective was higher (see Table 24) for the non-invasive weaning group than for
the invasive weaning group (£2869 vs. £1749; p = 0.0494). Mean total broader societal costs were lower
over the 6 months for the non-invasive weaning group than for the invasive weaning group (£223 vs. £532;
p = 0.0142). There were also statistically significant differences between the groups in terms of broader
societal costs at 3 months: £138 in the non-invasive weaning group versus £456 in the invasive weaning
group (p = 0.0012).
Health-related quality-of-life outcomes
There were no statistically significant differences in suboptimal levels of function in HRQoL for participant-
reported dimensions of the EQ-5D-3L between the intervention and control groups prior to hospital
admission or at 3 months post ICU discharge (see Table 37 in Appendix 3). However, the mean EQ-5D-3L
utility score among complete cases was statistically significantly lower (see Table 37 in Appendix 3) at
6 months post randomisation in the non-invasive weaning group (0.53 vs. 0.66; p = 0.0147). In contrast,
the mean QALY value, which takes into account utility scores across multiple time points and sets a utility
score of zero from the date of death onwards, was, on average, higher for the non-invasive weaning
group than for the invasive weaning group (0.0928 vs. 0.0747; p = 0.4522), although the mean QALY
difference was not statistically significant (Table 25). There were no (statistically significant) differences in
the EQ VAS scores between the intervention and control groups at each of the time points of assessment.
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TABLE 24 Economic costs for complete cases by trial allocation, trial period and cost category (GBP, 2015–16 prices)
Resource use category by
time period
Trial group, mean (SE)
Mean
difference p-value Bootstrap 95% CINon-invasive Invasive
Randomisation to hospital
discharge n = 182 n = 182
Intensive care supporta 20,509.7 (1762.56) 22,018.9 (1685.17) –1509.2 0.5515 (–5533.9 to 2586.3)
Tracheostomy 980.9 (131.08) 1254.6 (141.7) –273.7 0.1570 (–584.1 to 57.2)
Antivirals/antifungals 455.7 (194.91) 758.2 (219.66) –302.5 0.3036 (–768.1 to 215.8)
Hospital care between ICU and
hospital discharge
7694.5 (695.69) 7967.0 (1038.27) –272.5 0.8275 (–2511.2 to 1682.5)
Transfer by ambulance/NHS
transport
56.0 (7.97) 53.1 (7.82) 2.87 0.7971 (–16.1 to 20.7)
Total NHS and PSS costs 29,696.8 (2069.8) 32,051.8 (2204.56) –2355.0 0.4472 (–7291.5 to 2750.0)
Hospital discharge to
3 months post randomisation n = 130 n = 131
Health and social care resource use
Hospital inpatient care 686.8 (163.83) 381.8 (123.63) 305.0 0.1387 (–30.0 to 642.2)
Hospital outpatient care 130.7 (25.95) 86.7 (17.41) –4.0 0.1602 (–5.2 to 97.3)
Residential care 158.6 (55.55) 43.2 (22.64) 115.4 0.0560 (20.1 to 219.7)
Community health and
social care
280.7 (46.03) 301.3 (75.31) –20.6 0.8157 (–171.3 to 114.3)
Medications 67.8 (21.23) 139.5 (36.84) –71.7 0.0935 (–141.4 to -4.7)
Equipment and aids 32.2 (8.79) 13.9 (4.71) 18.3 0.0679 (2.8 to 35.5)
Total NHS and PSS costs 1356.8 (196.32) 966.4 (151.99) 390.4 0.0836 (–47.1 to 775.7)
Broader societal costs
Additionalb 108.6 (33.02) 297.7 (129.15) –189.1 0.0926 (–324.6 to –4.2)
Equipment and aids
(private and charity)
29.3 (10.53) 158.3 (120.1) –129 0.2854 (–259.3 to 131.4)
Total broader societal costs 137.9 (22.47) 456.0 (93.68) –318.1 0.0012 (–434.1 to –158.4)
Total societal costs 1494.7 (179.61) 1422.4 (202.29) 72.3 0.3869 (–219.2 to 676.5)
3 months post randomisation
to 6 months post
randomisation n = 129 n = 127
Health and social care resource use
Hospital inpatient care 788.4 (203.12) 403.0 (144.18) 385.4 0.1233 (–7.0 to 1101.3)
Hospital outpatient care 131.5 (20.23) 123.0 (24.85) 28.50 0.7913 (–56.8 to 105.0)
Residential care 264.4 (140.96) 0.0 (0.00) 264.0 0.0630 (57.6 to 515.2)
Community health and
social care
373.2 (102.74) 214.5 (66.54) 158.7 0.1963 (–33.2 to 362.5)
Medications 176.2 (45.39) 206.0 (46.65) –29.8 0.6480 (–135.9 to 78.5)
Equipment and aids 30.9 (6.30) 17.4 (5.25) –13.5 0.1010 (–0.27 to 26.9)
Total NHS and PSS costs 1764.6 (258.47) 963.9 (157.71) 798.6 0.0031 (308.9 to 1294.7)
continued
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TABLE 24 Economic costs for complete cases by trial allocation, trial period and cost category (GBP, 2015–16 prices)
(continued )
Resource use category by
time period
Trial group, mean (SE)
Mean
difference p-value Bootstrap 95% CINon-invasive Invasive
Broader societal costs
Additionalb 171.8 (70.17) 245.9 (110.38) –74.1 0.3864 (–207.6 to 52.9)
Equipment and aids
(private and charity)
25.9 (9.67) 14.7 (12.5) 11.2 0.4788 (–10.8 to 33.2)
Total broader societal costs 197.7 (45.3) 260.6 (66.3) –62.9 0.4336 (–173.9 to 48.1)
Total societal costs 1962.3 (265.94) 1224.5 (178.96) 737.8 0.2262 (–432.6 to 1928.3)
From randomisation to
6 months post randomisation n = 129 n = 127
Initial hospitalisation costs
Intensive care supporta 20,815.7 (2134.03) 21,659.9 (2059.30) –844.2 0.7761 (–5699 to 4114)
Tracheostomy 922.6 (149.01) 1129.5 (159.01) –206.9 0.3435 (–570.1 to 151.2)
Antivirals/antifungals 448.2 (234.98) 968.8 (288.76) –520.6 0.1635 (–1131.2 to 89.9)
Hospital care between ICU
and hospital discharge
6613.3 (707.09) 6914.7 (896.01) –301.4 0.7921 (–2229 to 1519)
Transfer by ambulance/NHS
transport
42.6 (8.33) 46.1 (8.57) –3.5 0.7681 (–23.3 to 16.1)
Total NHS and PSS costs 28,842.4 (2462.57) 30,719.0 (2501.67) –1876.6 0.5934 (–7612 to 3989)
Post-initial-hospitalisation costs
Health and social care resource use
Hospital inpatient care 1323.6 (294.88) 698.2 (221.55) 625.4 0.0913 (28.3 to 1236.9)
Hospital outpatient care 240.7 (39.10) 188.8 (34.85) 51.9 0.3222 (–33.4 to 139.6)
Residential care 405.4 (150.44) 41.6 (21.81) 363.8 0.0180 (132.7 to 632.6)
Community health and
social care
613.8 (129.40) 475.5 (124.74) 138.3 0.4426 (–153.7 to 424.5)
Medications 226.3 (59.99) 315.8 (68.56) –89.5 0.3268 (–237.9 to 60.7)
Equipment and aids 59.1 (10.89) 28.6 (8.45) 30.5 0.0276 (7.3 to 53.4)
Total NHS and PSS costs 2868.9 (392.94) 1748.5 (276.45) 1120.4 0.0494 (176.5 to 1542.9)
Broader societal costs
Additionalb 171.7 (67.65) 374.6 (164.09) –202.9 0.2542 (–441.1 to –23.3)
Equipment and aids
(private and charity)
51.2 (24.45) 157.0 (98.87) –105.8 0.2498 (–179.3 to 16.0)
Total broader societal costs 222.9 (97.44) 531.6 (120.33) –309.7 0.0142 (–489.5 to 272.6)
Total societal costs 3091.8 (392.94) 2280.1 (276.45) 811.7 0.3163 (–128.3 to 1371.6)
Total NHS/PSS including ICU 31,711.3 (2498.47) 32,467.5 (2550.99) –756.2 0.8321 (–6642.1 to 5245.7)
Total societal including ICU 31,934.2 (2498.58) 32,999.1 (2547.95) –1064.9 0.7981 (–6804.2 to 5055.9)
a Costs based on the number of organs supported daily during the critical care period.
b This includes costs of travel, child care, housework help and laundry services, as well as income lost.
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Cost-effectiveness results
Base-case analysis
The incremental cost-effectiveness of non-invasive weaning is shown in Table 26 for the participants with
costs and health outcomes data subject to MI. When a NHS/PSS perspective was adopted (i.e. that which
was adopted for the baseline analysis) and health outcomes were measured in terms of QALYs, the mean
total cost was £36,313 in the NIV group, compared with £36,615 in the IMV group, generating a mean
incremental cost of –£302. The NIV intervention was also associated with a non-statistically significant
increase in QALYs (0.02 QALYs, 95% CI –0.01 to 0.05) over the entire 6-month follow-up period. In health
economic terms, the intervention was dominant as average costs were lower and the net effect was higher.
Incremental net monetary benefit
The associated mean INMB of non-invasive weaning at cost-effectiveness thresholds of £15,000, £20,000
and £30,000 per QALY was £541, £620 and £779, respectively (see Table 25). The base-case mean INMB
was > £0, suggesting that adopting the NIV protocol would result in a net economic gain of £620, on average,
from a NHS/PSS perspective (INMB £541, 95% CI –£4545 to £5928), assuming a cost-effectiveness threshold
of £20,000 per QALY. The cost-effectiveness plane (Figure 17) shows that the ICERs are largely spread across
the north-east and south-east quadrants. These result in a probability of cost-effectiveness of between 57%
and 59% (Figure 18); that is, if decision-makers are willing to pay between £15,000 and £30,000 for an
additional QALY, the probability that the non-invasive weaning intervention is cost-effective falls just below
60% (see Table 25).
Sensitivity analyses
Several sensitivity analyses were undertaken to assess the impact of uncertainty surrounding key parameters
or methodological features on the cost-effectiveness results. The probability that the non-invasive weaning
intervention is cost-effective remained relatively static (at about 60%) for the majority of the sensitivity
analyses (i.e. complete cases, societal costs, SF-6D-converted QALYs and using the recalled pre-randomisation
EQ-5D-3L utility score as an additional covariate). All sensitivity analyses show that the average INMB is always
> £0. However, because of high variability, the (bootstrap) 95% CIs cross zero and a conclusion of no difference
between non-invasive weaning and invasive weaning in terms of the mean INMB cannot be completely
(statistically) ruled out (see Table 26 and Figures 19–21).
Subgroup analyses
Four subgroups were subjected to cost-effectiveness analyses to explore the heterogeneity in cost-effectiveness
results: COPD (presence/absence) and operative status (operative/non-operative). All subgroup analyses were
based on the patient-reported EQ-5D-3L and MI and covariate adjustments. COPD presence had a notable
impact on the INMB values, with mean INMB values ranging between £7076 and £8829, depending on the
value of the cost-effectiveness threshold. The probability of cost-effectiveness increased to a range of 82–87%
TABLE 25 Patient-reported EQ-5D-3L QALYs (complete cases, baseline fixed)
Parameter
QALY (EQ-5D-3L participant)a
n Mean
Non-invasive (SE) 120 0.0928 (0.0616)
Invasive (SE) 118 0.0747 (0.0179)
Mean differenceb – 0.0181
p-value (95% CI) – 0.4522 (–0.0293 to 0.0656)
a Estimated QALYs are determined using fixed baseline and also setting utilities to zero from the date of death for
participants who died.
b Comparisons of EQ-5D-3L QALYs using student’s t-test for unequal variances assuming a fixed baseline of –0.402.
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TABLE 26 Cost-effectiveness, cost per QALY (GBP, 2016): non-invasive vs. invasive weaning
Scenario
Probability of cost-effectiveness INMB
Incremental cost
(95% CI)
Incremental QALYs
(95% CI) ICERa p-valueb p-valuec p-valued INMBb INMBc INMBd
Base case (NHS/PSS perspective)
Imputed attributable costs and QALYs
(fixed baseline), adjusted for covariates
–302
(–5489 to 4761)
0.01589
(–0.01262 to 0.0465)
NIV dominant 0.57 0.58 0.59 541
(–4598 to 5833)
620
(–4545 to 5928)
779
(–4470 to 6162)
Sensitivity analyses
1. Imputed societal attributable costs and QALYs
(fixed baseline), adjusted for covariates
–339
(–5422 to 4645)
0.01631
(–0.01271 to 0.04714)
NIV dominant 0.57 0.58 0.60 584
(–4509 to 5733)
665
(–4473 to 5862)
828
(–4369 to 6075)
2. Complete cases (NHS/PSS) attributable costs and
QALYs (fixed baseline), adjusted for covariates
–739.5
(–7139 to 5641)
0.01605
(–0.0211 to 0.0557)
NIV dominant 0.59 0.60 0.62 980
(–5539 to 7442)
1060
(–5505 to 7559)
1220
(–5456 to 7833)
3. Imputed attributable costs and QALYs
(fixed baseline using SF-6D utility score),
covariates adjusted
–330
(–540 to 4692)
0.0295
(–0.1367 to 0.1762)
NIV dominant 0.58 0.60 0.62 774
(–5033 to 6521)
922
(–5357 to 7025)
1218
(–6163 to 8267)
4. Imputed attributable costs and QALYs (fixed
baseline), adjusted for covariates and pre-admission
EQ-5D-3L covariate
–445
(–5305 to 4486)
0.0156
(–0.0151 to 0.0479)
NIV dominant 0.59 0.60 0.61 625
(–4809 to 5114)
735
(–4914 to 5044)
894
(–5182 to 4962)
Subgroup analyses (COPD and operative status)
COPD: presence of COPD – imputed attributable
costs and QALYs (fixed baseline), covariates adjusted
EQ-5D-3L utility score
–5322
(–17,899 to 6431)
0.1169
(0.0353 to 0.215)
NIV dominant 0.82 0.84 0.87 7076
(–4817 to 19,814)
7660
(–4308 to 20,451)
8829
(–3368 to 21,731)
COPD: absence of COPD – imputed attributable
costs and QALYs (fixed baseline), covariates adjusted
EQ-5D-3L utility score
756
(–4768 to 6380)
–0.0050
(–0.0352 to 0.0258)
NIV dominated 0.40 0.40 0.39 –831
(–6588 to 4793)
–856
(–6629 to 4801)
–906
(–6745 to 4863)
Operative status: non-operative – imputed
attributable costs and QALYs (fixed baseline),
covariates adjusted EQ-5D-3L utility score
–1915
(–7955 to 3932)
0.03743
(0.00105 to 0.0766)
NIV dominant 0.75 0.76 0.79 2477
(–3491 to 8559)
2664
(–3394 to 8806)
3038
(–3134 to 9264)
Operative status: operative – imputed attributable
costs and QALYs (fixed baseline), covariates adjusted
EQ-5D-3L utility score
3266
(–6808 to 13,041)
–0.0311
(–0.0747 to 0.0135)
NIV dominated 0.27 0.26 0.25 –3733
(–13,560 to 6415)
–3888
(–13,736 to 6284)
–4200
(–14,063 to 6042)
a CIs based on 10,000 simulations. Each simulation based on model based means adjusted sex, age, COPD status, operative status, SBT PaCO2 (post-SBT PaCO2), unless stated otherwise (35% of missing data were imputed for
QALYS and between 6% and 40% of costs were imputed depending on the cost component).
b Probability cost-effective or net monetary benefit if cost-effectiveness threshold is £15,000/QALY.
c Probability cost-effective or net monetary benefit if cost-effectiveness threshold is £20,000/QALY.
d Probability cost-effective or net monetary benefit if cost-effectiveness threshold is £30,000/QALY.
Note
ICER dominant indicates average costs were lower and average benefit greater for the non-invasive treatment group.
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depending on the value of the cost-effectiveness threshold in participants with COPD. Conversely, for
participants with an absence of COPD, non-invasive weaning was less cost-effective than invasive weaning
(see Figures 19 and 21 and Table 26), resulting in non-invasive weaning being dominated by invasive weaning
in health economic terms (as it was, on average, more costly and less effective). Similarly, for operative status,
non-invasive weaning was dominated by invasive weaning and was therefore less cost-effective for this
subgroup: non-invasive weaning was more costly and less effective, on average, and the mean INMB was
negative, ranging between –£3733 and –£4200, with probabilities of cost-effectiveness ranging between
25% and 27%, depending on the value of the cost-effectiveness threshold.
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FIGURE 17 Cost-effectiveness plane for base case: fixed utility baseline, imputed costs, adjustment for covariates.
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for covariates.
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– 30,000 – 24,000 – 18,000 – 12,000 – 6000 0 6000 12,000 18,000 24,000 30,000
 Favours invasive (INMB < £0)  Favours non-invasive (INMB > £0)
Base case
Societal
Complete cases
SF-6D utility
EQ-5D post-discharge adjustment
COPD: presence (n = 63)
COPD: absence (n = 301)
Operative: none (n = 252)
Operative: yes (n = 112)
541
584
980
774
625
7076
– 831
2477
– 3733
– 4598 to 5833
– 4509 to 5733
– 5539 to 7442
– 5033 to 6521
– 4809 to 5114
– 4817 to 19,814
– 6588 to 4793
– 3491 to 8559
– 13,560 to 6415
INMB (£) 95% CI (£)
INMB (£)
FIGURE 19 Sensitivity analyses and subgroup results (cost-effectiveness threshold of £15,000/QALY).
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– 20,000 – 15,000 – 10,000 – 5000 0 5000 10,000 15,000 20,000 25,000
 Favours invasive (INMB < £0)  Favours non-invasive (INMB > £0)
Base case
Societal
Complete cases
SF-6D utility
EQ-5D post-discharge adjustment
COPD: presence (n = 63)
COPD: absence (n = 301)
Operative: none (n = 252)
Operative: yes (n = 112)
620
665
1060
922
735
7660
– 856
2664
– 3888
– 4545 to 5928
– 4473 to 5862
– 5505 to 7559
– 5375 to 7025
– 4914 to 5044
– 4308 to 20,451
– 6629 to 4801
– 3394 to 8806
– 13,736 to 6284
INMB (£) 95% CI (£)
INMB (£)
FIGURE 20 Sensitivity analyses and subgroup results (cost-effectiveness threshold of £20,000/QALY).
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– 30,000 – 24,000 – 18,000 – 12,000 – 6000 0 6000 12,000 18,000 24,000 30,000
 Favours invasive (INMB < £0)  Favours non-invasive (INMB > £0)
Base case
Societal
Complete cases
SF-6D utility
EQ-5D post-discharge adjustment
COPD: presence (n = 63)
COPD: absence (n = 301)
Operative: none (n = 252)
Operative: yes (n = 112)
779
828
1220
1218
894
8829
– 906
3038
– 4200
– 4470 to 6162
– 4369 to 6075
– 5456 to 7833
– 6163 to 8267
– 5182 to 4962
– 3368 to 21,731
– 6745 to 4863
– 3134 to 9264
– 14,063 to 6042
INMB (£) 95% CI (£)
INMB (£)
FIGURE 21 Sensitivity analyses and subgroup results (cost-effectiveness threshold of £30,000/QALY).
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Results of the longer-term cost-effectiveness model
Survival rates
After fitting a Royston–Parmar49 three-knot model (the best model based on lowest Akaike information
criterion) using published SAS macros,50 using a 5-year time horizon yielded a mean survival time of about
41.9 months versus 33.3 months for NIV versus IMV, respectively. The mean observed survival for NIV versus
IMV was 4.12 months versus 4.07 months (Table 27) based on the observed Kaplan–Meier estimates from
the within-trial data. By 5 years (60 months) post randomisation, 67% of participants were expected to
remain alive in the NIV group, compared with 45% in the IMV group [see Figure 16b and Table 33 (see
Appendix 3)]. These survival rates are lower than the national average, as reported in mortality statistics of
the general population with a similar age distribution to this population. This would be 95% at 5 years from
a mean age of 63 years,51 which, logically, are higher than the rates observed here as the participants in the
study are patients from an ICU.
Both plots (Figure 22) of the log-survival (a) and the hazard (b) functions suggest that NIV has a trend of
decreasing hazards (lower risk of death over time) whereas IMV appears to have an increasing hazard trend
(higher risk of death over time). This is mainly as a result of the spike in hazards after month 6 because of
a later death event in the IMV group. Both hazard functions suggest that risk of death is decreasing in a
TABLE 27 Longer-term costs and effects (base case)
Outcome
Trial group
Difference (NIV vs. IMV)NIV IMV
Survival
Time horizon (months) 60 60 –
Mean observed survival (Kaplan–Meier) (months) 4.12 4.07 0.05
Royston–Parmar three-knot model, extrapolated
survivala (mean) (months)
41.9 33.3 8.6
Utilities
Constant (mean)a 0.444 0.361 0.083 (more effective)
QALYs
QALY (discounted)b 2.247 1.824 0.427 (more effective)
Costs
NHS/PSS during trialc £31,711 £32,476 £765 (less costly)
> 6 months to 5 yearsd £12,048 £9311 £2737 (more costly)
Total over 5 years, including ICU £43,759 £41,787 £1972 (more costly)
ICER – – £4618
INMB
Cost-effectiveness threshold of £20,000 – – £6568
Cost-effectiveness threshold of £30,000 – – £10,838
a Mean utilities calculated as means across all observed and predicted estimates between randomisation and 5 years; this
assumes utilities remain constant after 6 months post randomisation (i.e. carried forward).
b From baseline to 5 years as the area under the curve, when utilities are carried forward.
c Observed costs during the trial, including ICU costs (see Table 24).
d Extrapolated using predicted survival rates assuming equal future health resource use.
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similar trend until around 4 months post intervention, albeit with a more erratic hazard for the IMV group.
After about 4 months, patients may die at a slightly faster rate (ignoring the spike) in the IMV group. Owing
to a lack of further follow-up data, future death patterns may or may not be similar, although the curve
trajectory for NIV suggests that the hazard curve may lie slightly above that of the IMV group. These plots
partially support the extrapolated survival curves, suggesting that NIV patient death rates occur more slowly
than death rates in the IMV group, but that survival rates over time may converge. On the basis of these
results, an assumption of future costs and health utilities being similar between groups is not unreasonable.
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Health utilities and quality-adjusted life-years
The mean health utility scores, calculated as means across all observed and predicted estimates between
randomisation and 5 years, were estimated to be 0.444 versus 0.361 (NIV vs. IMV) assuming that utilities
remained constant beyond 6 months (base case for long-term cost-effectiveness). The mean discounted
expected QALYs over 5 years were 2.25 for NIV versus 1.82 for NIV (see Table 27), assuming constant
health utilities beyond 6 months, resulting in an incremental QALY gain of 0.427. The QALY difference
appears to be driven by higher expected survival rates over time.
Costs
Using observed 3–6 months post randomisation total costs, adjusted for covariates (e.g. age, centre, COPD
status), as a basis for estimating long-term costs, the total expected (discounted) costs up to 5 years post
randomisation were £12,048 for NIV compared with £9311 for IMV after assuming that long-term
(beyond 6 months) resource use is equal between groups.
Incremental cost-effectiveness (base case, long-term extrapolation)
The reported NHS and PSS costs over the first 6 months were £31,711 versus £32,476 for the NIV versus
IMV groups during the trial (see Table 24). The total expected (mean) NHS and PSS costs over 5 years
were £43,759 versus £41,787 with an incremental cost of £1972 for NIV. The 5-year ICER was therefore
£4618 (see Table 27), assuming future costs and health utilities are the same in survivors in both groups.
At a cost-effectiveness threshold of £30,000 per QALY, NIV was strongly cost-effective (see Table 27
and Figure 23). This is largely explained by a higher mean QALY estimate as a result of a higher survival
rate in the NIV group than in the IMV group. However, the probability of cost-effectiveness of NIV is highly
dependent on the assumptions about future costs and benefits beyond 6 months (see Table 27).
Additional information might therefore be needed to reduce this decision uncertainty.
Sensitivity analyses
In the first sensitivity analyses, survival rates in the NIV group were reduced by 10% and it was assumed that
costs and utilities were equal after 6 months (see Table 38; Appendix 3). This led to an incremental cost
associated with NIV of £237 and a reduced incremental QALY of 0.028, with a consequent ICER of £8393
and a probability of cost-effectiveness of about 0.96 at a cost-effectiveness threshold of £30,000 per QALY
(see Table 38 in Appendix 3, and Figure 24).
If costs and health utilities for survivors are assumed to remain constant as observed in the trial (i.e. carrying
forward costs and health utility values as observed at 6 months post randomisation in their groups), NIV is
no longer cost-effective (mean ICER of £349,000 per additional QALY at a cost-effectiveness threshold of
£30,000) (see Table 38 in Appendix 3).
If, after 6 months, costs are assumed to be equal, but expected health utilities are carried forward
(i.e. differ over time), the incremental cost associated with NIV falls to £2737 and the incremental QALY
falls to 0.019, resulting in an ICER of £144,052 and a probability of cost-effectiveness of 2% (at a £30,000
cost-effectiveness threshold).
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FIGURE 23 Cost-effectiveness acceptability curve and cost-effectiveness plane for long-term effectiveness
(base-case long-term cost-effectiveness assuming equal future costs and effects). (a) CEAC showing the probability
of cost-effectiveness of NIV at varying cost-effectiveness thresholds, assuming that future costs and effects are
equal between the NIV and IMV groups; and (b) cost-effectiveness plane showing the joint distribution of projected
5-year differences in costs and QALYs between the NIV and IMV groups, assuming that costs beyond the 6-month
trial period and effects are equal between groups.
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FIGURE 24 Cost-effectiveness acceptability curve and cost-effectiveness plane for long-term effectiveness (sensitivity
analyses assuming that survival in the NIV group is lower by 10%). (a) Cost-effectiveness plane showing the joint
distribution of projected 5-year differences in costs and QALYs between the NIV and IMV groups, assuming that
survival in the NIV group is lower by 10%; and (b) CEAC showing the probability of cost-effectiveness of NIV at
varying cost-effectiveness thresholds, assuming that survival in non-invasive group is lower by 10%.
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Chapter 6 Discussion
Summary of main results
The Breathe pragmatic RCT compared two protocolised weaning strategies – one that promoted early
extubation to NIV and one that involved sequential reduction in Psupp with daily SBTs prior to extubation.
Early extubation to NIV had no effect on the primary outcome (liberation from ventilation) or mortality,
despite a higher rate of reintubation in the NIV group than in the IMV group. The study showed clinically
beneficial effects for NIV as regards reduced sedation requirements and a lower proportion of patients
requiring respiratory antibiotics.
Interpretation
Despite no evidence of the effectiveness of early extubation to NIV on liberation from ventilation, these
findings present useful information about the role for NIV as an intermediate step in the weaning process.
Furthermore, adopting the approach outlined by Pocock and Stone,52 a finding of no effect on the primary
outcome should not be labelled as a ‘negative trial’. First, the primary outcome, time from liberation from all
forms of ventilation, was defined, in accordance with international guidelines, as being freedom from any
form of ventilation for 48 hours after extubation. The Breathe trial found a mean difference of 2.0 days total
ventilation time in favour of NIV (95% CI –4.61 to 0.69 days). The upper boundary of the CI crosses the line
of no effect but the lower boundary falls below the a priori-defined minimal clinically important difference
of 1 day. Owing to a lower than anticipated dropout rate (25% predicted, 17% observed), a post hoc
power calculation reveals that the study had 93% power to detect the a priori-defined minimal clinically
important difference of 1 day in total ventilation days. The primary outcome represents an overall measure
of the effectiveness of weaning but does not account for the benefits of transitioning from IMV to NIV.
This suggests that the use of NIV as a weaning strategy shows some indication of potential benefit.
Second, early liberation from IMV reduces exposure to the risk of ventilator-associated lung injury and VAP.
Participants in the NIV group had 3 days fewer IMV (–3.1 days, 95% CI –5.75 to –0.51 days) than those in
the IMV group. This conferred additional beneficial effects including less sedation, a lower proportion of
participants requiring antibiotics for presumed respiratory infection and fewer days in intensive care.
The findings from the Breathe trial add new insights to evidence from a Cochrane systematic review and
meta-analysis that comprised 16 RCTs and 994 participants.20 Unlike the Breathe trial, these were mostly small
(range of 20 to 264 participants), single-centre trials and included a high proportion of participants with COPD
(nine of the trials enrolled exclusively COPD participants and two enrolled predominantly COPD participants).
The Breathe trial differed from these previous trials as only a small proportion (3.5%) of enrolled participants
had COPD as the main indication for respiratory failure. This may reflect current UK practice, with NIV being
used as a tool to prevent intubation for COPD patients. Unlike the Breathe trial, the Cochrane systematic
review found strong evidence that weaning using NIV reduced mortality (RR 0.52, 95% CI 0.36 to 0.80),
although moderate heterogeneity was noted.20 Subgroup analysis showed that the beneficial effects were
limited to trials that exclusively enrolled participants with COPD as the main cause of acute respiratory failure
(RR 0.36, 95% CI 0.24 to 0.56). This finding is consistent with the evidence in which NIV is used to supplement
usual medical care during COPD exacerbation.53 From a pathophysiological perspective, NIV reduces respiratory
muscle fatigue and tachypnoea, augments tidal volume and reduces intrinsic PEEP in patients with COPD. With
the increasing adoption of NIV as a tool to prevent the need for intubation, fewer COPD patients are admitted
to ICU for IMV;6 thus, the population recruited to the Breathe trial probably better reflects contemporary
ventilation practice. In addition, the Breathe trial reflects contemporary weaning practice by comparing NIV
with a protocol using weaning of Psupp. Some of the studies included in the Cochrane report compared NIV
DOI: 10.3310/hta23480 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 48
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Perkins et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
69
with a weaning protocol using a mechanical ventilation mode that incorporates mandatory ventilations, which
is considered a less effective weaning strategy.
The Breathe trial evaluated NIV in patients with difficult and prolonged weaning. The 2005 international
consensus conference on weaning defined difficult weaning as a failure of the initial weaning attempt and a
requirement for up to three SBTs or 7 days of weaning.7 Prolonged weaning was defined as a situation in
which patients require more than three SBTs or 7 days of weaning after the first SBT.7 In the Breathe trial,
the early visual separation of the Kaplan–Meier curves over the first 7–10 days after randomisation before
they later come together suggests that NIV might be most beneficial in the difficult-weaning group. This has
some biological rationale as the most common causes of difficult weaning (e.g. accumulation of sedative
drugs, fluid overload, respiratory muscle weakness) may be resolved more quickly than the most common
underlying causes of prolonged weaning (e.g. severe/chronic cardiovascular and respiratory failure, prolonged
respiratory muscle weakness).54 To test this hypothesis, future studies might seek to prospectively identify and
evaluate NIV in patients predicted to face difficult rather than prolonged weaning.
Overall, the use of NIV was well tolerated. However, the proportion of participants who failed a trial of NIV
and required reintubation was twice as high in the NIV group as in the IMV group (37.4% vs. 23.1%).
ICU mortality among those who required reintubation was higher (20%) than among those that did not
require reintubation (6%). However, as the overall mortality rates were similar at ICU discharge (12.1%
in the NIV group and 13.7% in the IMV group), death after reintubation may reflect the severity of the
underlying illness as opposed to reintubation causing excess mortality per se. Other than this, the rate and
patterns of AEs and SAEs were similar between groups.
Strengths and limitations
The Breathe trial benefited from several design advantages compared with previous studies on IMV and
NIV. First, the use of a protocolised weaning regime in both trial groups allowed the separation of the
treatment intervention from the effect of protocolised weaning.55 The inclusion of optimised best practice
guidelines (i.e. ventilation bundle, daily SBTs, tracheostomy) should reduce heterogeneity between treatment
groups. Second, antibiotic use was selected as a surrogate for VAP to limit the risk of detection bias arising
from different approaches to obtaining respiratory samples for culture. The trial also has important limitations.
By the nature of the intervention, it was not possible to blind clinicians, participants or outcome assessors.
This may have led to performance and/or detection bias. Nearly half of the participants were recruited from
three large centres, which might limit generalisability. However, a sensitivity analysis found no evidence of a
difference in outcomes between these three centres and the other 39 participating centres. A prerequisite
for centres to participate in the Breathe trial was that they were experienced in the use of NIV. Nevertheless,
it is possible that performance and outcomes may have improved as centres became more experienced in the
use of the NIV weaning intervention.
Health economic evaluation
This trial-based economic evaluation revealed that the NIV protocol has some potential to be cost-effective,
compared with IMV, particularly for the patients who present with COPD or do not require surgery
(operative status). NIV is unlikely to be cost-effective compared with IMV for patients admitted to the ICU
who do not have COPD or who require surgery. The INMB estimate was positive for the NIV protocol, a
finding that remained generally robust to several sensitivity and subgroup analyses. The main reason for
cost-effectiveness appears to stem from lower costs associated with the experimental group and improved
effectiveness based on EQ-5D-3L-derived QALYs. However, from a NHS and PSS perspective, some costs
were higher, on average, for the NIV intervention group (although not always statistically significant) than
for the IMV group.
DISCUSSION
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A strength of the Breathe trial was that it was prospectively designed for a cost-effectiveness analysis using
individual-level data. Costs and outcomes were carefully considered in the design of this trial with the
purpose of reaching a robust conclusion with respect to cost-effectiveness in a large sample of individuals.
There were, however, several limitations to this cost-effectiveness analysis.
First, organ support costs after the initial 30 days were collected in such a way such that it was impossible
to distinguish between the costs for multiple organs or zero or just one organ. For example, when 5 additional
days were required for organ support beyond the first 30 days post randomisation, it was impossible to
disentangle whether the organ support costs for these 5 days were due to the cost of supporting several
organs for, for instance, the first 3 days and fewer organs for the last 2 days, or vice versa.
Second, in terms of QALYs, a baseline utility score of –0.402 was assumed, the value assigned by the
EQ-5D-3L tariff to an unconscious health state, and this was considered to be the same for each participant,
regardless of underlying heterogeneity in health states. This may be an unrealistic assumption, but it is in
keeping with broader methodological practice for trial-based economic evaluations conducted in emergency
and critical care settings.56 Moreover, we have recently demonstrated that assuming an alternative fixed
baseline utility score, for example a utility score of zero representing death, would have no effect on the
area under the curve within the incremental QALY calculations.56 Furthermore, the utility assessments
performed around the point of hospital discharge required participants to reflect on their health state of
at least 1 month earlier, and may, therefore, suffer from some recall bias. Consequently, the QALY values
generated for the purposes of the baseline cost-effectiveness analysis were based on one fixed baseline
time point and utility value. The assumption of linearity of HRQoL between data collection points is open
to scrutiny and more uncertain when missing data are present.
Third, the proportion of missing data and how missingness is handled is critical as this can affect the
conclusions of a cost-effectiveness analysis. In this trial, approximately 35% of QALY data and between 6%
and 40% of costs (at the component level) were missing by 6 months. Had the base-case cost-effectiveness
analysis considered only those individuals with complete QALY and cost data, approximately 50% of
participants (with possibly informative data) would have been removed from the analysis. This approach
would have probably biased the results. After investigating that the data were likely to be MAR, it seemed
sensible to use MI to ‘replace’ missing values in order to allow a complete-case analysis using the whole
data set data.
Fourth, despite the longitudinal nature of the study, resource use was retrospectively recalled by trial
participants, which is also likely to result in recall bias.
Fifth, similar pilot or Phase II trials may have been useful in identifying the critical costs that drive
cost-effectiveness. Instead, a broad set of NHS and PSS costs and broader societal costs were collected,
some of which had little impact on the ICER values. Some costs items did not occur (e.g. see Table 35 in
Appendix 3) and a reduced form of such a type of data collection in this setting may be advisable with a
focus on the largest and most relevant costs.
Finally, the potential for a more rigorous longer-term cost-effectiveness analysis may be needed because
it appears that the effectiveness of NIV appears to deteriorate over time, reflected in shorter projected
survival. The impact of non-linear extrapolation functions should be considered to assess the sensitivity of
long-term cost-effectiveness.57 This is because utility after hospital discharge may increase because of the
use of additional therapies (including palliation) before declining (and may increase the QALY). A longer
follow-up would have helped to reduce the uncertainty of extrapolated patient survival and patient utility.
In conclusion, the data collected in the Breathe trial support a hypothesis that a NIV protocol intervention
compared with an IMV protocol in this population of patients is likely to be cost-effective in the short term,
particularly for some subgroups. However, initial longer-term cost-effectiveness modelling suggests that
the benefits of NIV may not be cost-effective.
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Patient and public involvement
In the formative stages of the trial, the Intensive Care Society’s Patients and Relatives Committee helped
to inform the design of the study. Guidance was provided about selecting and defining the primary
and secondary end points of the trial. The group assisted us to identify the optimal timing and way to
approach patients and relatives for consent, both in the early phases of the trial and during follow-up.
Through ongoing involvement in the TSC, two patient and public representatives (a patient and a relative
of a patient) maintained oversight of the conduct of the trial and assisted with the interpretation of the
trial findings. Insights from these members highlighted the physical discomfort of a tracheal tube during
weaning, an aspect of patient experience that was not captured in the design of the trial. A systematic
review of qualitative studies identified physical discomfort from the endotracheal tube, suctioning and
inability to communicate as common adverse patient experiences.58 It is possible that earlier liberation from
IMV may have improved patient experience; although this was not formally measured in this trial, it is a
relevant outcome to consider in future studies.
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Chapter 7 Conclusion
The Breathe trial, a pragmatic RCT, compared two protocolised weaning strategies in patients who faileda SBT. One strategy promoted early extubation to NIV and one involved sequential reduction in Psupp
with daily SBTs prior to extubation. Early extubation to NIV did not reduce the overall time to liberation
from ventilation. However, participants in the early extubation/NIV group spent less time receiving IMV
and required less sedation and fewer respiratory antibiotics than those in the IMV group. Although the
early extubation/NIV group had a higher rate of reintubation than the IMV group, there was no overall
difference in AEs, SAEs or mortality. The mean incremental cost-effectiveness of the NIV intervention was
estimated at £19,006 per QALY, that is, on average, the intervention was associated with a lower net cost
and a higher net effect and was dominant in health economic terms. A strategy of early extubation to NIV
seems to be a reasonable alternative to continuing invasive weaning procedures.
Recommendations for research
In patients who fail a SBT, which factors predict an adverse outcome (reintubation, tracheostomy, death)
if extubated and weaned using NIV?
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Patient data
This work uses data provided by patients and collected by the NHS as part of their care and support. Using
patient data is vital to improve health and care for everyone. There is huge potential to make better use of
information from people’s patient records, to understand more about disease, develop new treatments,
monitor safety, and plan NHS services. Patient data should be kept safe and secure, to protect everyone’s
privacy, and it’s important that there are safeguards to make sure that it is stored and used responsibly.
Everyone should be able to find out about how patient data are used. #datasaveslives You can find out
more about the background to this citation here: https://understandingpatientdata.org.uk/data-citation.
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Appendix 1 Summary of screening
TABLE 28 Summary of screening of patients through to randomisation
Site name Number screened
Excluded from
trial, n (%)
Had
SBT, n (%) Failed SBT, n (%)
Randomised
patients, n (%)
Addenbrooke’s 792 666 (84) 126 (16) 35 (28) 19 (2)
Basildon 73 62 (85) 11 (15) 1 (9) 1 (1)
Bedford 308 258 (84) 50 (16) 4 (8) 3 (1)
BHH 609 463 (76) 146 (24) 60 (34) 60 (10)
Blackpool 291 278 (96) 13 (4) 6 (50) 6 (2)
Bradford RI 270 246 (91) 24 (9) 10 (42) 9 (3)
Bristol RI 199 174 (87) 25 (13) 0 (0) 0 (0)
Broomfield 90 82 (91) 8 (9) 0 (0) 0 (0)
Edinburgh RI 330 317 (96) 13 (4) 4 (31) 3 (1)
Forth Valley 132 100 (76) 32 (24) 0 (0) 0 (0)
Freeman 175 166 (95) 9 (5) 2 (22) 1 (1)
George Eliot 86 80 (93) 6 (7) 3 (50) 2 (2)
Glenfield 99 91 (92) 8 (8) 2 (25) 2 (2)
Hillingdon 85 56 (66) 29 (34) 14 (48) 13 (15)
Hull RI 393 375 (95) 18 (5) 2 (11) 1 (0)
James Paget 95 93 (98) 2 (2) 0 (0) 0 (0)
John Radcliffe 93 60 (65) 33 (35) 1 (3) 0 (0)
King’s Lynn QE 137 117 (85) 20 (15) 8 (40) 7 (5)
Leicester RI 291 271 (93) 20 (7) 6 (30) 5 (2)
Leighton 226 212 (94) 14 (6) 3 (21) 3 (1)
Manchester RI 566 503 (89) 63 (11) 9 (14) 6 (1)
Milton Keynes 154 148 (96) 6 (4) 1 (17) 1 (1)
Monklands 223 223 (100) 0 (0) 0 (0) 0 (0)
Musgrove Park 206 187 (91) 19 (9) 4 (21) 4 (2)
New Cross 256 211 (82) 45 (18) 6 (13) 2 (1)
Papworth 127 125 (98) 2 (2) 0 (0) 0 (0)
Peterborough 258 235 (91) 23 (9) 13 (57) 13 (5)
Poole 373 336 (90) 37 (10) 4 (11) 3 (1)
Portsmouth 335 328 (98) 7 (2) 2 (29) 2 (1)
QEHB 1838 1618 (88) 220 (12) 71 (32) 51 (3)
Royal Blackburn 572 545 (95) 27 (5) 3 (11) 6 (1)
Royal Gwent 187 173 (93) 14 (7) 5 (36) 4 (2)
Royal Liverpool 425 375 (88) 50 (12) 10 (20) 8 (2)
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TABLE 28 Summary of screening of patients through to randomisation (continued )
Site name Number screened
Excluded from
trial, n (%)
Had
SBT, n (%) Failed SBT, n (%)
Randomised
patients, n (%)
Royal Surrey 71 68 (96) 3 (4) 1 (33) 0 (0)
Royal Sussex 486 465 (96) 21 (4) 3 (14) 3 (1)
Russells Hall 105 73 (70) 32 (30) 11 (34) 7 (7)
RVH Belfast 1106 870 (79) 236 (21) 21 (9) 12 (1)
RVI Newcastle 567 558 (98) 9 (2) 2 (22) 2 (0)
Southampton 409 400 (98) 9 (2) 4 (44) 5 (1)
Southend 13 13 (100) 0 (0) 0 (0) 0 (0)
St James’s Leeds 409 371 (91) 38 (9) 14 (37) 15 (4)
St Thomas’ London 1054 950 (90) 104 (10) 45 (43) 50 (5)
UHCW 380 358 (94) 22 (6) 2 (9) 2 (1)
UHNS 427 417 (98) 10 (2) 4 (40) 3 (1)
UHOW 745 710 (95) 35 (5) 10 (29) 8 (1)
UHSM 138 127 (92) 11 (8) 1 (9) 1 (1)
Western General 452 399 (88) 53 (12) 12 (23) 8 (2)
West Middlesex 101 96 (95) 5 (5) 2 (40) 2 (2)
Wexham Park 65 58 (89) 7 (11) 2 (29) 0 (0)
Yeovil 69 66 (96) 3 (4) 1 (33) 1 (1)
York 235 201 (86) 34 (14) 18 (53) 10 (4)
Total 17,126 15,374 (90) 1752 (10) 432 (25) 364 (2)
QE, Queen Elizabeth; RI, Royal Infirmary; RVH, Royal Victoria Hospital; RVI, Royal Victoria Infirmary; UHCW, University
Hospital Coventry and Warwickshire; UHNS, University Hospitals of North Midlands; UHOW, University Hospital of Wales;
UHSM, University Hospital of South Manchester.
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TABLE 29 Summary of reasons why patients were not randomised
Site name
Number
screened
Not meeting
inclusion
criteria, n (%) Meeting exclusion criteria, n (%)
Other
reasons
for
exclusion
SBT process, n (%)
Aged
> 16
years
Passed
SBT Pregnant Tracheostomy
Neurological
deficit
NIV
contraindication
Home
ventilation
Withdrawal/
patient died
Further surgery/
procedure
requiring sedation
planned in next
48 hours
Previous
participation
in the
Breathe trial
Had SBT
(patients who
are ready for
weaning)
Failed
SBT
Addenbrooke’s 792 0 (0) 91 (72) 0 (0) 212 (27) 115 (15) 78 (10) 9 (1) 189 (24) 4 (1) 1 (0) 58 (7) 126 (16) 35 (4)
Basildon 73 0 (0) 10 (91) 0 (0) 5 (7) 33 (45) 6 (8) 0 (0) 18 (25) 0 (0) 0 (0) 0 (0) 11 (15) 1 (1)
Bedford 308 21 (4) 46 (92) 3 (1) 36 (12) 21 (7) 4 (1) 0 (0) 138 (45) 2 (1) 1 (0) 32 (10) 50 (16) 4 (1)
BHH 609 0 (0) 96 (66) 1 (0) 97 (16) 18 (3) 41 (7) 0 (0) 162 (27) 1 (0) 3 (0) 139 (23) 146 (24) 50 (8)
Blackpool 291 2 (0) 7 (54) 2 (0) 114 (39) 14 (5) 46 (16) 0 (0) 82 (28) 0 (0) 0 (0) 18 (6) 13 (4) 6 (2)
Bradford RI 270 0 (0) 14 (58) 0 (0) 82 (30) 21 (8) 7 (3) 0 (0) 125 (46) 0 (0) 1 (0) 10 (4) 24 (9) 10 (4)
Bristol RI 199 0 (0) 25 (100) 0 (0) 52 (26) 13 (7) 2 (1) 0 (0) 11 (6) 6 (3) 1 (1) 89 (45) 25 (13) 0 (0)
Broomfield 90 0 (0) 8 (100) 0 (0) 33 (37) 7 (8) 8 (9) 0 (0) 18 (20) 2 (2) 0 (0) 14 (16) 8 (9) 0 (0)
Edinburgh RI 330 1 (0) 9 (69) 0 (0) 49 (15) 44 (13) 22 (7) 3 (1) 114 (35) 0 (0) 0 (0) 84 (25) 13 (4) 4 (1)
Forth Valley 132 4 (2) 32 (100) 0 (0) 20 (15) 4 (3) 7 (5) 7 (5) 50 (38) 1 (1) 0 (0) 7 (5) 32 (24) 0 (0)
Freeman 175 0 (0) 7 (78) 0 (0) 54 (31) 16 (9) 12 (7) 0 (0) 57 (33) 2 (1) 0 (0) 25 (14) 9 (5) 2 (1)
George Eliot 86 0 (0) 3 (50) 0 (0) 37 (43) 0 (0) 11 (13) 0 (0) 26 (30) 1 (1) 0 (0) 5 (6) 6 (7) 3 (3)
Glenfield 99 0 (0) 6 (75) 0 (0) 50 (51) 11 (11) 5 (5) 0 (0) 11 (11) 1 (1) 0 (0) 13 (13) 8 (8) 2 (2)
Hillingdon 85 0 (0) 15 (52) 0 (0) 12 (14) 9 (11) 8 (9) 0 (0) 16 (19) 0 (0) 0 (0) 11 (13) 29 (34) 14 (16)
Hull RI 393 11 (1) 16 (89) 0 (0) 96 (24) 63 (16) 21 (5) 0 (0) 170 (43) 0 (0) 0 (0) 13 (3) 18 (5) 2 (1)
James Paget 95 5 (3) 2 (100) 2 (2) 25 (26) 3 (3) 1 (1) 0 (0) 50 (53) 0 (0) 0 (0) 7 (7) 2 (2) 0 (0)
John Radcliffe 93 0 (0) 32 (97) 0 (0) 11 (12) 11 (12) 1 (1) 0 (0) 8 (9) 7 (8) 0 (0) 22 (24) 33 (35) 1 (1)
King’s Lynn QE 137 1 (0) 12 (60) 0 (0) 15 (11) 8 (20) 3 (2) 0 (0) 63 (46) 1 (1) 0 (0) 26 (19) 20 (15) 8 (6)
Leicester RI 291 0 (0) 14 (70) 0 (0) 76 (26) 52 (18) 37 (13) 1 (0) 62 (21) 5 (2) 0 (0) 38 (13) 20 (7) 6 (2)
Leighton 226 1 (0) 11 (79) 0 (0) 18 (8) 15 (7) 14 (6) 0 (0) 141 (62) 0 (0) 0 (0) 23 (10) 14 (6) 3 (1)
Manchester RI 566 0 (0) 54 (86) 2 (1) 114 (20) 170 (30) 37 (7) 0 (0) 125 (22) 4 (1) 2 (0) 49 (9) 63 (11) 9 (2)
Milton Keynes 154 2 (1) 5 (83) 0 (0) 28 (18) 2 (1) 0 (0) 0 (0) 104 (68) 0 (0) 0 (0) 12 (8) 6 (4) 1 (1)
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TABLE 29 Summary of reasons why patients were not randomised (continued )
Site name
Number
screened
Not meeting
inclusion
criteria, n (%) Meeting exclusion criteria, n (%)
Other
reasons
for
exclusion
SBT process, n (%)
Aged
> 16
years
Passed
SBT Pregnant Tracheostomy
Neurological
deficit
NIV
contraindication
Home
ventilation
Withdrawal/
patient died
Further surgery/
procedure
requiring sedation
planned in next
48 hours
Previous
participation
in the
Breathe trial
Had SBT
(patients who
are ready for
weaning)
Failed
SBT
Monklands 223 1 (0) 0 (0) 0 (0) 48 (22) 18 (8) 13 (6) 0 (0) 103 (46) 5 (2) 0 (0) 35 (16) 0 (0) 0 (0)
Musgrove Park 206 10 (2) 15 (79) 0 (0) 16 (8) 17 (8) 15 (7) 3 (1) 95 (46) 1 (0) 0 (0) 30 (15) 19 (9) 4 (2)
New Cross 256 0 (0) 39 (87) 0 (0) 62 (24) 21 (27) 8 (3) 0 (0) 99 (39) 1 (0) 1 (0) 19 (7) 45 (18) 6 (2)
Papworth 127 0 (0) 2 (100) 0 (0) 30 (24) 1 (7) 12 (9) 0 (0) 25 (20) 2 (2) 0 (0) 55 (43) 2 (2) 0 (0)
Peterborough 258 3 (1) 10 (43) 1 (0) 62 (24) 19 (18) 11 (4) 0 (0) 94 (36) 0 (0) 0 (0) 45 (17) 23 (9) 13 (5)
Poole 373 1 (0) 33 (89) 1 (0) 67 (18) 67 (5) 85 (23) 3 (1) 76 (20) 0 (0) 0 (0) 36 (10) 37 (10) 4 (1)
Portsmouth 335 21 (3) 5 (71) 0 (0) 55 (16) 16 (6) 24 (7) 0 (0) 142 (42) 0 (0) 0 (0) 70 (21) 7 (2) 2 (1)
QEHB 1838 1 (0) 149 (68) 2 (0) 633 (34) 361 (5) 41 (2) 0 (0) 264 (14) 6 (0) 4 (0) 306 (17) 220 (12) 71 (4)
Royal
Blackburn
572 1 (0) 24 (89) 3 (0) 176 (31) 26 (20) 12 (2) 8 (1) 277 (48) 1 (0) 0 (0) 41 (7) 27 (5) 3 (1)
Royal Gwent 187 0 (0) 9 (64) 0 (0) 44 (24) 43 (23) 1 (1) 0 (0) 82 (44) 0 (0) 2 (1) 1 (1) 14 (7) 5 (3)
Royal Liverpool 425 1 (0) 40 (80) 0 (0) 62 (15) 83 (5) 36 (8) 2 (0) 136 (32) 1 (0) 1 (0) 53 (12) 50 (12) 10 (2)
Royal Surrey 71 0 (0) 2 (67) 0 (0) 16 (23) 10 (20) 18 (25) 2 (3) 14 (20) 0 (0) 0 (0) 8 (11) 3 (4) 1 (1)
Royal Sussex 486 0 (0) 18 (86) 0 (0) 175 (36) 24 (14) 14 (3) 1 (0) 224 (46) 0 (0) 0 (0) 27 (6) 21 (4) 3 (1)
Russells Hall 105 0 (0) 21 (66) 0 (0) 6 (6) 19 (5) 10 (10) 1 (1) 25 (24) 0 (0) 0 (0) 12 (11) 32 (30) 11 (10)
RVH Belfast 1106 16 (1) 215 (91) 1 (0) 204 (18) 98 (18) 12 (1) 1 (0) 358 (32) 3 (0) 0 (0) 177 (16) 236 (21) 21 (2)
Newcastle RVI 567 1 (0) 7 (78) 0 (0) 133 (23) 155 (1) 55 (10) 5 (1) 172 (30) 5 (1) 0 (0) 32 (6) 9 (2) 2 (0)
Southampton 409 1 (0) 5 (56) 0 (0) 59 (14) 62 (9) 40 (10) 0 (0) 164 (40) 8 (2) 0 (0) 66 (16) 9 (2) 4 (1)
Southend 13 0 (0) 0 (0) 0 (0) 1 (8) 4 (15) 1 (8) 0 (0) 3 (23) 0 (0) 0 (0) 4 (31) 0 (0) 0 (0)
St James’s
Leeds
409 0 (0) 24 (63) 0 (0) 105 (26) 85 (31) 13 (3) 4 (1) 134 (33) 0 (0) 3 (1) 27 (7) 38 (9) 14 (3)
St Thomas’
London
1054 5 (0) 59 (57) 10 (1) 300 (28) 82 (21) 59 (6) 9 (1) 292 (28) 2 (0) 1 (0) 190 (18) 104 (10) 45 (4)
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Site name
Number
screened
Not meeting
inclusion
criteria, n (%) Meeting exclusion criteria, n (%)
Other
reasons
for
exclusion
SBT process, n (%)
Aged
> 16
years
Passed
SBT Pregnant Tracheostomy
Neurological
deficit
NIV
contraindication
Home
ventilation
Withdrawal/
patient died
Further surgery/
procedure
requiring sedation
planned in next
48 hours
Previous
participation
in the
Breathe trial
Had SBT
(patients who
are ready for
weaning)
Failed
SBT
UHCW 380 0 (0) 20 (91) 0 (0) 98 (26) 53 (8) 22 (6) 1 (0) 81 (21) 0 (0) 0 (0) 103 (27) 22 (6) 2 (1)
UHNS 427 0 (0) 6 (60) 0 (0) 127 (30) 156 (14) 15 (4) 0 (0) 92 (22) 1 (0) 0 (0) 26 (6) 10 (2) 4 (1)
UHOW 745 1 (0) 25 (71) 1 (0) 101 (14) 168 (37) 121 (16) 3 (0) 273 (37) 0 (0) 0 (0) 42 (6) 35 (5) 10 (1)
UHSM 138 0 (0) 10 (91) 0 (0) 59 (43) 17 (23) 11 (8) 2 (1) 38 (28) 0 (0) 0 (0) 0 (0) 11 (8) 1 (1)
Western
General
452 5 (1) 41 (77) 0 (0) 57 (13) 209 (8) 12 (3) 10 (2) 83 (18) 0 (0) 0 (0) 23 (5) 53 (12) 12 (3)
West
Middlesex
101 0 (0) 3 (60) 0 (0) 25 (25) 8 (12) 3 (3) 0 (0) 52 (51) 1 (1) 1 (1) 6 (6) 5 (5) 2 (2)
Wexham Park 65 0 (0) 5 (71) 0 (0) 16 (25) 6 (46) 4 (6) 1 (2) 28 (43) 0 (0) 0 (0) 3 (5) 7 (11) 2 (3)
Yeovil 69 0 (0) 2 (67) 0 (0) 3 (4) 9 (9) 11 (16) 0 (0) 41 (59) 0 (0) 0 (0) 2 (3) 3 (4) 1 (1)
York 235 0 (0) 16 (47) 0 (0) 26 (11) 28 (13) 16 (7) 1 (0) 104 (44) 3 (1) 0 (0) 23 (10) 34 (14) 18 (8)
Total 17,126 116
(1)
1320
(75)
29 (0) 4002 (23) 2515 (12) 1066 (10) 77 (1) 5311 (24) 79 (1) 22 (0) 2157 (7) 1752 (10) 432 (4)
QE, Queen Elizabeth; RI, Royal Infirmary; RVH, Royal Victoria Hospital; RVI, Royal Victoria Infirmary; UHCW, University Hospital Coventry and Warwickshire; UHNS, University Hospitals of North Midlands; UHOW, University Hospital of Wales;
UHSM, University Hospital of South Manchester.
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TABLE 30 Summary of other reasons why patients were excluded from the screening process
Site name
Number
screened
Other reasons for exclusion, n (%)
Consultant
refusal
Patient
refusal
Relative
refused
Other
studies
Total other
exclusions
Blanks,
missing data
Addenbrooke’s 792 5 (1) 0 (0) 2 (0) 15 (2) 28 (4) 8 (1)
Basildon 73 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Bedford 308 0 (0) 0 (0) 0 (0) 0 (0) 32 (10) 0 (0)
BHH 609 10 (2) 0 (0) 5 (1) 9 (1) 23 (4) 92 (15)
Blackpool 291 1 (0) 0 (0) 0 (0) 4 (1) 13 (4) 0 (0)
Bradford RI 270 1 (0) 0 (0) 5 (2) 0 (0) 4 (1) 0 (0)
Bristol RI 199 7 (4) 0 (0) 0 (0) 20 (10) 23 (12) 39 (20)
Broomfield 90 2 (2) 0 (0) 4 (4) 0 (0) 4 (4) 4 (4)
Edinburgh RI 330 24 (7) 0 (0) 7 (2) 15 (5) 36 (11) 2 (1)
Forth Valley 132 0 (0) 0 (0) 2 (2) 0 (0) 5 (4) 0 (0)
Freeman 175 6 (3) 0 (0) 4 (2) 0 (0) 14 (8) 1 (1)
George Eliot 86 1 (1) 0 (0) 0 (0) 0 (0) 4 (5) 0 (0)
Glenfield 99 1 (1) 0 (0) 4 (4) 2 (2) 6 (6) 0 (0)
Hillingdon 85 0 (0) 1 (1) 5 (6) 0 (0) 5 (6) 0 (0)
Hull RI 393 2 (1) 0 (0) 0 (0) 0 (0) 11 (3) 0 (0)
James Paget 95 1 (1) 0 (0) 0 (0) 0 (0) 5 (5) 1 (1)
John Radcliffe 93 3 (3) 0 (0) 0 (0) 0 (0) 5 (5) 14 (15)
King’s Lynn QE 137 3 (2) 0 (0) 15 (11) 0 (0) 6 (4) 2 (1)
Leicester RI 291 13 (4) 0 (0) 2 (1) 0 (0) 23 (8) 0 (0)
Leighton 226 0 (0) 4 (2) 7 (3) 0 (0) 12 (5) 0 (0)
Manchester RI 566 24 (4) 1 (0) 7 (1) 2 (0) 14 (2) 1 (0)
Milton Keynes 154 3 (2) 0 (0) 1 (1) 0 (0) 8 (5) 0 (0)
Monklands 223 14 (6) 2 (1) 0 (0) 0 (0) 19 (9) 0 (0)
Musgrove Park 206 10 (5) 0 (0) 5 (2) 1 (0) 14 (7) 0 (0)
New Cross 256 0 (0) 0 (0) 1 (0) 4 (2) 13 (5) 1 (0)
Papworth 127 6 (5) 1 (1) 3 (2) 5 (4) 40 (31) 0 (0)
Peterborough 258 5 (2) 1 (0) 15 (6) 1 (0) 23 (9) 0 (0)
Poole 373 7 (2) 1 (0) 14 (4) 2 (1) 12 (3) 0 (0)
Portsmouth 335 3 (1) 0 (0) 11 (3) 2 (1) 47 (14) 7 (2)
QEHB 1838 17 (1) 8 (0) 5 (0) 18 (1) 210 (11) 48 (3)
Royal Blackburn 572 6 (1) 0 (0) 2 (0) 2 (0) 31 (5) 0 (0)
Royal Gwent 187 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 0 (0)
Royal Liverpool 425 4 (1) 1 (0) 36 (8) 0 (0) 12 (3) 0 (0)
Royal Surrey 71 5 (7) 0 (0) 0 (0) 0 (0) 3 (4) 0 (0)
Royal Sussex 486 0 (0) 1 (0) 3 (1) 6 (1) 17 (3) 0 (0)
Russells Hall 105 2 (2) 0 (0) 3 (3) 0 (0) 6 (6) 1 (1)
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TABLE 30 Summary of other reasons why patients were excluded from the screening process (continued )
Site name
Number
screened
Other reasons for exclusion, n (%)
Consultant
refusal
Patient
refusal
Relative
refused
Other
studies
Total other
exclusions
Blanks,
missing data
RVH Belfast 1106 2 (0) 0 (0) 2 (0) 18 (2) 125 (11) 30 (3)
RVI Newcastle 567 7 (1) 2 (0) 5 (1) 0 (0) 18 (3) 0 (0)
Southampton 409 1 (0) 0 (0) 4 (1) 5 (1) 56 (14) 0 (0)
Southend 13 0 (0) 0 (0) 0 (0) 0 (0) 4 (31) 0 (0)
St James’s Leeds 409 3 (1) 0 (0) 0 (0) 1 (0) 8 (2) 15 (4)
St Thomas’ London 1054 15 (1) 3 (0) 15 (1) 61 (6) 80 (8) 16 (2)
UHCW 380 7 (2) 0 (0) 1 (0) 14 (4) 11 (3) 70 (18)
UHNS 427 3 (1) 0 (0) 2 (0) 10 (2) 11 (3) 0 (0)
UHOW 745 7 (1) 1 (0) 4 (1) 3 (0) 27 (4) 0 (0)
UHSM 138 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Western General 452 1 (0) 0 (0) 2 (0) 0 (0) 20 (4) 0 (0)
West Middlesex 101 0 (0) 0 (0) 0 (0) 0 (0) 6 (6) 0 (0)
Wexham Park 65 0 (0) 0 (0) 1 (2) 0 (0) 2 (3) 0 (0)
Yeovil 69 0 (0) 0 (0) 0 (0) 0 (0) 2 (3) 0 (0)
York 235 2 (1) 3 (1) 9 (4) 0 (0) 9 (4) 0 (0)
Total 17,126 234 (1) 30 (0) 213 (0) 220 (2) 1108 (4) 352 (1)
QE, Queen Elizabeth; RI, Royal Infirmary; RVH, Royal Victoria Hospital; RVI, Royal Victoria Infirmary; UHCW, University
Hospital Coventry and Warwickshire; UHNS, University Hospitals of North Midlands; UHOW, University Hospital of Wales;
UHSM, University Hospital of South Manchester.
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Appendix 2 Randomised participants by site
and treatment
TABLE 31 Randomised participants by site and treatment
Site name
Trial group, n (%)
Total
(N= 364), n (%)
Invasive weaning
(N= 182)
Non-invasive weaning
(N= 182)
Addenbrooke’s 10 (5) 9 (5) 19 (5)
Basildon 0 1 (1) 1 (0)
Bedford 1 (1) 2 (1) 3 (1)
BHH 30 (16) 30 (16) 60 (16)
Blackpool 3 (2) 3 (2) 6 (2)
Bradford RI 4 (2) 5 (3) 9 (2)
Edinburgh RI 1 (1) 2 (1) 3 (1)
Freeman 0 1 (1) 1 (0)
George Eliot 0 2 (1) 2 (1)
Glenfield 1 (1) 1 (1) 2 (1)
Hillingdon 7 (4) 6 (3) 13 (4)
Hull RI 0 1 (1) 1 (0)
King’s Lynn QE 3 (2) 4 (2) 7 (2)
Leicester RI 2 (1) 3 (2) 5 (1)
Leighton 1 (1) 2 (1) 3 (1)
Manchester RI 3 (2) 3 (2) 6 (2)
Milton Keynes 1 (1) 0 1 (0)
Musgrove Park 2 (1) 2 (1) 4 (1)
New Cross 1 (1) 1 (1) 2 (1)
Peterborough 7 (4) 6 (3) 13 (4)
Poole 1 (1) 2 (1) 3 (1)
Portsmouth 1 (1) 1 (1) 2 (1)
QEHB 26 (14) 25 (14) 51 (14)
Royal Blackburn 3 (2) 3 (2) 6 (2)
Royal Gwent 2 (1) 2 (1) 4 (1)
Royal Liverpool 4 (2) 4 (2) 8 (2)
Royal Sussex 2 (1) 1 (1) 3 (1)
Russells Hall 4 (2) 3 (2) 7 (2)
RVH Belfast 6 (3) 6 (3) 12 (3)
RVI Newcastle 1 (1) 1 (1) 2 (1)
Southampton 2 (1) 3 (2) 5 (1)
continued
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TABLE 31 Randomised participants by site and treatment (continued )
Site name
Trial group, n (%)
Total
(N= 364), n (%)
Invasive weaning
(N= 182)
Non-invasive weaning
(N= 182)
St James’s Leeds 9 (5) 6 (3) 15 (4)
St Thomas’ London 26 (14) 24 (13) 50 (14)
UHCW 2 (1) 0 2 (1)
UHNS 1 (1) 2 (1) 3 (1)
UHOW 4 (2) 4 (2) 8 (2)
UHSM 1 (1) 0 1 (0)
Western General 4 (2) 4 (2) 8 (2)
West Middlesex 0 2 (1) 2 (1)
Yeovil 1 (1) 0 1 (0)
York 5 (3) 5 (3) 10 (3)
QE, Queen Elizabeth; RI, Royal Infirmary; RVH, Royal Victoria Hospital; RVI, Royal Victoria Infirmary; UHCW, University
Hospital Coventry and Warwickshire; UHNS, University Hospitals of North Midlands; UHOW, University Hospital of Wales;
UHSM, University Hospital of South Manchester.
TABLE 32 Randomised participants by randomisation strata and treatment
Site name
Absence of COPD Presence of COPD
Non-operative Postoperative Non-operative Postoperative
Invasive
weaning
Non-invasive
weaning
Invasive
weaning
Non-invasive
weaning
Invasive
weaning
Non-invasive
weaning
Invasive
weaning
Non-invasive
weaning
Addenbrooke’s 4 6 5 1 – – 1 2
Basildon – 1 – – – – – –
Bedford 1 – – 1 – 1 – –
BHH 18 21 5 7 7 1 1
Blackpool 2 3 – – 1 – – –
Bradford RI 3 3 – 2 – – 1 –
Edinburgh RI – 1 1 – – 1 – –
Freeman – 1 – – – – – –
George Eliot – 1 – – – 1 – –
Glenfield – – – 1 – – 1 –
Hillingdon 3 3 3 1 1 2
Hull RI – – – 1 – – – –
King’s Lynn QE 1 2 – 1 2 1 – –
Leicester RI 2 1 – 1 – 1 – –
Leighton 1 2 – – – – – –
Manchester RI 2 2 – 1 1 – – –
Milton Keynes – – 1 – – – – –
Musgrove Park 1 1 1 – – 1 – –
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TABLE 32 Randomised participants by randomisation strata and treatment (continued )
Site name
Absence of COPD Presence of COPD
Non-operative Postoperative Non-operative Postoperative
Invasive
weaning
Non-invasive
weaning
Invasive
weaning
Non-invasive
weaning
Invasive
weaning
Non-invasive
weaning
Invasive
weaning
Non-invasive
weaning
New Cross – – 1 – – 1 – –
Peterborough 6 4 1 1 – – – 1
Poole 1 2 – – – – – –
Portsmouth – 1 – – 1 – – –
QEHB 14 13 11 8 1 3 1
Royal
Blackburn
2 1 – 1 – 1 1 –
Royal Gwent 2 1 – – – 1 – –
Royal Liverpool 1 2 2 1 – 1 1 –
Royal Sussex – 1 2 – – – – –
Russells Hall 4 2 – 1 – – – –
RVH Belfast 4 2 – 3 – – 2 1
RVI Newcastle 1 – – – – 1 – –
Southampton 1 2 1 1 – – – –
St James’s
Leeds
4 3 3 2 2 1 – –
St Thomas’
London
15 11 7 11 3 1 1 1
UHCW – – 2 – – – – –
UHNS 1 – – – – 2 – –
UHOW 3 2 1 1 – 1 – –
UHSM – – – – – – 1 –
Western
General
4 1 – 2 – 1 – –
West
Middlesex
– 1 – – – 1 – –
Yeovil – – – – 1 – – –
York 2 5 – – 3 – – –
Total 103 102 47 49 23 24 9 7
QE, Queen Elizabeth; RI, Royal Infirmary; RVH, Royal Victoria Hospital; RVI, Royal Victoria Infirmary; UHCW, University
Hospital Coventry and Warwickshire; UHNS, University Hospitals of North Midlands; UHOW, University Hospital of Wales;
UHSM, University Hospital of South Manchester.
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Appendix 3 Health economics tables
TABLE 33 Derivation of expected costs (discounted raw data)
Time
(months)
NIV survival
rate
IMV survival
rate
NIV expected costs
(equal resource use)a (£)
IMV expected
costs (£)
NIV expected
costsb (£)
0 1 1 Use observed Use observed Use observed
3 0.79 0.76 Use observed Use observed Use observed
6 0.76 0.70 Use observed Use observed Use observed
9 0.75 0.67 801 716 1056
12 0.74 0.64 790 684 1042
15 0.73 0.61 728 608 959
18 0.72 0.60 717 598 946
21 0.71 0.58 708 578 933
24 0.71 0.56 708 558 933
27 0.70 0.55 674 529 889
30 0.70 0.54 674 520 889
33 0.69 0.53 665 511 876
36 0.69 0.52 665 501 876
39 0.69 0.51 642 475 847
42 0.68 0.50 633 465 834
45 0.68 0.49 633 456 834
48 0.68 0.48 602 447 834
51 0.67 0.47 602 423 794
54 0.67 0.47 602 423 794
57 0.67 0.46 602 414 794
60 0.67 0.45 602 405 794
Total 12,048 9311 15,924
a Assuming IMV and NIV future (after 6 months) health resource use are equal (only extrapolate costs > 6 months included
in estimates).
b Assuming future costs on the NIV are carried forward (as observed).
Note
All costs after 1 year were discounted at 3.5% per annum.
TABLE 34 Summary of longer-term cost-effectiveness analyses scenarios
Analyses Survival Utilities between groups Costs between groups
1. Primary Different between
groups
Equal between groups after 6 months
(set NIV = IMV)
Equal between groups after 6 months
(set NIV = IMV)
Sensitivity analyses
2. Decrease by 10%
on NIV
Equal between groups after 6 months
(set NIV = IMV)
Equal between groups after 6 months
(set NIV = IMV)
3. Different between
groups
Unequal between groups (carried forward) Unequal between groups (carried forward)
4. Different between
groups
Unequal between groups (carried forward) Equal between groups after 6 months
(set NIV = IMV)
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TABLE 35 Resource use by trial allocation, resource category and trial period for complete cases
Resource use category by time period
Trial group
Non-invasive weaning
(N= 182)
Invasive weaning
(N= 182)
Randomisation to hospital discharge
Number of days in ICU [mean (SE)] 14.0 (1.078) 15.0 (1.12)
Maximum number of organs supported [n (%)]
0 1 (< 1) 0
1 5 (3) 6 (3)
2 131 (72) 139 (76)
3 43 (24) 34 (19)
4 2 (1) 3 (2)
Days in ICU for supporting [n (%)]
0 organs 7.0 (n/c)a 0
1 organ 12.8 (3.07) 8.0 (2.2)
2 organs 9.7 (0.64) 12.9 (0.7)
3 organs 18.1 (1.50) 13.1 (1.6)
4 organs 10.5 (3.50) 16.0 (7.4)
Highest level of care [n (%)]
0/1 0 0
2 18 (10) 2 (1)
3 164 (9) 180 (99)
Days in ICU with highest level of care as: [mean (SE)]
0/1 10.2 (0.78) 13.4 (1.06)
2 10.4 (0.83) 10.7 (0.74)
3 19.7 (2.15) 17.1 (1.78)
Days in ICU with highest level of care as: [n (%)]
Tracheostomy 43 (24) 55 (30)
Antifungal use 10 (5) 21 (12)
Antiviral use 2 (1) 0
Emergency transport 37 (20) 39 (21)
Post discharge to 3 months (post randomisation) (3 months)
Non-invasive weaning
(N = 95)
Invasive weaning
(N = 91)
Inpatient care (hospital readmission) [mean (SE) n (%)]
Length of stay (days) 2.8 (1.01) 19 (20) 6.0 (1.61) 22 (24)
Outpatient care (hospitals/clinics) [mean (SE) n (%)]
Outpatient clinic (number of visits) 1.3 (0.20) 51 (54) 1.6 (0.30) 54 (59)
Radiology: MRI scan (number of visits) 0.1 (0.03) 4 (4) 0.0 (0.02) 4 (4)
Radiology: CT (number of visits) 0.1 (0.05) 7 (7) 0.1 (0.04) 10 (11)
Radiology: radiography (number of visits) 0.3 (0.09) 16 (17) 0.2 (0.05) 15 (17)
Radiology: ultrasonography (number of visits) 0.0 (0.02) 4 (4) 0.1 (0.03) 6 (7)
Hospital A&E (number of visits) 0.2 (0.05) 9 (10) 0.2 (0.06) 8 (9)
Other service: (number of visits) 1.1 (0.49) 24 (25) 0.8 (0.19) 26 (29)
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TABLE 35 Resource use by trial allocation, resource category and trial period for complete cases (continued )
Resource use category by time period
Trial group
Non-invasive weaning
(N= 182)
Invasive weaning
(N= 182)
Residential care services [mean (SE) n (%)]
Residential care home (number of days) 0.1 (0.08) 1 (1) 0.4 (0.24) 3 (3)
Rehabilitation centre (number of days) 0.7 (0.33) 5 (5) 1.6 (0.69) 6 (7)
Warden-controlled residence (number of days) 0.0 (0.00) 0 (0) 0.0 (0.00) 0 (0)
Day centre run by your local authority (number of days) 0.0 (0.00) 0 (0) 0.0 (0.00) 0 (0)
Other service (number of days) 0.5 (0.35) 4 (4) 0.2 (0.15) 2 (2)
Community health and social care [mean (SE) n (%)]
GP surgery visit (number of visits) 2.1 (0.26) 59 (62) 1.9 (0.29) 58 (64)
GP home visit (number of visits) 0.3 (0.07) 19 (20) 0.5 (0.15) 20 (22)
GP telephone consultation (number of visits) 0.5 (0.12) 18 (19) 0.5 (0.13) 19 (21)
District nurse (number of visits) 3.5 (0.96) 33 (35) 3.7 (1.15) 29 (32)
Health visitor (number of visits) 0.0 (0.00) 0 (0) 0.0 (0.03) 2 (2)
Social worker (number of visits) 0.2 (0.11) 3 (3) 0.2 (0.05) 9 (10)
Physiotherapist (number of visits) 1.3 (0.41) 23 (24) 1.2 (0.29) 22 (24)
Occupational therapist (number of visits) 0.8 (0.29) 13 (14) 0.4 (0.10) 15 (16)
Counsellor (number of visits) 0.2 (0.14) 4 (4) 0.0 (0.04) 1 (1)
Psychologist (number of visits) 0.0 (0.02) 2 (2) 0.1 (0.07) 4 (4)
Home help/care worker (number of visits) 6.8 (2.40) 12 (13) 3.9 (2.10) 9 (10)
Other (number of visits) 2.2 (1.06) 18 (19) 2.2 (1.05) 19 (21)
Medication (on prescription)
Number of medications [mean (SE) n (%)] 5.1 (0.46) 73 (77) 4.0 (0.39) 68 (75)
0 medications [n (%)] 17 (18) 22 (24)
1 medication [n (%)] 8 (8) 11 (12)
2 medications [n (%)] 9 (9) 4 (4)
3 medications [n (%)] 5 (5) 8 (9)
> 3 medications [n (%)] 51 (54) 45 (50)
Medication (over the counter)
Number of medications [mean (SE) n (%)] 4.7 (1.11) 13 (14) 5.9 (1.36) 12 (13)
0 medications [n (%)] 78 (82) 81 (89)
1 medication [n (%)] 6 (6) 2 (2)
2 medications [n (%)] 0 0
3 medications [n (%)] 0 0
> 3 medications [n (%)] 7 (7) 8 (9)
Equipment and aids
Patients who required equipment and aids [n (%)] 53 (56) 59 (65)
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TABLE 35 Resource use by trial allocation, resource category and trial period for complete cases (continued )
Resource use category by time period
Trial group
Non-invasive weaning
(N= 182)
Invasive weaning
(N= 182)
Provider, n (%)
Health service/NHS 44 (46) 46 (51)
Patient 8 (8) 16 (18)
Charity 1 (1) 4 (4)
Social services 7 (7) 4 (4)
Other/not stated 1 (1) 2 (2)
Additional resource use by patient or partner/relative, n (%)
Patients/partner/relative that used an additional resource 30 (32) 32 (35)
Travel cost incurred 19 (20) 25 (27)
Child care 1 (1) 1 (1)
Income lost 7 (7) 9 (10)
Housework 8 (8) 3 (3)
Laundry 4 (4) 3 (3)
Other 1 (1) 2 (2)
Post discharge 3 months to 6 months (post randomisation)
(3 to 6 months)
Non-invasive weaning
(N = 93)
Invasive weaning
(N = 84)
Inpatient care (hospital readmission) [mean (SE) n (%)]
Length of stay (days)/number of hospital visits 3.1 (1.26) 16 (17) 4.3 (2.19) 23 (27.4)
Outpatient care (hospitals/clinics) (number of visits) [mean (SE) n (%)]
Outpatient clinic 1.9 (0.35) 49 (53) 1.5 (0.16) 61 (73)
Radiology: MRI scan 0.1 (0.05) 7 (8) 0.1 (0.04) 9 (11)
Radiology: CT 0.2 (0.06) 15 (16) 0.2 (0.04) 14 (17)
Radiology: radiography 0.2 (0.05) 12 (13) 0.2 (0.06) 12 (14)
Radiology: ultrasonography 0.1 (0.03) 6 (7) 0.1 (0.04) 11 (13)
Hospital A&E 0.1 (0.05) 7 (8) 0.2 (0.06) 10 (12)
Other service: 0.8 (0.30) 16 (17) 1.1 (0.45) 28 (33)
Residential care services (number of days) [mean (SE) n (%)]
Residential care home 0.0 (0.00) 0 (0) 1.3 (1.02) 2 (2)
Rehabilitation centre 0.0 (0.00) 0 (0) 1.8 (1.23) 3 (4)
Warden-controlled residence 0.0 (0.00) 0 (0) 0.0 (0.00) 0 (0)
Day centre run by local authority 0.0 (0.00) 0 (0) 0.0 (0.01) 1 (1)
Other service 0.0 (0.00) 0 (0) 0.0 (0.00) 0 (0)
Community health and social care (number of visits) [mean (SE) n (%)]
GP surgery visit 1.9 (0.34) 48 (52) 2.0 (0.23) 61 (73)
GP home visit 0.2 (0.06) 9 (10) 0.4 (0.14) 12 (14)
GP telephone consultation 0.4 (0.09) 20 (22) 0.2 (0.07) 13 (16)
District nurse 3.9 (1.66) 18 (19) 5.4 (2.16) 28 (33)
Health visitor 0.1 (0.05) 3 (3) 1.0 (0.98) 4 (5)
Social worker 0.0 (0.04) 2 (2) 0.2 (0.15) 4 (5)
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TABLE 35 Resource use by trial allocation, resource category and trial period for complete cases (continued )
Resource use category by time period
Trial group
Non-invasive weaning
(N= 182)
Invasive weaning
(N= 182)
Physiotherapist 0.7 (0.24) 14 (15) 0.9 (0.37) 14 (17)
Occupational therapist 0.2 (0.15) 5 (5) 0.3 (0.14) 9 (11)
Counsellor 0.2 (0.16) 4 (4) 0.1 (0.04) 2 (2)
Psychologist 0.1 (0.04) 2 (2) 0.1 (0.04) 5 (6.0)
Home help/care worker 2.5 (1.43) 4 (4) 3.8 (2.35) 5 (6)
Other 1.1 (0.35) 13 (14) 1.5 (0.80) 16 (19)
Medication (on prescription)
Number of medications [mean (SE) n (%)] 4.8 (0.46) 67 (72) 4.9 (0.50) 67 (80)
0 medications [n (%)] 15 (16) 25 (30)
1 medication [n (%)] 13 (14) 12 (14)
2 medications [n (%)] 5 (5) 2 (2)
3 medications [n (%)] 5 (5) 4 (5)
> 3 medications [n (%)] 44 (47) 49 (58)
Medication (over the counter)
Number of medications [mean (SE) n (%)] 4.7 (1.11) 13 (14) 5.9 (1.36) 12 (14)
0 medications [n (%)] 74 (80) 80 (95)
1 medication [n (%)] 3 (3) 3 (4)
2 medications [n (%)] 0 (0) 1 (1)
3 medications [n (%)] 2 (2) 1 (1)
> 3 medications [n (%)] 3 (3) 7 (8)
Equipment and aids
Patients who required equipment and aids [n (%)] 27 (29) 42 (50)
Provider, n (%)
Health service/NHS 24 (26) 25 (30)
Patient 4 (4) 12 (14)
Charity 0 (0) 4 (5)
Social services 2 (2) 7 (8)
Other/not stated 2 (2) 4 (5)
Additional resource use by patient or partner/relative, n (%)
Patients/partner/relative that used an additional resource 23 (25) 35 (42)
Travel cost incurred 19 (20) 23 (27)
Child care 0 (0) 0 (0)
Income lost 7 (8) 8 (10)
Housework 5 (5) 6 (7)
Laundry 4 (4) 4 (5)
Other 0 (0) 1 (1)
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TABLE 35 Resource use by trial allocation, resource category and trial period for complete cases (continued )
Resource use category by time period
Trial group
Non-invasive weaning
(N= 182)
Invasive weaning
(N= 182)
Post discharge to 6 months (post randomisation) (6 months)
Non-invasive weaning
(N = 93)
Invasive weaning
(N = 84)
Inpatient care (hospital readmission) [mean (SE) n (%)]
Length of stay (days)/number of hospital visits 9.5 (2.45) 35 (38) 5.2 (1.52) 28 (33)
Outpatient care (hospitals/clinics) (number of visits) [mean (SE) n (%)]
Outpatient clinic 2.9 (0.35) 77 (83) 2.8 (0.37) 71 (85)
Radiology: MRI scan 0.1 (0.04) 13 (14) 0.1 (0.05) 10 (12)
Radiology: CT 0.3 (0.06) 20 (22) 0.3 (0.08) 18 (21)
Radiology: radiography 0.3 (0.07) 25 (27) 0.4 (0.10) 23 (27)
Radiology: ultrasonography 0.2 (0.05) 15 (16) 0.1 (0.03) 10 (12)
Hospital A&E 0.3 (0.09) 15 (16) 0.2 (0.08) 14 (17)
Other service: 1.7 (0.44) 48 (52) 1.7 (0.52) 35 (42)
Residential care services (number of days) [mean (SE) n (%)]
Residential care home 1.5 (0.99) 4 (4) 0.1 (0.07) 1 (1)
Rehabilitation centre 3.1 (1.27) 9 (10) 0.6 (0.31) 5 (6)
Warden-controlled residence 0.0 (0.00) 0 (0) 0.0 (0.00) 0 (0)
Day centre run by your local authority 0.0 (0.01) 1 (1) 0.0 (0.00) 0 (0)
Other service 0.2 (0.14) 2 (2) 0.5 (0.32) 4 (5)
Community health and social care (number of visits) [mean (SE) n (%)]
GP surgery visit 3.5 (0.41) 76 (82) 3.5 (0.44) 77 (92)
GP home visit 0.8 (0.24) 23 (25) 0.4 (0.10) 24 (29)
GP telephone consultation 0.6 (0.15) 27 (29) 0.8 (0.14) 29 (35)
District nurse 8.4 (2.75) 46 (49) 6.6 (2.00) 42 (50)
Health visitor 1.0 (0.89) 6 (6) 0.1 (0.04) 3 (4)
Social worker 0.3 (0.16) 11 (12) 0.2 (0.12) 3 (4)
Physiotherapist 1.9 (0.44) 30 (32) 1.8 (0.46) 31 (37)
Occupational therapist 0.6 (0.16) 21 (23) 0.9 (0.34) 17 (20)
Counsellor 0.1 (0.06) 3 (3) 0.4 (0.25) 5 (6)
Psychologist 0.2 (0.09) 8 (9) 0.1 (0.06) 2 (2)
Home help/care worker 7.1 (2.98) 13 (14) 8.3 (2.95) 13 (15)
Other 3.4 (1.21) 28 (30) 2.9 (1.09) 24 (29)
Medication (on prescription)
Number of medications [mean (SE) n (%)] 4.6 (0.849) 21 (23) 5.8 (0.953) 24 (29)
0 medications 61 (66) 68 (81)
1 medication 9 (10) 5 (6)
2 medications 0 3 (4)
3 medications 2 (2) 1 (1)
> 3 medications 10 (11) 15 (18)
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TABLE 35 Resource use by trial allocation, resource category and trial period for complete cases (continued )
Resource use category by time period
Trial group
Non-invasive weaning
(N= 182)
Invasive weaning
(N= 182)
Medication (over the counter)
Number of medications [mean (SE) n (%)] 4.6 (0.849) 21 (23) 5.8 (0.953) 24 (29)
0 medications 61 (66) 68 (81)
1 medication 9 (10) 5 (6)
2 medications 0 3 (4)
3 medications 2 (2) 1 (1)
> 3 medications 10 (11) 15 (18)
Equipment and aids
Patients who required equipment and aids [n (%)] 70 (75) 61 (73)
Provider, n (%)
Health service/NHS 54 (58) 54 (64)
Patient 24 (26) 10 (12)
Charity 6 (6) 1 (1)
Social services 10 (11) 7 (8)
Other/not stated 6 (6) 3 (4)
Additional resource use by patient or partner/relative, n (%)
Patients/partner/relative that used an additional resource 46 (49) 41 (49)
Travel cost incurred 35 (38) 32 (38)
Child care 1 (1) 1 (1)
Income lost 11 (12) 10 (12)
Housework 7 (8) 10 (12)
Laundry 6 (6) 6 (7)
Other 3 (3) 1 (1)
A&E, accident and emergency; n/c, not calculable.
a The SE was not calculable because only one participant had a stay of 7 days in ICU.
Note
n indicates the number of participants who used a health resource at least once at a given assessment.
Patients with missing data at 3 months present with data at 6 months and patients with missing data at 6 months present
with data at 3 months.
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TABLE 36 Unit costs for resource items
Resource item
Unit cost
(2015–16 prices)a
(£)
Unit of
analysis Source
Intervention related
Number of organs supported in the ICU (includes antimicrobial and sedative costs)
0 759.00 Per day NHS Reference Costs 2016 to 2017, Critical Care59
1 1031.00 Per day NHS Reference Costs 2016 to 2017, Critical Care59
2 1399.00 Per day NHS Reference Costs 2016 to 2017, Critical Care59
3 1619.00 Per day NHS Reference Costs 2016 to 2017, Critical Care59
4 1794.00 Per day NHS Reference Costs 2016 to 2017, Critical Care59
5 1977.00 Per day NHS Reference Costs 2016 to 2017, Critical Care59
≥ 6 2274.00 Per day NHS Reference Costs 2016 to 2017, Critical Care59
Highest level of care
Level 3 1641.92 NICE – Rehabilitation After Critical Illness (CG83) 200960
Level 2 1641.92 NICE – Rehabilitation After Critical Illness (CG83) 200960
Level 1 303.65 NHS Reference Costs 2013 to 201461
Tracheostomy 4151.51 Per
procedure
NHS Reference Costs 2014 to 201536
High-cost drugs
Antibiotics
Linezolid 0.074 Per mg Prescription Cost Analysis – England, 201637
Meropenem 0.016 Per mg Prescription Cost Analysis – England, 201637
Metronidazole 0.002 Per mg Prescription Cost Analysis – England, 201637
Antifungals
Amphotericin
Liposomal
1.644 Per mg Prescription Cost Analysis – England, 201637
Caspofungin 6.553 Per mg Prescription Cost Analysis – England, 201637
Voriconazole 0.197 Per mg Prescription Cost Analysis – England, 201637
Anidulafungin 3.000 Per mg Prescription Cost Analysis – England, 201637
Micafungin 3.41 Per mg Prescription Cost Analysis – England, 201637
Antiviral
Abacavir 0.010 Per mg Prescription Cost Analysis – England, 201637
Atazanavir 0.034 Per mg Prescription Cost Analysis – England, 201637
Didanosine 0.013 Per mg Prescription Cost Analysis – England, 201637
Efavirenz 0.011 Per mg Prescription Cost Analysis – England, 201637
Emtricitabine 0.023 Per mg Prescription Cost Analysis – England, 201637
Enfuvirtide 10.02 Per mg Prescription Cost Analysis – England, 201637
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TABLE 36 Unit costs for resource items (continued )
Resource item
Unit cost
(2015–16 prices)a
(£)
Unit of
analysis Source
Fesamprenavir 0.005 Per mg Prescription Cost Analysis – England, 201637
Idinavir 0.003 Per mg Prescription Cost Analysis – England, 201637
Lopinavir with
Ritonavir
0.013 Per mg Prescription Cost Analysis – England, 201637
Navirapine 0.010 Per mg Prescription Cost Analysis – England, 201637
Ritonavir 0.006 Per mg Prescription Cost Analysis – England, 201637
Saquinavir 0.004 Per mg Prescription Cost Analysis – England, 201637
Stavudine 0.125 Per mg Prescription Cost Analysis – England, 201637
Tenofovir disoproxil 0.028 Per mg Prescription Cost Analysis – England, 201637
Zidovudine with
lamivudine and
Abacavir
0.024 Per mg Prescription Cost Analysis – England, 201637
Darunavir 0.012 Per mg Prescription Cost Analysis – England, 201637
Health resource use
Inpatient care
Cost per inpatient stay 173.56 Per bed-day PSSRU – Unit Costs of Health and Social Care 2010,62 p. 31
General medical ward 400.0 Per day DHCS Communication (2015) https://data.gov.uk/
data-request/nhs-hospital-stay (Department of Health
and Social Care, March 2017, personal communication)
Outpatient care
Outpatient clinic 115.52 Per visit NHS Reference Costs 2014 to 201536
MRI scan 170.74 Per test NHS Reference Costs 2013 to 201436
CT 94.06 Per test NHS Reference Costs 2013 to 201436
Radiography 27.60 Per test Portsmouth Clinical Commissioning Group63
Ultrasonography 48.05 Per test NHS Reference Costs 2013 to 201461
Emergency
department
133.76 Per session NHS Reference Costs 2014 to 201536
Emergency transport £261.35 Per transfer PSSRU – Unit Costs of Health and Social Care 201164
Residential care
Residential care home 151.63 Per day PSSRU – Unit Costs of Health and Social Care 201338
Rehabilitation centre 101.08 Per day PSSRU – Unit Costs of Health and Social Care 201338
Warden-controlled
residence
63.06 Per day PSSRU – Unit Costs of Health and Social Care 201338
Local authority day
centre
39.87 Per day PSSRU – Unit Costs of Health and Social Care 201338
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TABLE 36 Unit costs for resource items (continued )
Resource item
Unit cost
(2015–16 prices)a
(£)
Unit of
analysis Source
Community health and social care
GP surgery 44.59 Per contact PSSRU – Unit Costs of Health and Social Care 2015,39 p. 177
GP home visit 138.35 Per home
visit
PSSRU – Unit Costs of Health and Social Care 2010,62 p. 167
GP telephone call 27.36 Per call PSSRU – Unit Costs of Health and Social Care 2015,39 p. 177
District nurse 38.51 Per contact PSSRU – Unit Costs of Health and Social Care 2015,39 p. 169
Health visitor 54.72 Per hour PSSRU – Unit Costs of Health and Social Care 2015,39 p. 169
Social worker 57.76 Per contact
(average)
PSSRU – Unit Costs of Health and Social Care 2015,39 p. 188
Community
physiotherapist
49.02 Per contact PSSRU – Unit Costs of Health and Social Care 201338
Occupational therapist 74.63 Per contact
(average)
PSSRU – Unit Costs of Health and Social Care 2013,38 p. 176
Counsellor 49.07 Per hour PSSRU – Unit Costs of Health and Social Care 2013,38 p. 54
Community
psychologist
60.32 Per hour PSSRU – Unit Costs of Health and Social Care 201338
Home help/care
worker
24.32 Per hour PSSRU – Unit Costs of Health and Social Care 2015,39 p. 201
Medication
Various medications Range £0.01 –
£271.88
Per dose Prescription Cost Analysis – England, 201637
Equipment and adaptations
Various aidsb Range: 4.8 –
930.0
Per item National Catalogue (2014–15)41
a Inflated to 2015–16 prices using Unit Costs of Health and Social Care 2016.40
b Equipment aids include support rails, bathroom aids and accessories, ramps, beds, wheelchairs and bed supports.
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TABLE 37 Patient-reported EQ-5D-3L by trial allocation, trial period and dimension
Time point
EQ-5D-3L dimension, n (%)
EQ VAS UtilityMobility Self care Usual activities Pain/discomfort Anxiety/depression
Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 Mean (SE) Mean (SE)
Prior to hospital admissiona
NIV (N = 122) 63 (52) 56 (46) 3 (2) 93 (76) 27 (22) 2 (2) 69 (57) 39 (32) 14 (11) 63 (52) 43 (35) 16 (13) 74 (61) 37 (30) 10 (8) 58.7 (1.98) 0.66 (0.031)
IMV (N = 120) 65 (54) 49 (41) 6 (5) 88 (73) 25 (21) 7 (6) 76 (63) 35 (29) 9 (8) 66 (55) 39 (33) 15 (13) 78 (65) 34 (28) 8 (7) 60.7 (2.01) 0.67 (0.033)
p-valueb 0.491 0.733
3 months post ICU discharge
NIV (N = 91) 25 (27) 66 (71) 2 (2) 53 (58) 36 (40) 3 (3) 21 (23) 52 (57) 19 (21) 26 (29) 56 (62) 11 (12) 39 (43) 45 (49) 8 (9) 60.9 (2.03) 0.53 (0.035)
IMV (N = 88) 24 (27) 64 (71) 2 (2) 52 (59) 35 (40) 4 (5) 21 (24) 54 (61) 15 (17) 26 (30) 55 (63) 9 (10) 49 (56) 36 (41) 5 (6) 62.5 (2.11) 0.56 (0.035)
p-valueb 0.593 0.543
6 months post ICU discharge
NIV (N = 91) 28 (31) 59 (65) 4 (4) 54 (59) 32 (35) 5 (5) 27 (30) 46 (51) 19 (21) 30 (33) 47 (52) 15 (16) 45 (49) 40 (44) 6 (7) 61.7 (2.35) 0.53 (0.032)
IMV (N = 82) 31 (38) 50 (61) 1 (1) 53 (65) 26 (32) 2 (2) 25 (30) 48 (59) 7 (9) 33 (40) 45 (55) 3 (4) 50 (61) 26 (32) 4 (5) 65.0 (2.34) 0.66 (0.039)
p-valueb 0.377 0.0147
a These data were recollected using questionnaires administered at the point of discharge following the initial hospitalisation.
b Comparisons of EQ VAS and Utility score using student’s t-test for unequal variances based on complete cases.
Note
Some categories have missing values (not included in percentage computation); for EQ VAS, n = 92 and 91 for NIV and IMV respectively at 3 months.
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TABLE 38 Longer-term cost-effectiveness results and sensitivity analyses
Analyses
Incremental
cost (£)
Incremental
QALY ICER INMBa (£)
Probability of
cost-effectivenessa
Base case (trial) (302) 0.01589 NIV
dominant
779 0.59
1. Assuming costs and utilities are
equal between groups after 6 monthsb
2737 0.424 £4651 10,748 1.0
Sensitivity analyses
2. Decrease in extrapolated survival
rates in NIV group by 10%, equal costs
and utilities carried forwardc
237 0.028 £8393 603 0.96
3. Assuming costs and utilities are
unequal between groups, costs and
utilities carried forwardd
6631 0.019 £349,000 (6061) 0.01
4. Assumes costs are equal between
groups, but utilities carried forwarde
2737 0.019 £144,052 (2167) 0.02
a Willingness to pay of £30,000.
b No further future differential benefits or costs assumed between treatments.
c Survival rates on NIV are lower by 10%; costs assumed equal between groups, but utilities carried forward.
d Future costs (after 6 months) assumed unequal between groups; utility and costs observed at 6 months in trial carried forward.
e Assumes no differential costs, but utilities carried forward differ between groups (because of projected survival patterns).
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